

Request: Paul Schultzy

1249

Access DB# 136040

# SEARCH REQUEST FORM

Scientific and Technical Information Center

OCT 25 2004

Requester's Full Name: Sabiha Qazi Examiner #: 74141 Date: 10/25/04  
Alt Unit: 1616 Phone Number: 20622 Serial Number: 10/720487  
Mail Box and Bldg/Room Location: 4C70 Rem. 4A45 Results Format Preferred (check): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept of novelty of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, et. al. known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Pharmaceutical Prep - - -

Inventors (please provide full names): Ludwig Wild et al

Earliest Priority Filing Date: 4/15/19 6/26/2001

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search for the methods  
of use of estro 1, 3, 5 (10)-triene-3  
17 $\beta$ -diol-17-Valerate, as in cl  
1-9.

Please see attached sheets

Thank you

## STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: _____	NA Sequence (#) _____	STN <u>292.43</u>
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>1</u>	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: <u>10/28</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>20</u>	Fulltext _____	Sequence Systems _____
Critical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>18</u>	Other _____	Other (specify) _____

**This Page Blank (uspto)**

=> fil reg; d ide

FILE IN REGISTRY ENTERED AT 10:45:36 ON 02 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9  
DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.


REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN ~~9719-32-8~~ REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA  
INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Estradiol valerate (6CI)  
CN Estradiol, 17-valerate (7CI, 8CI)  
OTHER NAMES:  
CN 3-Hydroxy-17 $\beta$ -valeroyloxyestra-1,3,5(10)-triene  
CN Atladiol  
CN Climaval  
CN Deladiol  
CN Delahormone unimatic  
CN Delestrogen  
CN Delestrogen 4x  
CN Dura-Estradiol  
CN ~~Estra-1,3,5(10)-triene-3,17 $\beta$ -diol-17-valerate~~  
CN Estradiol 17 $\beta$ -valerate  
CN Estradiol valerianate

CN Estraval  
CN Femogex  
CN Gynogen LA  
CN Gynogen LA 40  
CN Gynokadin  
CN Neofollin  
CN NSC 17590  
CN Nuvelle  
CN Oestradiol valerate  
CN Pelanin Depot  
CN Pharlon  
CN Primofol-Depot  
CN Primogyn-Depot  
CN Progynon-Depot  
CN Progynova  
CN Valergen  
FS STEREOSEARCH  
DR 907-12-0, 69557-95-5  
MF C23 H32 O3  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK\*, NIOSHTIC, PATDPASPC, PROMT, PS, RTECS\*, SCISEARCH, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

916 REFERENCES IN FILE CA (1907 TO DATE)  
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
920 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
39 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> => d ide

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 9034-40-6 REGISTRY  
ED Entered STN: 16 Nov 1984

Searched by Barb O'Bryen, STIC 2-2518



CN Luteinizing hormone-releasing factor (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN Fertiral

CN GnRH

CN GonaCon/AdjuVac

CN Gonadoliberin

CN Gonadotropin-releasing factor

CN Gonadotropin-releasing hormone

CN Gonadotropin-releasing peptide

CN Kryptocur

CN LH-releasing factor

CN LH-releasing hormone

CN LH-RF

CN LH-RH

CN LRF

CN LRH

CN Luliberin

CN Luteinizing hormone-releasing hormone

CN Luteostimulin

CN Nialutin

CN Relefact LH-RH

CN Reproboost

MF Unspecified

CI COM, MAN

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CABA,  
CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, EMBASE, IFICDB, IFIPAT, IFIUDB,  
IPA, MRCK\*, NIOSHTIC, PROMT, RTECS\*, TOXCENTER, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16339 REFERENCES IN FILE CA (1907 TO DATE)

1488 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

16360 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> =>

=> fil reg; d stat que l12  
FILE 'REGISTRY' ENTERED AT 12:08:13 ON 02 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9  
DICTIONARY FILE UPDATES: 1 MAR 2006 HIGHEST RN 875609-25-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

L2 1 SEA FILE=REGISTRY ABB=ON 979-32-8  
L3 STR



Searched by Barb O'Bryen, STIC 2-2518

NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE

L5 29 SEA FILE=REGISTRY FAM FUL L3  
 L6 SEL L2 1- RN : 1 TERM  
 L7 25 SEA FILE=REGISTRY ABB=ON L6/CRN  
 L9 4 SEA FILE=REGISTRY ABB=ON L5 NOT L7  
 L11 2 SEA FILE=REGISTRY ABB=ON L9 AND A  
~~L12 27 SEA FILE=REGISTRY ABB=ON L5 NOT L11~~

=> fil capl; d que nos l18; d que nos l30

FILE 'CAPLUS' ENTERED AT 12:08:14 ON 02 MAR 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Mar 2006 VOL 144 ISS 10  
 FILE LAST UPDATED: 1 Mar 2006 (20060301/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>  
 'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L2 1 SEA FILE=REGISTRY ABB=ON 979-32-8  
 L3 STR  
 L5 29 SEA FILE=REGISTRY FAM FUL L3  
 L6 SEL L2 1- RN : 1 TERM  
 L7 25 SEA FILE=REGISTRY ABB=ON L6/CRN  
 L9 4 SEA FILE=REGISTRY ABB=ON L5 NOT L7  
 L11 2 SEA FILE=REGISTRY ABB=ON L9 AND A  
 L12 27 SEA FILE=REGISTRY ABB=ON L5 NOT L11  
 L14 1074 SEA FILE=CAPLUS ABB=ON L12  
 L15 1 SEA FILE=REGISTRY ABB=ON 9034-40-6  
 L16 16360 SEA FILE=CAPLUS ABB=ON L15  
 L17 209 SEA FILE=CAPLUS ABB=ON L16 (L) ADV/RL - Role ADV = adverse effect  
 L18 1 SEA FILE=CAPLUS ABB=ON L17 AND L14

```
L2          1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3          STR
L5          29 SEA FILE=REGISTRY FAM FUL L3
L6          SEL  L2 1- RN :          1 TERM
L7          25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9          4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11         2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12         27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
L14         1074 SEA FILE=CAPLUS ABB=ON  L12
L15         1 SEA FILE=REGISTRY ABB=ON  9034-40-6
L16         16360 SEA FILE=CAPLUS ABB=ON  L15
L21         499 SEA FILE=CAPLUS ABB=ON  RETENTION/OBI (L) FLUID#/OBI
L22         661 SEA FILE=CAPLUS ABB=ON  HOT/OBI (L) FL!SH?/OBI
L23         5507 SEA FILE=CAPLUS ABB=ON  HEADACHE#/OBI
L24         2103 SEA FILE=CAPLUS ABB=ON  NAUSEA/OBI
L25         11069 SEA FILE=CAPLUS ABB=ON  DEPRESSION/OBI (L) MENTAL/OBI
L26         40 SEA FILE=CAPLUS ABB=ON  (MAMMARY/OBI OR BREAST#/OBI) (L) TENDER?/
          OBI
L27         50049 SEA FILE=CAPLUS ABB=ON  CARDIOVASCULAR/OBI
L28         294 SEA FILE=CAPLUS ABB=ON  GYNECOMASTI?/OBI
L29         56 SEA FILE=CAPLUS ABB=ON  PROSTAT?/OBI (L) ENLARG?/OBI
L30         3 SEA FILE=CAPLUS ABB=ON  L16 AND L14 AND (L21 OR L22 OR L23 OR
          L24 OR L25 OR L26 OR L27 OR L28 OR L29)
```

=> s l18 or l30

L166 3 L18 OR L30

=> fil toxcenter; d que nos l37

FILE 'TOXCENTER' ENTERED AT 12:08:16 ON 02 MAR 2006  
COPYRIGHT (C) 2006 ACS

FILE COVERS 1907 TO 28 Feb 2006 (20060228/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2006 MEDLINE data and features. See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

See <http://www.nlm.nih.gov/mesh/>

[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)

[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

for a description of changes.

```
L2          1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3          STR
L5          29 SEA FILE=REGISTRY FAM FUL L3
L6          SEL  L2 1- RN :          1 TERM
L7          25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9          4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11         2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12         27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
```

L15 1 SEA FILE=REGISTRY ABB=ON 9034-40-6  
L35 558 SEA FILE=TOXCENTER ABB=ON L12  
L36 3200 SEA FILE=TOXCENTER ABB=ON L15  
L37 7 SEA FILE=TOXCENTER ABB=ON L35 AND L36

=> fil biosis; d que nos l66

\*FILE 'BIOSIS' ENTERED AT 12:08:17 ON 02 MAR 2006  
Copyright (c) 2006 The Thomson Corporation

FILE COVERS 1969 TO DATE.  
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 1 March 2006 (20060301/ED)

L2 1 SEA FILE=REGISTRY ABB=ON 979-32-8  
L3 STR  
L5 29 SEA FILE=REGISTRY FAM FUL L3  
L6 SEL L2 1- RN : 1 TERM  
L7 25 SEA FILE=REGISTRY ABB=ON L6/CRN  
L9 4 SEA FILE=REGISTRY ABB=ON L5 NOT L7  
L11 2 SEA FILE=REGISTRY ABB=ON L9 AND A  
L12 27 SEA FILE=REGISTRY ABB=ON L5 NOT L11  
L15 1 SEA FILE=REGISTRY ABB=ON 9034-40-6  
L50 1002 SEA FILE=BIOSIS ABB=ON L12  
L51 13923 SEA FILE=BIOSIS ABB=ON L15  
L53 1583 SEA FILE=BIOSIS ABB=ON (RETENTION OR RETAIN?) (2A) FLUID#  
L54 1296 SEA FILE=BIOSIS ABB=ON HOT FL!SH?  
L55 24834 SEA FILE=BIOSIS ABB=ON HEADACHE#  
L56 20197 SEA FILE=BIOSIS ABB=ON NAUSEA  
L57 119520 SEA FILE=BIOSIS ABB=ON DEPRESSION  
L58 262 SEA FILE=BIOSIS ABB=ON (MAMMARY OR BREAST#) (2A) TENDER?  
L59 1807338 SEA FILE=BIOSIS ABB=ON CARDIOVASCULAR  
L60 1659 SEA FILE=BIOSIS ABB=ON GYNECOMASTI?  
L61 652 SEA FILE=BIOSIS ABB=ON PROSTAT? (2A) ENLARG?  
L62 185953 SEA FILE=BIOSIS ABB=ON (SIDE OR ADVERSE) (2A) (EFFECT? OR  
EVENT?)  
L65 21420 SEA FILE=BIOSIS ABB=ON (LUTEINIZING OR GONADOTROPIN) (1W) RELEAS  
ING HORMONE#  
L66 3 SEA FILE=BIOSIS ABB=ON L50 AND (L51 OR L65) AND (L53 OR L54;  
OR L55 OR L56 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62)

=> fil uspatf; d que nos l69

\*FILE 'USPATFULL' ENTERED AT 12:08:18 ON 02 MAR 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Feb 2006 (20060228/PD)  
FILE LAST UPDATED: 28 Feb 2006 (20060228/ED)  
HIGHEST GRANTED PATENT NUMBER: US7007305  
HIGHEST APPLICATION PUBLICATION NUMBER: US2006041984  
CA INDEXING IS CURRENT THROUGH 28 Feb 2006 (20060228/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Feb 2006 (20060228/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

```
L2      1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3      STR
L5      29 SEA FILE=REGISTRY FAM FUL L3
L6      SEL  L2 1- RN :          1 TERM
L7      25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9      4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11     2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12     27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
L15     1 SEA FILE=REGISTRY ABB=ON  9034-40-6
L67     117 SEA FILE=USPATFULL ABB=ON  L12
L68     1036 SEA FILE=USPATFULL ABB=ON  L15
L69     5 SEA FILE=USPATFULL ABB=ON  L67 AND L68
```

=> fil embase; d que nos l75 ; d que nos l78

FILE 'EMBASE' ENTERED AT 12:08:19 ON 02 MAR 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE COVERS 1974 TO 24 Feb 2006 (20060224/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

```
L2      1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3      STR
L5      29 SEA FILE=REGISTRY FAM FUL L3
L6      SEL  L2 1- RN :          1 TERM
L7      25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9      4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11     2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12     27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
L70     2369 SEA FILE=EMBASE ABB=ON  L12
L71     2157 SEA FILE=EMBASE ABB=ON  ESTRADIOL VALERATE/CT
L72     20312 SEA FILE=EMBASE ABB=ON  GONADORELIN/CT
L74     197 SEA FILE=EMBASE ABB=ON  L72 (L) AE/CT
L75     1 SEA FILE=EMBASE ABB=ON  L74 AND (L70 OR L71)
```

```
L2      1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3      STR
L5      29 SEA FILE=REGISTRY FAM FUL L3
L6      SEL  L2 1- RN :          1 TERM
L7      25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9      4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11     2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12     27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
L70     2369 SEA FILE=EMBASE ABB=ON  L12
L71     2157 SEA FILE=EMBASE ABB=ON  ESTRADIOL VALERATE/CT
L72     20312 SEA FILE=EMBASE ABB=ON  GONADORELIN/CT
L73     67 SEA FILE=EMBASE ABB=ON  (L70 OR L71) AND L72
L77     363126 SEA FILE=EMBASE ABB=ON  SIDE EFFECT/CT
L78     5 SEA FILE=EMBASE ABB=ON  L73 AND L77
```

=> s 175 or 178

<L167-----5-L75 OR L78-->

=> fil biotechno; d que nos 194

FILE 'BIOTECHNO' ENTERED AT 12:08:20 ON 02 MAR 2006  
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>  
FILE COVERS 1980 TO 2003..

>>> BIOTECHNO IS NO LONGER BEING UPDATED AS OF 2004 <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN  
/CT AND BASIC INDEX <<<

L2 1 SEA FILE=REGISTRY ABB=ON 979-32-8  
L3 STR  
L5 29 SEA FILE=REGISTRY FAM FUL L3  
L6 SEL L2 1- RN : 1 TERM  
L7 25 SEA FILE=REGISTRY ABB=ON L6/CRN  
L9 4 SEA FILE=REGISTRY ABB=ON L5 NOT L7  
L11 2 SEA FILE=REGISTRY ABB=ON L9 AND A  
L12 27 SEA FILE=REGISTRY ABB=ON L5 NOT L11  
L15 1 SEA FILE=REGISTRY ABB=ON 9034-40-6  
L79 357 SEA FILE=BIOTECHNO ABB=ON L12  
L80 385 SEA FILE=BIOTECHNO ABB=ON ESTRADIOL VALERATE  
L81 5768 SEA FILE=BIOTECHNO ABB=ON L15  
L82 9488 SEA FILE=BIOTECHNO ABB=ON GONADORELIN OR ((LUTEINIZING OR  
GONADOTROPIN) (1W) RELEASING (W) (FACTOR# OR HORMONE#))  
L83 48 SEA FILE=BIOTECHNO ABB=ON (L79 OR L80) AND (L81 OR L82)  
L84 279 SEA FILE=BIOTECHNO ABB=ON (RETENTION OR RETAIN?) (2A) FLUID#  
L85 287 SEA FILE=BIOTECHNO ABB=ON HOT FL!SH?  
L86 2536 SEA FILE=BIOTECHNO ABB=ON HEADACHE#  
L87 3002 SEA FILE=BIOTECHNO ABB=ON NAUSEA  
L88 5916 SEA FILE=BIOTECHNO ABB=ON DEPRESSION  
L89 17 SEA FILE=BIOTECHNO ABB=ON (MAMMARY OR BREAST#) (2A) TENDER?  
L90 9915 SEA FILE=BIOTECHNO ABB=ON CARDIOVASCULAR  
L91 187 SEA FILE=BIOTECHNO ABB=ON GYNECOMASTI?  
L92 43 SEA FILE=BIOTECHNO ABB=ON PROSTAT? (2A) ENLARG?  
L93 14495 SEA FILE=BIOTECHNO ABB=ON (SIDE OR ADVERSE) (2A) (EFFECT? OR  
EVENT?)  
<L94-----5 SEA FILE=BIOTECHNO ABB=ON L83 AND (L84 OR L85 OR L86 OR L87  
<OR L88 OR L89 OR L90 OR L91 OR L92 OR L93)

=> fil agricola; d que nos 1116; d que nos 1119

FILE 'AGRICOLA' ENTERED AT 12:08:23 ON 02 MAR 2006

FILE COVERS 1970 TO 7 Feb 2006 (20060207/ED)

Compiled and distributed by the National Agricultural Library  
of the Department of Agriculture of the United States of  
America. It contains copyrighted material. All rights

reserved. (2006)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```

L2          1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3          STR
L5          29 SEA FILE=REGISTRY FAM FUL L3
L6          SEL  L2 1- RN :          1 TERM
L7          25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9          4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11         2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12        27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
L15         1 SEA FILE=REGISTRY ABB=ON  9034-40-6
L101       111 SEA FILE=AGRICOLA ABB=ON  L12
L102        60 SEA FILE=AGRICOLA ABB=ON  ESTRADIOL VALERATE
L103      1744 SEA FILE=AGRICOLA ABB=ON  L15
L104     1358 SEA FILE=AGRICOLA ABB=ON  GONADORELIN OR ((LUTEINIZING OR
      GONADOTROPIN) (1W)RELEASING (W) (FACTOR# OR  HORMONE#))
L105         7 SEA FILE=AGRICOLA ABB=ON  (L101 OR L102) AND (L103 OR L104)
L106        53 SEA FILE=AGRICOLA ABB=ON  (RETENTION OR RETAIN?) (2A) FLUID#
L107        16 SEA FILE=AGRICOLA ABB=ON  HOT FL!SH?
L108       206 SEA FILE=AGRICOLA ABB=ON  HEADACHE#
L109       221 SEA FILE=AGRICOLA ABB=ON  NAUSEA
L110     3636 SEA FILE=AGRICOLA ABB=ON  DEPRESSION
L111        36 SEA FILE=AGRICOLA ABB=ON  (MAMMARY OR BREAST#) (2A) TENDER?
L112     6079 SEA FILE=AGRICOLA ABB=ON  CARDIOVASCULAR
L113         5 SEA FILE=AGRICOLA ABB=ON  GYNECOMASTI?
L114         5 SEA FILE=AGRICOLA ABB=ON  PROSTAT? (2A) ENLARG?
L115     7300 SEA FILE=AGRICOLA ABB=ON  (SIDE OR ADVERSE) (2A) (EFFECT? OR
      EVENT?)
L116         0 SEA FILE=AGRICOLA ABB=ON  L105 AND (L106 OR L107 OR L108 OR
      L109 OR L110 OR L111 OR L112 OR L113 OR L114 OR L115)

```

```

L2          1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3          STR
L5          29 SEA FILE=REGISTRY FAM FUL L3
L6          SEL  L2 1- RN :          1 TERM
L7          25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9          4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11         2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12        27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
L15         1 SEA FILE=REGISTRY ABB=ON  9034-40-6
L101       111 SEA FILE=AGRICOLA ABB=ON  L12
L102        60 SEA FILE=AGRICOLA ABB=ON  ESTRADIOL VALERATE
L103      1744 SEA FILE=AGRICOLA ABB=ON  L15
L104     1358 SEA FILE=AGRICOLA ABB=ON  GONADORELIN OR ((LUTEINIZING OR
      GONADOTROPIN) (1W)RELEASING (W) (FACTOR# OR  HORMONE#))
L105         7 SEA FILE=AGRICOLA ABB=ON  (L101 OR L102) AND (L103 OR L104)
L117       7071 SEA FILE=AGRICOLA ABB=ON  MAN/CT
L118     10394 SEA FILE=AGRICOLA ABB=ON  WOMEN/CT
L119         0 SEA FILE=AGRICOLA ABB=ON  L105 AND (L117 OR L118)

```

=> fil drugu; d que nos 1135; d que nos 1146

FILE 'DRUGU' ENTERED AT 12:08:24 ON 02 MAR 2006



COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED: 1 MAR 2006 <20060301/UP>  
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<  
>>> THESAURUS AVAILABLE IN /CT <<<

L2 1 SEA FILE=REGISTRY ABB=ON 979-32-8  
L3 STR  
L5 29 SEA FILE=REGISTRY FAM FUL L3  
L6 SEL L2 1- RN : 1 TERM  
L7 25 SEA FILE=REGISTRY ABB=ON L6/CRN  
L9 4 SEA FILE=REGISTRY ABB=ON L5 NOT L7  
L11 2 SEA FILE=REGISTRY ABB=ON L9 AND A  
L12 27 SEA FILE=REGISTRY ABB=ON L5 NOT L11  
L120 371 SEA FILE=DRUGU ABB=ON L12  
L123 2266 SEA FILE=DRUGU ABB=ON GONADORELIN OR ((LUTEINIZING OR  
GONADOTROPIN) (1W) RELEASING (W) (FACTOR# OR HORMONE#))  
L125 765 SEA FILE=DRUGU ABB=ON ESTRADIOL-VALERATE/CT  
L127 8458 SEA FILE=DRUGU ABB=ON RELEASING-FACTOR#/CT  
L130 10 SEA FILE=DRUGU ABB=ON (L120 OR L125) AND L127 AND L123  
L131 311308 SEA FILE=DRUGU ABB=ON AE = *adverse effect*  
L134 240306 SEA FILE=DRUGU ABB=ON ADVERSE REACTIONS/CC  
L135 6 SEA FILE=DRUGU ABB=ON L130 AND (L131 OR L134) p

L2 1 SEA FILE=REGISTRY ABB=ON 979-32-8  
L3 STR  
L5 29 SEA FILE=REGISTRY FAM FUL L3  
L6 SEL L2 1- RN : 1 TERM  
L7 25 SEA FILE=REGISTRY ABB=ON L6/CRN  
L9 4 SEA FILE=REGISTRY ABB=ON L5 NOT L7  
L11 2 SEA FILE=REGISTRY ABB=ON L9 AND A  
L12 27 SEA FILE=REGISTRY ABB=ON L5 NOT L11  
L120 371 SEA FILE=DRUGU ABB=ON L12  
L123 2266 SEA FILE=DRUGU ABB=ON GONADORELIN OR ((LUTEINIZING OR  
GONADOTROPIN) (1W) RELEASING (W) (FACTOR# OR HORMONE#))  
L125 765 SEA FILE=DRUGU ABB=ON ESTRADIOL-VALERATE/CT  
L127 8458 SEA FILE=DRUGU ABB=ON RELEASING-FACTOR#/CT  
L130 10 SEA FILE=DRUGU ABB=ON (L120 OR L125) AND L127 AND L123  
L136 6084 SEA FILE=DRUGU ABB=ON FLUSHING/CT  
L137 24956 SEA FILE=DRUGU ABB=ON HEADACHE/CT  
L138 42819 SEA FILE=DRUGU ABB=ON NAUSEA/CT  
L139 15233 SEA FILE=DRUGU ABB=ON DEPRESSION/CT  
L140 3693 SEA FILE=DRUGU ABB=ON WEIGHT-GAIN/CT  
L141 606 SEA FILE=DRUGU ABB=ON GYNECOMASTIA/CT  
L142 676 SEA FILE=DRUGU ABB=ON PROSTATE-HYPERPLASIA/CT OR PROSTATE-HYPE  
RTROPHY/CT  
L143 582 SEA FILE=DRUGU ABB=ON (MAMMARY OR BREAST#) (2A) TENDER?  
L144 1427 SEA FILE=DRUGU ABB=ON (RETENTION OR RETAIN?) (2A) FLUID#  
L145 23742 SEA FILE=DRUGU ABB=ON CARDIOVASCULAR  
L146 5 SEA FILE=DRUGU ABB=ON L130 AND (L136 OR L137 OR L138 OR L139  
OR L140 OR L141 OR L142 OR L143 OR L144 OR L145)

=> s l135 or l146

L168 6 L135 OR L146

=> fil ipa; d que nos l152

FILE 'IPA' ENTERED AT 12:08:26 ON 02 MAR 2006  
Copyright (c) 2006 The Thomson Corporation

FILE COVERS 1970 TO 1 MAR 2006 (20060301/ED)

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

L2 1 SEA FILE=REGISTRY ABB=ON 979-32-8  
L3 STR  
L5 29 SEA FILE=REGISTRY FAM FUL L3  
L6 SEL L2 1- RN : 1 TERM  
L7 25 SEA FILE=REGISTRY ABB=ON L6/CRN  
L9 4 SEA FILE=REGISTRY ABB=ON L5 NOT L7  
L11 2 SEA FILE=REGISTRY ABB=ON L9 AND A  
L12 27 SEA FILE=REGISTRY ABB=ON L5 NOT L11  
L15 1 SEA FILE=REGISTRY ABB=ON 9034-40-6  
L148 71 SEA FILE=IPA ABB=ON L12  
L149 81 SEA FILE=IPA ABB=ON ESTRADIOL VALERATE  
L150 1 SEA FILE=IPA ABB=ON L15  
L151 764 SEA FILE=IPA ABB=ON GONADORELIN OR ((LUTEINIZING OR GONADOTROP  
IN) (1W) RELEASING (W) (HORMONE# OR FACTOR#))  
L152 4 SEA FILE=IPA ABB=ON (L148 OR L149) AND (L150 OR L151)

=> fil imsre; d que nos l157

FILE 'IMSRESEARCH' ENTERED AT 12:08:27 ON 02 MAR 2006  
COPYRIGHT (C) 2006 IMSWORLD Publications Ltd

FILE COVERS 1977 TO 24 Feb 2006 (20060224/ED)

```
#####  
#                                     #  
#             !!! ATTENTION !!!      #  
#                                     #  
# Welcome to IMSRESEARCH. A special subscriber rate  
# is available to purchasers of the IMSworld publication,  
# R&D Focus, part of the Drug Intelligence range.  
#                                     #  
# For detailed information regarding eligibility and  
# authorization for this subscriber discount, please contact  
# IMS HEALTH Customer Services directly by phone  
# at +44(0)20-7393-5888, or email globaldirect@uk.imshealth.com  
# See HELP SUBSCRIPTION for more information.  
#                                     #  
#####
```

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

The file name was changed from DRUGUPDATES to IMSRESEARCH on 7 Dec. 2003.  
The file name DRUGUPDATES is now an alias for IMSRESEARCH.

```

L2      1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3      STR
L5      29 SEA FILE=REGISTRY FAM FUL L3
L6      SEL  L2 1- RN :          1 TERM
L7      25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9      4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11     2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12     27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
L153    2 SEA FILE=IMSRESEARCH ABB=ON  L12
L154    13 SEA FILE=IMSRESEARCH ABB=ON  ESTRADIOL VALERATE
L156    74 SEA FILE=IMSRESEARCH ABB=ON  GONADORELIN OR ((LUTEINIZING OR
      GONADOTROPIN) (1W) RELEASING (W) (HORMONE# OR FACTOR#))
L157    0 SEA FILE=IMSRESEARCH ABB=ON  (L153 OR L154) AND L156

```

=> fil adisin; d que nos l162

FILE 'ADISINSIGHT' ENTERED AT 12:08:28 ON 02 MAR 2006  
 COPYRIGHT (C) 2006 Adis Data Information BV

FILE COVERS 1998 TO 23 Feb 2006 (20060223/ED)  
 FILE LAST UPDATED: 23 FEB 2006 (20060223/ED)

```

L2      1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3      STR
L5      29 SEA FILE=REGISTRY FAM FUL L3
L6      SEL  L2 1- RN :          1 TERM
L7      25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9      4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11     2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12     27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
L158    2 SEA FILE=ADISINSIGHT ABB=ON  L12
L159    9 SEA FILE=ADISINSIGHT ABB=ON  ESTRADIOL VALERATE
L161    64 SEA FILE=ADISINSIGHT ABB=ON  GONADORELIN OR ((LUTEINIZING OR
      GONADOTROPIN) (1W) RELEASING (W) (HORMONE# OR FACTOR#))
L162    1 SEA FILE=ADISINSIGHT ABB=ON  (L158 OR L159) AND L161

```

=> fil medl; d que nos l100

FILE 'MEDLINE' ENTERED AT 12:08:29 ON 02 MAR 2006

FILE LAST UPDATED: 1 MAR 2006 (20060301/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details  
 on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).  
 See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L2 1 SEA FILE=REGISTRY ABB=ON 979-32-8  
L3 STR  
L5 29 SEA FILE=REGISTRY FAM FUL L3  
L6 SEL L2 1- RN : 1 TERM  
L7 25 SEA FILE=REGISTRY ABB=ON L6/CRN  
L9 4 SEA FILE=REGISTRY ABB=ON L5 NOT L7  
L11 2 SEA FILE=REGISTRY ABB=ON L9 AND A  
L12 27 SEA FILE=REGISTRY ABB=ON L5 NOT L11  
L95 655 SEA FILE=MEDLINE ABB=ON L12  
L96 4412 SEA FILE=MEDLINE ABB=ON ESTRADIOL/CT(L)AA/CT  
L97 22442 SEA FILE=MEDLINE ABB=ON GONADORELIN+NT/CT  
L99 966 SEA FILE=MEDLINE ABB=ON L97(L)AE/CT  
L100 7 SEA FILE=MEDLINE ABB=ON L99 AND (L95 OR L96)

=> => dup rem l166,l69,l100,l168,l94,l152,l66,l167,l37,l162

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'CAPLUS' ENTERED AT 12:10:30 ON 02 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:10:30 ON 02 MAR 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:10:30 ON 02 MAR 2006

FILE 'DRUGU' ENTERED AT 12:10:30 ON 02 MAR 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 12:10:30 ON 02 MAR 2006

COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IPA' ENTERED AT 12:10:30 ON 02 MAR 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'BIOSIS' ENTERED AT 12:10:30 ON 02 MAR 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:10:30 ON 02 MAR 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 12:10:30 ON 02 MAR 2006

COPYRIGHT (C) 2006 ACS

FILE 'ADISINSIGHT' ENTERED AT 12:10:30 ON 02 MAR 2006

COPYRIGHT (C) 2006 Adis Data Information BV

PROCESSING COMPLETED FOR L166

PROCESSING COMPLETED FOR L69

PROCESSING COMPLETED FOR L100

PROCESSING COMPLETED FOR L168

PROCESSING COMPLETED FOR L94

PROCESSING COMPLETED FOR L152  
 PROCESSING COMPLETED FOR L66  
 PROCESSING COMPLETED FOR L167  
 PROCESSING COMPLETED FOR L37  
 PROCESSING COMPLETED FOR L162

L169 41-DUP REM L166 L69 L100 L168 L94 L152 L66 L167 L37 (5-DUPLICATES  
 REMOVED)

ANSWERS '1-3' FROM FILE CAPLUS  
 ANSWERS '4-7' FROM FILE USPATFULL  
 ANSWERS '8-14' FROM FILE MEDLINE  
 ANSWERS '15-19' FROM FILE DRUGU  
 ANSWERS '20-24' FROM FILE BIOTECHNO  
 ANSWERS '25-27' FROM FILE IPA  
 ANSWERS '28-30' FROM FILE BIOSIS  
 ANSWERS '31-35' FROM FILE EMBASE  
 ANSWERS '36-40' FROM FILE TOXCENTER  
 ANSWER '41' FROM FILE ADISINSIGHT

<=> d ibib ed abs hitstr 1-7; d iall 8-41

L169 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1  
 ACCESSION NUMBER: 2004:701801 CAPLUS  
 DOCUMENT NUMBER: 141:200203  
 TITLE: Pharmaceutical preparations containing modified  
 estradiol or modified estriol for treating side  
 effects during and/or after GnRHa therapy  
 INVENTOR(S): Oettel, Michael; Wild, Ludwig; Licht, Peter;  
 Neuwinger, Joachim; Hummel, Wolfgang; Dittrich, Ralph  
 PATENT ASSIGNEE(S): Germany  
 SOURCE: U.S. Pat. Appl. Publ., 7 pp., Cont.-in-part of U.S.  
 Ser. No. 891,722.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167111	A1	20040826	US 2003-729487	20031205
US 2002002153	A1	20020103	US 1999-291385	19990414
US 2002065260	A1	20020530	US 2001-891722	20010626
US 6689768	B2	20040210		
PRIORITY APPLN. INFO.:			US 1998-81791P	P 19980415
			US 1999-291385	B2 19990414
			US 2001-891722	A2 20010626
			DE 1998-19815060	A 19980403

ED Entered STN: 27 Aug 2004

AB The pharmaceutical preps. for treating side effects, such as hot flashes, prostate enlargement and gynecomastia, during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone (GnRHa therapy) contain an effective amount of a chemical modified derivative of 17 $\alpha$ -estradiol, a chemical modified derivative of 17 $\beta$ -estradiol and/or a chemical modified derivative of estriol. Pharmaceutical preps. containing estro  
 1,3,5(10)-triene-3,17 $\beta$ -diol-17-valerate as the effective ingredient are particularly preferred. Hot flashes tripped by GnRHa therapy with Decapeptyl-Depot in the treatment of endometriosis or fibroid tumors of the uterus were effectively eliminated in the treated females by administration of 14 $\alpha$ ,15 $\alpha$ -methylene-1,3,5(10),8-tetraene-


3,17 $\alpha$ -diol.

IT 9034-40-6D, Gonadotropin-releasing hormone, analogs  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modified estradiol or modified estriol for treating side effects during and/or after GnRHa therapy)  
 RN 9034-40-6 CAPLUS  
 CN Luteinizing hormone-releasing factor (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 979-32-8, Estra 1,3,5(10)-triene-3,17 $\beta$ -diol-17-valerate  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modified estradiol or modified estriol for treating side effects during and/or after GnRHa therapy)  
 RN 979-32-8 CAPLUS  
 CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L169 ANSWER 2 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2  
 ACCESSION NUMBER: 2002:353298 CAPLUS  
 DOCUMENT NUMBER: 136:350812  
 TITLE: GnRH analogues for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs  
 INVENTOR(S): Arnold, Susi; Reichler, Iris; Hubler, Madeleine  
 PATENT ASSIGNEE(S): University of Zurich, Switz.  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036144	A1	20020510	WO 2001-CH636	20011026
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				

SOURCE: Hospital Medical School, London, UK.  
British journal of obstetrics and gynaecology, (1993 Apr)  
Vol. 100, No. 4, pp. 360-4.  
Journal code: 7503752. ISSN: 0306-5456.

PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199306  
ENTRY DATE: Entered STN: 19930702  
Last Updated on STN: 19930702  
Entered Medline: 19930623

## ABSTRACT:

OBJECTIVE: To assess whether GnRH analogues are effective in relieving pelvic pain and congestion and whether menopausal symptoms caused by GnRH analogues can be minimised by supplementation with low dose continuous combined hormone replacement therapy (HRT). DESIGN: Open prospective study. SETTING: Tertiary referral clinic at a teaching hospital. PATIENTS: Twenty-one women with chronic pelvic pain. INTERVENTION: Four months' therapy with goserelin 3.6 mg/month combined with continuous oestradiol valerate 1 mg daily and medroxyprogesterone acetate 5 mg daily. MAIN OUTCOME MEASURES: Visual analogue scale for pain, menopausal symptoms, bleeding patterns, uterine area, endometrial status, oestradiol concentrations and venogram scores. RESULTS: Amenorrhoea was maintained in all but two women. Endometrial atrophy was maintained despite HRT supplementation. Two women had moderate menopausal symptoms but none had severe symptoms. Significant reduction of uterine cross sectional area was maintained throughout the study. There was no significant relief of pain. CONCLUSIONS: HRT supplementation of GnRH analogues abolishes menopausal symptoms and thus may improve patient acceptability. Potentially beneficial effects such as endometrial atrophy, reduction of uterine volume and amenorrhoea were not negated by HRT. This combination is not effective in the treatment of chronic pelvic pain and congestion.

CONTROLLED TERM: Check Tags: Female  
Adult  
Chronic Disease  
\*Estradiol: AA, analogs & derivatives  
Estradiol: TU, therapeutic use  
\*Estrogen Replacement Therapy  
\*Goserelin: AE, adverse effects  
Goserelin: TU, therapeutic use  
Humans  
Hysterectomy  
\*Medroxyprogesterone 17-Acetate: TU, therapeutic use  
Menopause: DE, drug effects  
Pain Measurement  
Patient Satisfaction  
\*Pelvic Inflammatory Disease: DT, drug therapy  
Prospective Studies  
Time Factors

CAS REGISTRY NO.: 50-28-2 (Estradiol); 65807-02-5 (Goserelin); 71-58-9 (Medroxyprogesterone 17-Acetate); 979-32-8 (estradiol valerate)

L169 ANSWER 13 OF 41 MEDLINE on STN  
ACCESSION NUMBER: 93101379 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8416441  
TITLE: The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy.  
AUTHOR: Leather A T; Studd J W; Watson N R; Holland E F  
CORPORATE SOURCE: Premenstrual Syndrome Clinic, Dulwich Hospital, London,

SOURCE: United Kingdom.  
Obstetrics and gynecology, (1993 Jan) Vol. 81, No. 1, pp.  
104-7.  
Journal code: 0401101. ISSN: 0029-7844.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(RANDOMIZED CONTROLLED TRIAL)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199301  
ENTRY DATE: Entered STN: 19930205  
Last Updated on STN: 19930205  
Entered Medline: 19930121

## ABSTRACT:

OBJECTIVE: To determine whether the addition of a low dose of oral estrogen replacement therapy (ERT) taken daily can prevent the bone loss associated with continuous GnRH analogue use. METHODS: In a double-blind, placebo-controlled study, 60 women aged 21-45 years were randomized to one of three treatment groups: placebo implant every 4 weeks plus placebo ERT tablets daily, Zoladex (goserelin 3.6 mg) implant every 4 weeks plus placebo ERT tablets daily, or Zoladex (3.6 mg) implant every 4 weeks plus estradiol valerate, 2 mg/day, with norethisterone 5 mg from days 22-28. A dual x-ray bone density scan was performed before treatment and again after six treatment cycles. The percentage bone change with respect to the initial bone density was calculated. RESULTS: There was a significant loss of bone density at both the lumbar spine and proximal femur in the group receiving Zoladex plus placebo after 6 months compared with both pre-treatment values and with the group receiving placebo plus placebo. The addition of estrogen "add-back" therapy to GnRH analogue treatment (Zoladex plus ERT) resulted in no significant change in bone density compared with either pre-treatment values or the group receiving placebo plus placebo. The study had a dropout rate of 32%. CONCLUSION: The addition of "add-back" estrogen therapy to continuous GnRH analogue use can prevent bone loss.

CONTROLLED TERM: Check Tags: Female  
Administration, Oral  
Adult  
Bone Density  
Double-Blind Method  
Drug Implants  
Estradiol: AD, administration & dosage  
Estradiol: AA, analogs & derivatives  
\*Estrogens: AD, administration & dosage  
Goserelin: AD, administration & dosage  
\*Goserelin: AE, adverse effects  
Humans  
Middle Aged  
Norethindrone: AD, administration & dosage  
Osteoporosis: CI, chemically induced  
Osteoporosis: DI, diagnosis  
\*Osteoporosis: PC, prevention & control  
Premenstrual Syndrome: DT, drug therapy  
Research Support, Non-U.S. Gov't  
CAS REGISTRY NO.: 50-28-2 (Estradiol); 65807-02-5 (Goserelin); 68-22-4  
(Norethindrone); 979-32-8 (estradiol valerate)  
CHEMICAL NAME: 0 (Drug Implants); 0 (Estrogens)

L169 ANSWER 14 OF 41 MEDLINE on STN  
ACCESSION NUMBER: 94121451 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8291869



TITLE: Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.  
AUTHOR: Aro J; Ruutu M; Juusela H; Hansson E; Permi J  
CORPORATE SOURCE: Malmi Hospital, Helsinki, Finland.  
SOURCE: Annales chirurgiae et gynaecologiae. Supplementum, (1993) Vol. 206, pp. 5-8.  
Journal code: 7702959. ISSN: 0355-9874.  
PUB. COUNTRY: Finland  
DOCUMENT TYPE: (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199402  
ENTRY DATE: Entered STN: 19940312  
Last Updated on STN: 19970203  
Entered Medline: 19940224

## ABSTRACT:

The clinical efficacy, cardiovascular complications and mortality of polyestradiol phosphate (PEP) 160 mg/month i.m. were compared with the luteinizing hormone releasing hormone (LHRH) analog, buserelin, in a prospective, randomised multicentre study including 147 patients with prostatic cancer. The cumulative non-progression rate at three years was 0.53 in the PEP group and 0.70 in the LHRH group. The mortality from cardiovascular diseases was the same in the two treatment groups. The parenterally given PEP was not associated with an increased risk of cardiovascular complications. The dosage of PEP 160 mg monthly seems, however, to be insufficient in the treatment of prostatic cancer.

## CONTROLLED TERM:

Check Tags: Male

\*Adenocarcinoma: DT, drug therapy

Adenocarcinoma: EP, epidemiology

Aged

Buserelin: AD, administration &amp; dosage

**Buserelin: AE, adverse effects**

\*Buserelin: TU, therapeutic use

\*Cardiovascular Diseases: CI, chemically induced

Cardiovascular Diseases: EP, epidemiology

Comparative Study

Estradiol: AD, administration &amp; dosage

Estradiol: AE, adverse effects

**\*Estradiol: AA, analogs & derivatives**

Estradiol: TU, therapeutic use

Estradiol Congeners: AD, administration &amp; dosage

Estradiol Congeners: AE, adverse effects

Estradiol Congeners: TU, therapeutic use

Finland: EP, epidemiology

Humans

Prospective Studies

\*Prostatic Neoplasms: DT, drug therapy

Prostatic Neoplasms: EP, epidemiology

Research Support, Non-U.S. Gov't

CAS REGISTRY NO.: 28014-46-2 (polyestradiol phosphate); 50-28-2 (Estradiol);  
57982-77-1 (Buserelin)

CHEMICAL NAME: 0 (Estradiol Congeners)

L169 ANSWER 15 OF 41 DRUGU COPYRIGHT 2006 THE THOMSON CORP on STN DUPLICATE

3

ACCESSION NUMBER: 1992-49273 DRUGU T S E

Searched by Barb O'Bryen, STIC 2-2518

TITLE: A Case of Hidradenitis Suppurativa Treated with  
**Gonadotropin-Releasing Hormone**  
 Agonist and by Total Abdominal Hysterectomy with Bilateral  
 Salpingo-Oophorectomy.

AUTHOR: Bogers J W; Minderhoud Bassie W; Huikeshoven F J M

LOCATION: Rotterdam, Netherlands

SOURCE: Am.J.Obstet.Gynecol. (167, No. 2, 517-18, 1992) 2 Ref.  
 CODEN: AJOGAH ISSN: 0002-9378

AVAIL. OF DOC.: Department of Obstetrics and Gynecology, AZR-Dijkzigt, Dr.  
 Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.  
 (F.J.M.H.).

LANGUAGE: English

DOCUMENT TYPE: Journal

## ABSTRACT:

A case of hidradenitis suppurativa (HS) treated successfully with buserelin acetate (BU) and by total abdominal hysterectomy and bilateral salpingo-oophorectomy is reported. Prior unsuccessful treatment included antibacterial drugs, isotretinoin, surgery (full-thickness skin excision and skinning vulvectomy), oral contraceptives, cyproterone acetate, tamoxifen acetate, p.o. progestogens and medroxyprogesterone acetate depot. BU induced disease regression, with mild vasomotor and other signs of estrogen deprivation. Addition of estradiol valerate did not alter disease remission. Surgical treatment was then carried out followed by estradiol valerate therapy. 6 Mth afterwards the pt was without complaint.

SECTION HEADING: T Therapeutics  
 S Adverse Effects  
 E Endocrinology

CLASSIF. CODE: 15 Drugs in Fertility  
 35 Adverse Reactions  
 49 Peptide Hormones

CONTROLLED TERM:  
 [01] BUSERELIN \*TR; BUSERELIN \*AE; HIDRADENITIS \*TR;  
 SUPPURATIVE \*TR; FLUSHING \*AE;  
 ESTRADIOL-VALERATE \*RC; HYSTERECTOMY \*FT;  
 SALPINGO-OVARIECTOMY \*FT; CASE-HISTORY \*FT; IN-VIVO \*FT;  
 LULIBERIN-AGONIST \*FT; SURGERY \*FT; CASES \*FT;  
 RELEASING-FACTOR \*FT; RELEASING-FACTORS  
 \*FT; LULIBERIN-AGONISTS \*FT; BUSERELIN \*RN; TR \*FT;  
 AE \*FT

CAS REGISTRY NO.: 57982-77-1

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

L169 ANSWER 16 OF 41 DRUGU COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 1996-13640 DRUGU T E S

TITLE: High bone density in hyperandrogenic women: effect of  
**gonadotropin-releasing hormone**  
 agonist alone or in conjunction with estrogen-progestin  
 replacement.

AUTHOR: Simberg N; Tiitinen A; Silfast A; Viinikka L; Ylikorkala O

LOCATION: Helsinki; Espoo, Fin.

SOURCE: J.Clin.Endocrinol.Metab. (81, No. 2, 646-51, 1996) 4 Fig. 2  
 Tab. 43 Ref.

CODEN: JCEMAZ ISSN: 0021-972X

AVAIL. OF DOC.: Department of Obstetrics and Gynecology, Helsinki University

Central Hospital, FIN-00290 Helsinki, Finland.  
LANGUAGE: English  
DOCUMENT TYPE: Journal

## ABSTRACT:

In a randomized, follow-up study of 20 hirsute women with ovarian hyperandrogenism, showing greater bone mineral density (BMD) than 19 age-matched normal controls, long-term goserelin (Zoladex depot, Zeneca) treatment resulted in a decrease of BMD which was regained after cessation of treatment, or was attenuated in those randomized to receive added estradiol valerate/medroxyprogesterone acetate (HRT, Divina, Orion). Urinary collagen pyridinoline (PY), deoxy-PY cross-links and hydroxyproline (HP) output (markers of bone resorption) increased after short-term GnRF treatment, although BMD and serum levels of collagen type I telopeptide and bone-specific alkaline phosphatase (AP) were not changed. Early changes in serum telopeptide and urinary PY and deoxy-PY were correlated with later decreases in femoral neck BMD.

SECTION HEADING: T Therapeutics  
E Endocrinology  
S Adverse Effects

CLASSIF. CODE: 24 Bones and Joints  
35 Adverse Reactions  
47 Sex Hormones  
49 Peptide Hormones  
64 Clinical Trials

## CONTROLLED TERM:

HYPERANDROGENISM \*TR; OVARY-DISEASE \*TR; HIRSUTISM \*TR; CASES \*FT; HUMAN \*FT; IN-VIVO \*FT; RANDOM \*FT; BONE \*FT; CLIN.TRIAL \*FT

[01] GOSERELIN \*TR; ZOLADEX \*TR; GOSERELIN \*AE; ZOLADEX \*AE; ZENECA \*FT; OSTEOPATHY \*AE; GOSERELIN \*RN; DEPOT \*FT; LULIBERIN-AGONIST \*FT; PHARM.PREP. \*FT; RELEASING-FACTOR \*FT; RELEASING-FACTORS \*FT; LULIBERIN-AGONISTS \*FT; TR \*FT; AE \*FT

CAS REGISTRY NO.: 65807-02-5

[02] ESTRADIOL-VALERATE \*TR; DIVINA \*TR; ORION \*FT; OSTEOPATHY \*TR; ESTRADIOV \*RN; ESTROGEN \*FT; COMB.PREP. \*FT; ESTROGENS \*FT; TR \*FT

CAS REGISTRY NO.: 979-32-8

[03] MEDROXYPROGESTERONE-ACETATE \*TR; DIVINA \*TR; ORION \*FT; OSTEOPATHY \*TR; MEDOXPRAC \*RN; PROGESTOGEN \*FT; COMB.PREP. \*FT; PROGESTOGENS \*FT; TR \*FT

CAS REGISTRY NO.: 71-58-9

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

L169 ANSWER 17 OF 41 DRUGU COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 1995-44271 DRUGU T E S

TITLE: Steroidal and nonsteroidal "add-back" therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient.

AUTHOR: Surrey E S

CORPORATE SOURCE: Univ.California

LOCATION: Beverly Hills; Los Angeles, Cal., USA

SOURCE: Fertil.Steril. (64, No. 4, 673-85, 1995) 3 Fig. 6 Tab. 87

## Ref.

CODEN: FESTAS ISSN: 0015-0282  
 AVAIL. OF DOC.: Center for Reproductive Medicine and Surgery, 9675 Brighton  
 Way, Suite 420, Beverly Hills, California 90210, U.S.A.  
 LANGUAGE: English  
 DOCUMENT TYPE: Journal

## ABSTRACT:

The use of steroidal and non-steroidal add-back therapy to reduce the hypoestrogenic side-effects of long-term GnRF agonists in gynecologic patients is reviewed. The **cardiovascular** risks, vasomotor symptoms and effects on bone mineral density (BMD) of long-term GnRF therapy are described. The rationale for add-back therapy with estrogens, progestogens and other agents is discussed with reference to clinical studies of conjugated equine estrogens (CEE), estropipate, estradiol (E2), E2 valerate, medroxyprogesterone acetate (MPA), norethindrone, norgestrel, norethisterone, sodium etidronate and calcium carbonate, salmon calcitonin and tamoxifen in patients taking long-term goserelin acetate, Decapeptyl, nafarelin acetate, buserelin acetate, histrelin acetate and leuporelin.

SECTION HEADING: T Therapeutics  
 E Endocrinology  
 S Adverse Effects

CLASSIF. CODE: 15 Drugs in Fertility  
 35 Adverse Reactions  
 47 Sex Hormones  
 49 Peptide Hormones  
 64 Clinical Trials  
 69 Reviews

## CONTROLLED TERM:

GYNECOLOGY \*TR; UTERUS-DISEASE \*TR; VASCULAR-DISEASE \*  
**AE**; OSTEOPOROSIS \***AE**; OSTEOPOROSIS \*TR;  
 VASCULAR-DISEASE \*TR; OSTEOPATHY \***AE**; OSTEOPATHY  
 \*TR; CASES \*FT; REVIEW \*FT; IN-VIVO \*FT; ESTROGEN \*FT;  
 PROGESTOGEN \*FT; LULIBERIN-AGONIST \*FT; **RELEASING-FACTOR**  
 \*FT  
 [01] MAIN-TOPIC \*FT; ESTROGENS \*FT; PROGESTOGENS \*FT;  
 LULIBERIN-AGONISTS \*FT; COMB. \*FT; CLIN.TRIAL \*FT;  
**RELEASING-FACTORS** \*FT; TR \*FT; **AE** \*FT  
 [02] ENDOMETRIOSIS \*TR; LEIOMYOMA \*TR; HIRSUTISM \*TR;  
 PREMENSTRUAL-TENSION \*TR; GYNECOLOGY \*TR; NEOPLASM \*TR;  
 MENTAL-DISORDER \*TR; MENSTRUATION \*TR; LEUPRORELIN \*  
**AE**; LEUPRORELIN \*TR; NAFARELIN \***AE**;  
 TRIPTORELIN \***AE**; DECAPEPTYL \***AE**;  
 DECAPEPTYL \***AE**; BUSERELIN \***AE**; GOSERELIN  
 \***AE**; MEDROXYPROGESTERONE-ACETATE \*TR;  
 ESTROGEN-CONJUGATED \*TR; ESTROPIPATE \*TR; NORETHISTERONE \*TR;  
 ESTRADIOL \*TR; **ESTRADIOL-VALERATE** \*TR; NORGESTREL  
 \*TR; NORETHISTERONE \*TR; GOSERELIN \*TR; TRIPTORELIN \*TR;  
 DECAPEPTYL \*TR; DECAPEPTYL \*TR; BUSERELIN \*TR; HISTRELIN \*TR;  
 NORETHISTERONE \***AE**; MEDROXYPROGESTERONE-ACETATE \*  
**AE**; ETIDRONATE \*TR; CALCIUM-CARBONATE \*TR; CALCITONIN  
 \*TR; TAMOXIFEN \*TR; TR \*FT; **AE** \*FT  
 FIELD AVAIL.: AB; LA; CT  
 FILE SEGMENT: Literature

ACCESSION NUMBER: 1994-32331 DRUGU T E S  
TITLE: Menstrual asthma: use of a **gonadotropin-releasing hormone** analog for the treatment of cyclic aggravation of bronchial asthma.  
AUTHOR: Blumenfeld Z; Bentur L; Yoffe N; Alroy G; Rubin A H E  
CORPORATE SOURCE: Inst.Technol.Haifa  
LOCATION: Haifa, Israel  
SOURCE: Fertil.Steril. (62, No. 1, 197-200, 1994) 1 Tab. 6 Ref.  
CODEN: FESTAS ISSN: 0015-0282  
AVAIL. OF DOC.: No Reprint Address  
LANGUAGE: English  
DOCUMENT TYPE: Journal

## ABSTRACT:

I.m. depot triptorelin (Decapeptyl CR, Ferring) treatment was successfully used to treat severe cyclic asthma during ovulation and menstruation. The side-effects were amenorrhea and hot flushes. The patient also received p.o. prednisone, theophylline, inhaled beclometasone dipropionate (Becotide, Glaxo) and inhaled salbutamol (Ventolin, Glaxo), and cimetidine (Cimetag, Teva) for a peptic ulcer. Sequential hormone replacement with estradiol valerate and norgestrel (Progyluton, Schering-Berlin) aggravated respiratory symptoms, but low-dose estrogen (Premarin, Dexon) plus medroxyprogesterone acetate (Aragest, Dexon), to prevent osteoporosis, was better tolerated.

SECTION HEADING: T Therapeutics  
E Endocrinology  
S Adverse Effects

CLASSIF. CODE: 15 Drugs in Fertility  
33 Respiratory  
35 Adverse Reactions  
47 Sex Hormones  
49 Peptide Hormones

## CONTROLLED TERM:

[01]

PREDNISONE \*RC; THEOPHYLLINE \*RC; BECLOMETASONE-DIPROPIONATE \*RC; BECOTIDE \*RC; SALBUTAMOL \*RC; VENTOLIN \*RC; CIMETIDINE \*RC; CASE-HISTORY \*FT; IN-VIVO \*FT; CASES \*FT  
TRIPTORELIN \*TR; DECAPEPTYL \*TR; TRIPTORELIN \*AE;  
DECAPEPTYL \*AE; FERRING \*FT; ASTHMA \*TR; FLUSHING \*  
AE; AMENORRHEA \*AE; PNEUMOPATHY \*TR;  
GYNECOLOGY \*AE; MENSTRUATION \*AE;  
WY-42462 \*RN; LULIBERIN-AGONIST \*FT; I.M. \*FT; DEPOT \*FT;  
MENSTRUATION \*FT; OVULATION \*FT; **RELEASING-FACTOR** \*FT; INJECTION \*FT; PHARM.PREP. \*FT; OVARY \*FT;  
**RELEASING-FACTORS** \*FT; LULIBERIN-AGONISTS \*FT; TR \*FT; AE \*FT

CAS REGISTRY NO.: 57773-63-4

[02]

**ESTRADIOL-VALERATE** \*TR; ESTRADIOL-VALERATE \*  
AE; PROGYLUTON \*TR; PROGYLUTON \*AE;  
SCHERING-BERLIN \*FT; ASTHMA \*AE; PNEUMOPATHY \*  
AE; ESTRADIOV \*RN; COMB. \*FT; ESTROGEN \*FT; ESTROGENS \*FT; TR \*FT; AE \*FT

CAS REGISTRY NO.: 979-32-8

[03]

NORGESTREL \*TR; NORGESTREL \*AE; PROGYLUTON \*TR;  
PROGYLUTON \*AE; SCHERING-BERLIN \*FT; ASTHMA \*  
AE; PNEUMOPATHY \*AE; NORGESTRE \*RN; COMB. \*FT; PROGESTOGEN \*FT; PROGESTOGENS \*FT; TR \*FT; AE \*FT

CAS REGISTRY NO.: 6533-00-2  
[04] MEDROXYPROGESTERONE-ACETATE \*TR; ARAGEST \*TR; OSTEOPOROSIS \*TR; OSTEOPATHY \*TR; MEDOXPRAC \*RN; DEXON \*FT; PROGESTOGEN \*FT; PROPHYLAXIS \*FT; PROGESTOGENS \*FT; TR \*FT

CAS REGISTRY NO.: 71-58-9  
[05] ESTROGEN-CONJUGATED \*TR; PREMARIN \*TR; OSTEOPOROSIS \*TR; OSTEOPATHY \*TR; ESTROCONJ \*RN; DEXON \*FT; PROPHYLAXIS \*FT; ESTROGEN \*FT; ESTROGENS \*FT; TR \*FT

CAS REGISTRY NO.: 12126-59-9  
FIELD AVAIL.: AB; LA; CT  
FILE SEGMENT: Literature

L169 ANSWER 19 OF 41 DRUGU COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 1994-42641 DRUGU T E S

TITLE: Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism.

AUTHOR: Tiitinen A; Simberg N; Stenman U H; Ylikorkala O

CORPORATE SOURCE: Univ.Helsinki

LOCATION: Helsinki, Finland

SOURCE: J.Clin.Endocrinol.Metab. (79, No. 2, 447-51, 19 2 Fig. 2 Tab. 29 Ref.

CODEN: JCEMAZ ISSN: 0021-972X

AVAIL. OF DOC.: Department of Obstetrics and Gynecology, Helsinki University Central Hospital, FIN-00290 Helsinki, Finland.

LANGUAGE: English

DOCUMENT TYPE: Journal

#### ABSTRACT:

Estrogen replacement with estradiol valerate plus medroxyprogesterone acetate (EV + MA: Divina; Orion) did not potentiate the therapeutic effect of androgen suppression with s.c. implanted goserelin (GS: Zoladex; Zeneca) among 20 hirsute women (18 with polycystic ovary: PCO) during a randomized parallel-group trial. Estrogen replacement restored serum estradiol (E2) levels and increased sex hormone-binding globulin (SHBG) but did not decrease free testosterone (TS) levels. Estrogen replacement abolished or alleviated the hypoestrogenic vasomotor symptoms caused by GS, but itself caused bleeding, headache and premenstrual tension. Thus, estrogenic alleviation of ovarian hyperandrogenism may involve suppressing gonadotropins rather than increasing SHBG.

SECTION HEADING: T Therapeutics  
E Endocrinology  
S Adverse Effects

CLASSIF. CODE: 35 Adverse Reactions  
47 Sex Hormones  
49 Peptide Hormones  
64 Clinical Trials

#### CONTROLLED TERM:

HIRSUTISM \*TR; HYPERANDROGENISM \*TR; POLYCYSTIC-OVARY \*TR;  
OVARY-DISEASE \*TR; CASES \*FT; IN-VIVO \*FT;  
CONCOMITANT-DISEASE \*FT; RANDOM \*FT; CLIN.TRIAL \*FT;  
LONG-TERM-THERAPY \*FT  
[01] GOSERELIN \*TR; ZOLADEX \*TR; GOSERELIN \*AE; ZOLADEX \*AE;  
HYPOESTROGENIC \*AE; VASOMOTOR \*AE; FLUSHING \*AE; SWEATING \*AE;  
LIBIDO \*AE; DEPRESSION \*AE; SWEAT \*

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2427731 AA 20020510 CA 2001-2427731 20011026  
 AU 2001095359 A5 20020515 AU 2001-95359 20011026  
 EP 1330257 A1 20030730 EP 2001-975948 20011026  
 EP 1330257 B1 20050831  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 BR 2001015067 A 20040406 BR 2001-15067 20011026  
 JP 2004512369 T2 20040422 JP 2002-538955 20011026  
 AT 303156 E 20050915 AT 2001-975948 20011026  
 US 2004023878 A1 20040205 US 2003-415519 20030430  
 PRIORITY APPLN. INFO.: EP 2000-811011 A 20001030  
 WO 2001-CH636 W 20011026

ED Entered STN: 12 May 2002

AB The use of at least one GnRH analog for the preparation of a medicament for the prevention and/or treatment of side effects of ovariectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed. The GnRH analog is selected from the group consisting of deslorelin acetate, goserelin acetate, nafarelin acetate, buserelin acetate, triptorelin acetate, gonadorelin acetate, leuprolid acetate, danazol, Cetorelix or mixts. thereof. The medicament can further comprise another active substance selected from the group consisting of an estrogenic agent, a partial estrogenic agent, a progestational agent, or mixts. thereof. The addnl. active ingredient can also be an  $\alpha$ -adrenergic agonist, a  $\beta$ -adrenergic receptor blocking agent, a cholinergic receptor blocking compound, a cholinergic receptor stimulating drug, a smooth muscle relaxant, a nitric oxide synthase substrate, a nitric oxide donor, or mixts. thereof.

IT 9034-40-6D, GnRH, analogs

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RN 9034-40-6 CAPLUS

CN Luteinizing hormone-releasing factor (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 979-32-8, Estradiol valerate


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RN 979-32-8 CAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L169 ANSWER 3 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:99929 CAPLUS

DOCUMENT NUMBER: 144:177480

TITLE: Pharmaceutical-encapsulated nanoparticles for transmucosal absorption

INVENTOR(S): Mizushima, Hiroshi; Ueno, Yukio; Udagawa, Masae; Kameyama, Mieko; Suzuki, Yoshiki; Sekine, Junzo

PATENT ASSIGNEE(S): Ltt Biopharma Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006028031	A2	20060202	JP 2004-205259	20040712
PRIORITY APPLN. INFO.:			JP 2004-205259	20040712

ED Entered STN: 03 Feb 2006

AB Title nanoparticles contain divalent metal salts, hydrophobic substances, and/or sugars, and pharmaceuticals encapsulated in cores having CO<sub>2</sub>H on the surface. Thus, rhodamine-encapsulated, carboxylated polystyrene nanoparticles were treated with CaCl<sub>2</sub> to give secondary nanoparticles with particle size 50 nm, which were almost completely absorbed from jejunum in mice.

IT 979-32-8, Estradiol valerate 9034-40-6, Luteinizing hormone-releasing hormone


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (transmucosal carboxylated nanoparticles with high drug bioavailability)

RN 979-32-8 CAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 9034-40-6 CAPLUS  
 CN Luteinizing hormone-releasing factor (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L169 ANSWER 4 OF 41 USPATFULL on STN  
 ACCESSION NUMBER: 2004:31736 USPATFULL  
 TITLE: GnRh analogues for treatment of urinary incontinence  
 INVENTOR(S): Arnold, Susi, UNITED STATES  
 Reichler, Iris, Z?uuml;rich, SWITZERLAND  
 Hubler, Madeleine, Wernetshausen, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023878	A1	20040205
APPLICATION INFO.:	US 2003-415519	A1	20030430 (10)
	WO 2001-CH636		20011026
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROTHWELL, FIGG, ERNST & MANBECK, P.C., 1425 K STREET, N.W., SUITE 800, WASHINGTON, DC, 20005		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	826		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of at least one GnRH analogue for the preparation of a medicament for the prevention and/or treatment of side effects of ovariectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 9034-40-6D, GnRH, analogs  
 (GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)


RN 9034-40-6 USPATFULL  
 CN Luteinizing hormone-releasing factor (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

IT 979-32-8, Estradiol valerate  
 (GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RN 979-32-8 USPATFULL  
 CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



L169 ANSWER 5 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2003:129817 USPATFULL

TITLE: Methods and compositions for disrupting the epithelial barrier function

INVENTOR(S): Elias, Peter M., Muir Beach, CA, United States  
 Feingold, Kenneth R., Saan Rafael, CA, United States  
 Holleran, Walter M., San Francisco, CA, United States

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)  
 Cellegy Pharmaceuticals, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6562606	B1	20030513
APPLICATION INFO.:	US 2000-608568		20000630 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-58401, filed on 9 Apr 1998, now patented, Pat. No. US 6190894 Continuation of Ser. No. US 1996-733712, filed on 23 Oct 1996, now abandoned Continuation-in-part of Ser. No. US 1994-260559, filed on 16 Jun 1994, now abandoned Continuation-in-part of Ser. No. US 1993-33811, filed on 19 Mar 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Lankford, Jr., Leon B.		
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	1114		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB A method for disrupting epithelial barrier function in a host in need of the topical administration of a physiologically active substance which comprises applying to the epithelium of the host, barrier-disrupting amount of at least one agent selected from the group consisting of an inhibitor of ceramide synthesis, inhibitor of acylceramide synthesis, inhibitor of glucosylceramide synthesis, and inhibitor of sphingomyelin

synthesis, an inhibitor of fatty acid synthesis, an inhibitor of cholesterol synthesis, a degradation enzyme of ceramides, acylceramide, glucosylceramides, sphingomyelin, an inhibitor of phospholipid, glycosphingolipid, including glucosylceramide, acylceramide or sphingomyelin degradation, and both inhibitors and stimulators of metabolic enzymes of free fatty acids, ceramide, and cholesterol, as well as a topical composition useful therefor are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 979-32-8, Estradiol valerate 9034-40-6, Lhrh

(permeation enhancement of topical pharmaceuticals by inducing phase separation of epithelial lipid bilayers)

RN 979-32-8 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9034-40-6 USPATFULL

CN Luteinizing hormone-releasing factor (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L169 ANSWER 6 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2001:25659 USPATFULL

TITLE: Method and compositions for disrupting the epithelial barrier function

INVENTOR(S): Thornfeldt, Carl R., Nampa, ID, United States  
 Elias, Peter M., Muir Beach, CA, United States  
 Feingold, Kenneth R., Saan Rafael, CA, United States  
 Holleran, Walter M., San Francisco, CA, United States  
 PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)  
 Cellegy Pharmaceuticals, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6190894	B1	20010220
APPLICATION INFO.:	US 1998-58401		19980409 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-733712, filed on 23 Oct 1996, now abandoned Continuation-in-part of Ser. No. US 1994-260559, filed on 16 Jun 1994, now abandoned Continuation-in-part of Ser. No. US 1993-33811, filed on 19 Mar 1993, now abandoned		

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Lankford, Jr., Leon B.  
 LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP  
 NUMBER OF CLAIMS: 82  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 9 Drawing Figure(s); 5 Drawing Page(s)  
 LINE COUNT: 1469

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for disrupting epithelial barrier function in a host in need of the topical administration of a physiologically active substance which comprises applying to the epithelium of the host, barrier-disrupting amount of at least one agent selected from the group consisting of an inhibitor of ceramide synthesis, inhibitor of acylceramide synthesis, inhibitor of glucosylceramide synthesis, and inhibitor of sphingomyelin synthesis, an inhibitor of fatty acid synthesis, an inhibitor of cholesterol synthesis, a degradation enzyme of ceramides, acylceramide, glucosylceramides, sphingomyelin, an inhibitor of phospholipid, glycosphingolipid, including glucosylceramide, acylceramide or sphingomyelin degradation, and both inhibitors and stimulators of metabolic enzymes of free fatty acids, ceramide, and cholesterol, as well as a topical composition useful therefore are disclosed.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 979-32-8, Estradiol valerate 9034-40-6, Lhrh  
 (permeation enhancement of topical pharmaceuticals by inducing phase separation of epithelial lipid bilayers)

RN 979-32-8 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9034-40-6 USPATFULL

CN Luteinizing hormone-releasing factor (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L169 ANSWER 7 OF 41 USPATFULL on STN

ACCESSION NUMBER: 94:73073 USPATFULL

TITLE: Method and formulations for use in treating benign gynecological disorders

INVENTOR(S): Pike, Malcolm C., Long Beach, CA, United States  
 Spicer, Darcy V., Pasadena, CA, United States

PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA,

United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5340585		19940823
APPLICATION INFO.:	US 1993-62883		19930517 (8)
DISCLAIMER DATE:	20100518		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-952513, filed on 3 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-684612, filed on 12 Apr 1991, now patented, Pat. No. US 5211952		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Robbins, Berliner & Carson		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
LINE COUNT:	901		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods which are effective to treat benign gynecological disorders for extended periods of time in women in who the risk of endometrial stimulation is minimized or absent are described, wherein an effective amount of a gonadotropin hormone releasing hormone composition and an effective amount of an estrogenic composition are provided over a period of time, optionally with addition of an androgenic composition.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 979-32-8, Estradiol valerate 9034-40-6, Gonadotropin releasing hormone  
(GnRH composition and estrogenic composition combination for treatment of benign gynecol. disorders)

RN 979-32-8 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9034-40-6 USPATFULL

CN Luteinizing hormone-releasing factor (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L169 ANSWER 8 OF 41 MEDLINE on STN DUPLICATE 4  
 ACCESSION NUMBER: 92103021 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 1836959  
 TITLE: The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding.  
 AUTHOR: Thomas E J; Okuda K J; Thomas N M  
 CORPORATE SOURCE: Department of Obstetrics and Gynaecology, Newcastle General Hospital, Newcastle-upon-Tyne.  
 SOURCE: British journal of obstetrics and gynaecology, (1991 Nov) Vol. 98, No. 11, pp. 1155-9.  
 Journal code: 7503752. ISSN: 0306-5456.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
 ENTRY MONTH: 199202  
 ENTRY DATE: Entered STN: 19920302  
 Last Updated on STN: 19920302  
 Entered Medline: 19920212

## ABSTRACT:

OBJECTIVE--To observe if a combination of a depot GnRH agonist and cyclical hormone replacement therapy decreases menstrual blood loss. DESIGN--An open, observational study comparing the objective assessment of menstrual blood loss before, during and after 3 months treatment. SUBJECTS--20 women with a subjective complaint of heavy menstrual loss in whom no cause could be discovered. INTERVENTIONS--Each woman received 3 months of depot goserelin (Zoladex) combined with cyclical hormone replacement therapy (Cyclo-Progynova, 1 mg). Menstrual loss and symptoms were assessed before, throughout and after the study. MAIN OUTCOME MEASURES--Changes in objective and subjective assessments of menstrual blood loss and the acceptability of the treatment. RESULTS--The median pretreatment menstrual loss was 68 ml (range 23-397). Only 8 (40%) of the patients had a loss exceeding 80 ml per period. The median blood loss was 30 ml, 16 ml, and 17 ml in the three treatment cycles (P less than 0.001 Wilcoxon rank sum for the third cycle). There was a significant decrease in the median length of menstruation (P less than 0.001) and the number of towels or tampons (P less than 0.01) used per period in the third treatment cycle. There was a significant decrease (P less than 0.005) in the number of women complaining of dysmenorrhoea, premenstrual symptoms, flooding and the passage of clots. Seventeen patients experienced hot flushes. Eighteen of the 20 patients were completely satisfied with the treatment and would have been happy to continue with it for longer than 12 months. CONCLUSIONS--The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy is a successful and acceptable treatment of dysfunctional uterine bleeding.

CONTROLLED TERM: Check Tags: Female  
 Adult  
 Buserelin: AD, administration & dosage  
 Buserelin: AE, adverse effects  
 \*Buserelin: AA, analogs & derivatives  
 Buserelin: TU, therapeutic use  
 Drug Therapy, Combination  
 Estradiol: AD, administration & dosage  
 Estradiol: AE, adverse effects  
 \*Estradiol: AA, analogs & derivatives  
 Estradiol: TU, therapeutic use  
 Goserelin

Humans  
Injections, Subcutaneous  
\*Menorrhagia: DT, drug therapy  
Middle Aged  
Prospective Studies  
Research Support, Non-U.S. Gov't  
Treatment Outcome

CAS REGISTRY NO.: 50-28-2 (Estradiol); 57982-77-1 (Buserelin); 65807-02-5 (Goserelin); 979-32-8 (estradiol valerate)

L169 ANSWER 9 OF 41 MEDLINE on STN

ACCESSION NUMBER: 2003111427 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12623503

TITLE: Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study Number 5.

AUTHOR: Hedlund Per Olov; Ala-Opas Martti; Brekkan Einar; Damberg Jan Erik; Damberg Lena; Hagerman Inger; Haukaas Svein; Henriksson Peter; Iversen Peter; Pousette Ake; Rasmussen Finn; Salo Jaakko; Vaage Sigmund; Varenhorst Eberhard

CORPORATE SOURCE: Department of Urology, Karolinska Hospital, Stockholm, Sweden. (Scandinavian Prostatic Cancer Group).  
krea@beta.telenordia.se

SOURCE: Scandinavian journal of urology and nephrology, (2002) Vol. 36, No. 6, pp. 405-13.  
Journal code: 0114501. ISSN: 0036-5599.

PUB. COUNTRY: Sweden

DOCUMENT TYPE: (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200305

ENTRY DATE: Entered STN: 20030308  
Last Updated on STN: 20030517  
Entered Medline: 20030516

## ABSTRACT:

OBJECTIVE: In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it influenced liver metabolism only marginally and had very few cardiovascular side-effects. In this study high-dose polyestradiol phosphate (PEP; Estradurin) was compared to combined androgen deprivation (CAD) for the treatment of patients with metastatic prostate cancer. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular side-effects. MATERIAL AND METHODS: A total of 917 patients with T0-4, NX, M1, G1-3 prostate cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were randomized to treatment with either PEP 240 mg i.m. twice a month for 2 months and thereafter once a month or flutamide (Eulexin) 250 mg t.i.d. per os in combination with either triptorelin (Decapeptyl) 3.75 mg per month i.m. or, on an optional basis, bilateral orchidectomy. A total of 556 patients had died at the time of this analysis. RESULTS: There was no difference between the treatment arms in terms of time to biochemical or clinical progression and overall or disease-specific survival. There was no increase in cardiovascular mortality in the PEP arm. The PEP group had a higher prevalence of cardiovascular disease prior to the study and a significantly higher incidence of non-fatal ischemic heart events and heart decompensation during the study. CONCLUSIONS: PEP has an equal anticancer efficacy to CAD and does not increase cardiovascular mortality. Final evaluation of cardiovascular morbidity is awaiting further analysis and follow-up. PEP is considerably cheaper than CAD.

CONTROLLED TERM: Check Tags: Male  
 Aged  
 \*Androgen Antagonists: AD, administration & dosage  
 Androgen Antagonists: AE, adverse effects  
 Antineoplastic Agents, Hormonal: AD, administration & dosage  
 Antineoplastic Agents, Hormonal: AE, adverse effects  
 Cardiovascular Diseases: CI, chemically induced  
 Comparative Study  
 Disease Progression  
 Drug Therapy, Combination  
 \*Estradiol: AD, administration & dosage  
 \*Estradiol: AE, adverse effects  
 \*Estradiol: AA, analogs & derivatives  
 \*Estradiol Congeners: AD, administration & dosage  
 \*Estradiol Congeners: AE, adverse effects  
 Flutamide: AD, administration & dosage  
 Flutamide: AE, adverse effects  
 Humans  
 Injections, Intravenous  
 \*Orchiectomy  
 Prostatic Neoplasms: MO, mortality  
 \*Prostatic Neoplasms: TH, therapy  
 Research Support, Non-U.S. Gov't  
 Triptorelin: AD, administration & dosage  
 Triptorelin: AE, adverse effects

CAS REGISTRY NO.: 13311-84-7 (Flutamide); 28014-46-2 (polyestradiol phosphate); 50-28-2 (Estradiol); 57773-63-4 (Triptorelin)

CHEMICAL NAME: 0 (Androgen Antagonists); 0 (Antineoplastic Agents, Hormonal); 0 (Estradiol Congeners)

L169 ANSWER 10 OF 41 MEDLINE on STN

ACCESSION NUMBER: 2000165076 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10699602

TITLE: Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.

AUTHOR: Hedlund P O; Henriksson P

CORPORATE SOURCE: Department of Urology, Karolinska Hospital, Stockholm, Sweden.

SOURCE: Urology, (2000 Mar) Vol. 55, No. 3, pp. 328-33.  
 Journal code: 0366151. E-ISSN: 1527-9995.

PUB. COUNTRY: United States

DOCUMENT TYPE: (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200003

ENTRY DATE: Entered STN: 20000413  
 Last Updated on STN: 20010521  
 Entered Medline: 20000331

ABSTRACT:

OBJECTIVES: To compare the effect on overall survival of total androgen ablation (TAA) with that of parenteral estrogen and to pay special attention to cardiovascular mortality. TAA (orchiectomy or a luteinizing hormone-releasing hormone analogue combined with an antiandrogen) has been proposed as superior to other endocrine treatments for patients with prostate carcinoma. Recently, the use of parenteral estrogen has been suggested to reduce or even negate the



well-known cardiovascular side effects of oral estrogens. **METHODS:** Nine hundred fifteen patients were randomized to intramuscular injections of 240 mg polyestradiol phosphate (PEP) every second week for the first 8 weeks (5 doses) followed by a maintenance dose of 240 mg every month (n = 458) or to bilateral orchiectomy or triptorelin 3.75 mg every month combined with the antiandrogen flutamide 250 mg three times daily. The choice between orchiectomy and triptorelin was at the discretion of the clinician and patient. Patients were stratified according to performance status, presence of cardiovascular disease, and alkaline phosphatase level. An observer totally unaware of the treatment given classified all deceased patients. **RESULTS:** At a median follow-up of 18.5 months, no signs of a difference in overall survival were found between TAA and PEP (P < 0.001). Of 458 patients, 266 (58.1%) had died in the PEP group compared with 269 (58.9%) of 457 patients in the TAA group. Within the TAA group, no difference in overall survival existed between patients who had undergone orchiectomy or who were given triptorelin. Furthermore, no differences in cardiovascular mortality were found (3.5% in the PEP group and 3.1% in the TAA group). **CONCLUSIONS:** The current parenteral estrogen regimen seems to be of comparable efficacy and cardiovascular safety as TAA in terms of overall survival. PEP has by far the lowest drug cost and also the lowest cumulative direct costs and thus has the highest cost-effectiveness. We suggest that parenteral estrogen be included as a therapeutic option in the endocrine management of prostate carcinoma.

**CONTROLLED TERM:** Check Tags: Male

Aged

Alkaline Phosphatase: BL, blood

\*Androgen Antagonists: AD, administration & dosage

Androgen Antagonists: AE, adverse effects

\*Antineoplastic Agents, Hormonal: AD, administration & dosage

Antineoplastic Agents, Hormonal: AE, adverse effects

Cardiovascular Diseases: MO, mortality

Comparative Study

Estradiol: AD, administration & dosage

Estradiol: AE, adverse effects

**\*Estradiol: AA, analogs & derivatives**

\*Estradiol Congeners: AD, administration & dosage

Estradiol Congeners: AE, adverse effects

\*Flutamide: AD, administration & dosage

Flutamide: AE, adverse effects

Humans

Injections, Intramuscular

\*Orchiectomy

Prostatic Neoplasms: MO, mortality

\*Prostatic Neoplasms: TH, therapy

Research Support, Non-U.S. Gov't

Survival Rate

\*Triptorelin: AD, administration & dosage

**Triptorelin: AE, adverse effects**

**CAS REGISTRY NO.:** 13311-84-7 (Flutamide); 28014-46-2 (polyestradiol phosphate); 50-28-2 (Estradiol); 57773-63-4 (Triptorelin)

**CHEMICAL NAME:** 0 (Androgen Antagonists); 0 (Antineoplastic Agents, Hormonal); 0 (Estradiol Congeners); EC 3.1.3.1 (Alkaline Phosphatase)

L169 ANSWER 11 OF 41

MEDLINE on STN

ACCESSION NUMBER: 95025705 MEDLINE

DOCUMENT NUMBER: PubMed ID: 7939468

**TITLE:** Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study.

AUTHOR: Lukkarinen O; Kontturi M  
CORPORATE SOURCE: Urological Unit, University of Oulu, Finland.  
SOURCE: Scandinavian journal of urology and nephrology, (1994 Jun)  
Vol. 28, No. 2, pp. 171-8.  
Journal code: 0114501. ISSN: 0036-5599.  
PUB. COUNTRY: Sweden  
DOCUMENT TYPE: (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199410  
ENTRY DATE: Entered STN: 19941222  
Last Updated on STN: 19941222  
Entered Medline: 19941028

## ABSTRACT:

In a prospective, randomized open study, a long-acting LHRH agonist (Zoladex) was compared with polyoestradiol phosphate (Estradurin), both widely used in Finland for palliative treatment of prostatic carcinoma, as regards efficacy and side effects. Of the 236 enrolled patients, 129 were randomized to receive LHRH agonist and 107 to oestrogen treatment. The median follow-up was 25 months. Reduction of prostatic volume was quicker and more effective in the LHRH than in the oestrogen group, and serum testosterone concentrations fell to castration level after 1 month and 1 year, respectively. In locally advanced (M0) and histologically well or moderately differentiated tumours, LHRH agonist therapy was considerably more effective than oestrogen as regards time to progression of the carcinoma, but in metastatic (M1) and histologically poorly differentiated tumours both methods gave similar results. Cardiovascular complications showed equal incidence in both groups. LHRH agonist therapy thus seemed to be more effective than polyoestradiol phosphate against locally advanced prostatic cancer in the doses used.

CONTROLLED TERM: Check Tags: Male  
Aged  
Aged, 80 and over  
Antineoplastic Agents: AE, adverse effects  
\*Antineoplastic Agents: TU, therapeutic use  
Comparative Study  
Estradiol: AE, adverse effects  
\*Estradiol: AA, analogs & derivatives  
Estradiol: TU, therapeutic use  
Goserelin: AE, adverse effects  
\*Goserelin: TU, therapeutic use  
Humans  
Middle Aged  
Prospective Studies  
\*Prostatic Neoplasms: DT, drug therapy  
Testosterone: BL, blood

CAS REGISTRY NO.: 28014-46-2 (polyestradiol phosphate); 50-28-2 (Estradiol);  
58-22-0 (Testosterone); 65807-02-5 (Goserelin)  
CHEMICAL NAME: 0 (Antineoplastic Agents)

L169 ANSWER 12 OF 41 MEDLINE on STN  
ACCESSION NUMBER: 93264361 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8494837  
TITLE: An alternative to hysterectomy? GnRH analogue combined with hormone replacement therapy.  
AUTHOR: Gangar K F; Stones R W; Saunders D; Rogers V; Rae T; Cooper S; Beard R W  
CORPORATE SOURCE: Department of Obstetrics and Gynaecology, St Mary's

ACCESSION NUMBER: 1982:12222175 BIOTECHNO  
TITLE: Effect of cortisol or adrenocorticotrophin on release  
of luteinizing hormone induced by luteinizing  
hormone releasing hormone in the  
dairy heifer  
AUTHOR: Matteri R.L.; Moberg G.P.  
CORPORATE SOURCE: Dept. Anim. Sci., Univ. California, Davis, CA 95616,  
United States.  
SOURCE: Journal of Endocrinology, (1982), 92/1 (141-146)  
CODEN: JOENAK  
DOCUMENT TYPE: Journal; Article  
COUNTRY: United Kingdom  
LANGUAGE: English  
ABSTRACT: During treatment with cortisol or ACTH, dairy heifers  
were given two doses of LH releasing hormone (LH-RH)  
spaced 1.5 h apart. Serum concentrations of cortisol  
and LH were monitored during each treatment. Treatment  
with both ACTH and cortisol raised plasma cortisol  
levels above the respective saline controls ( $P < 0.001$ ).  
Neither treatment affected basal LH concentrations. A  
slight **depression** in LH response was seen in  
the cortisol-treated animals after the first LH-RH  
injection, as shown by a statistically significant  
**depression** at three of the sample times. There  
was no significant difference between treated and  
control LH values after the second LH-RH  
administration. Treatment with ACTH resulted in  
significantly reduced LH values at all sample times  
after both injections of LH-RH.  
CONTROLLED TERM: \*corticotropin; \*dexamethasone; \*estradiol  
valerate; \*gonadorelin;  
\*hydrocortisone; \*hydrocortisone sodium succinate;  
\*luteinizing hormone; \*progesterone; \*tetracosactide;  
drug mixture; luteinizing hormone i 125; animal  
experiment; cattle; endocrine system  
CAS REGISTRY NUMBER: (corticotropin) 11136-52-0, 9002-60-2, 9061-27-2;  
(dexamethasone) 50-02-2; (estradiol  
valerate) 979-32-8; (  
gonadorelin) 33515-09-2, 9034-40-6;  
(hydrocortisone) 50-23-7; (hydrocortisone sodium  
succinate) 125-04-2, 2203-97-6; (luteinizing hormone)  
39341-83-8, 9002-67-9; (progesterone) 57-83-0;  
(tetracosactide) 16960-16-0  
CHEMICAL NAME: Drug Trade Name: delestrogen; solu cortef; adrenomone  
CORPORATE NAME: Drug Manufacturer: sigma, United States; calbiochem,  
United States; squibb, United States; burns biotec,  
United States; upjohn, United States

L169 ANSWER 25 OF 41 IPA COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 97:2070 IPA  
DOCUMENT NUMBER: 34-09283  
TITLE: Needleless implant delivery of gonadotropin  
releasing hormone enhances the calving  
rate of beef cows synchronized with norgestomet and  
estradiol valerate  
AUTHOR: Kesler, D. J.; Favero, R. J.  
CORPORATE SOURCE: Dept. of Animal Sci., Univ. of Illinois, Urbana, IL 61801,  
USA Reprints: 1207 W. Gregory Dr., Urbana, IL 61801, USA  
SOURCE: Drug Development and Industrial Pharmacy (USA), (1997) Vol.

CORPORATE NAME: Drug Manufacturer: Kade Pharmazeutische Fabrik,  
Germany; Serono, Switzerland; Schering AG, Germany

L169 ANSWER 23 OF 41 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN  
ACCESSION NUMBER: 1996:26158636 BIOTECHNO  
TITLE: Premature progesterone elevation does not alter oocyte  
quality in in vitro fertilization  
AUTHOR: Fanchin R.; Righini C.; Olivennes F.; De Ziegler D.;  
Selva J.; Frydman R.  
CORPORATE SOURCE: Dept. of Obstetrics and Gynecology, Hopital Antoine  
Beclere, 157, rue de la Porte de Trivaux, 92141,  
Clamart, France.  
SOURCE: Fertility and Sterility, (1996), 65/6 (1178-1183)  
CODEN: FESTAS ISSN: 0015-0282  
DOCUMENT TYPE: Journal; Article  
COUNTRY: United States  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ABSTRACT: Objective: To clarify whether premature P elevation  
during controlled ovarian hyperstimulation (COH) for  
IVF-ET affects adversely oocyte-embryo quality.  
Design: Controlled clinical study. Patients: We  
studied 102 fertile donors undergoing 106 oocyte  
retrievals and 117 recipients undergoing 162 ET.  
Interventions: Donors underwent COH with a  
time-release GnRH agonist and hMG. All recipients had  
inactive or absent ovaries and were primed with  
E.sub.2 and P. Main Outcome Measures: Measurement of  
LH, P, and E.sub.2; characteristics of COH; cleavage,  
pregnancy, and implantation rates. Results: According  
to donors' plasma P levels on the day of hCG, two  
groups were defined: P ≤ 0.9 ng/mL (conversion factor  
to SI unit, 3.18), group A, and P > 0.9 ng/mL, group  
B. Similar results of cleavage (65% and 72%), clinical  
(30% and 29%), and ongoing pregnancy (20% and 18%),  
and implantation (14% and 15%) rates were observed in  
both groups, respectively. Conclusions: The lack of  
difference in cleavage, pregnancy, and implantation  
rates between both groups suggests that preovulation  
increase in P production does not alter oocyte-embryo  
quality. Hence, the reported **adverse**  
**effects** on IVF outcome of pre-hCG elevation of  
P is likely to reflect an impaired endometrial  
receptivity in the high P group.

CONTROLLED TERM: \*estradiol; \*gonadorelin agonist; \*human  
menopausal gonadotropin; \*progesterone; \*fertilization  
in vitro; \*progesterone release; **estradiol**  
**valerate**; adult; article; female; hormonal  
regulation; human; human cell; human experiment; human  
tissue; implantation; normal human; oocyte maturation;  
ovary hyperstimulation; priority journal; treatment  
outcome

CAS REGISTRY NUMBER: (estradiol) 50-28-2; (human menopausal gonadotropin)  
61489-71-2; (progesterone) 57-83-0; (**estradiol**  
**valerate**) 979-32-8

CHEMICAL NAME: Drug Trade Name: progynova; utrogestan  
CORPORATE NAME: Drug Manufacturer: schering, France; besins iscovesco,  
France; organon, France; takeda, France

L169 ANSWER 24 OF 41 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

COUNTRY: Denmark  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ABSTRACT: Subject. Luteal phase support has been shown in the past to be an essential part of ovarian stimulation protocols, especially the long protocol. It could be shown that hCG is as effective as is progesterone for luteal phase support but hCG is accompanied by a higher rate of complications. Methods. Progesterone can be administered in several routes. The oral, intramuscular (i.m.) and vaginal routes have been chosen frequently in the past. The oral route is ineffective, since progesterone has a low oral bioavailability (<10%), and a high rate of metabolites, which may result in side effects such as somnolence etc. Intramuscular administration provides very high serum levels of progesterone and this route is effective with regard to pregnancy rates. Injection of progesterone, however, is painful and cannot be done by the patient herself. The vaginal route is also effective, progesterone can be administered by the patient herself and progesterone is delivered directly to the uterus, where high levels are achieved (first uterine pass effect). Results. Several studies could show, in the past, that the vaginal administration of progesterone is effective also with regard to the downregulation of uterine contractions. Crinone® 8% Vaginal Gel is especially designed for vaginal use with a special applicator and has to be administered once daily in the morning. It adheres to the vaginal epithelium, and leakage of the gel is substantially reduced as compared to other drugs like capsules or suppositories. Conclusions. Since progesterone is as effective as hCG for luteal phase support but provides a higher safety with regard to ovarian hyperstimulation syndromes, and vaginal progesterone is as effective as intramuscular progesterone, vaginal progesterone should be the standard choice for luteal phase support. Crinone® 8% seems to be the most comfortable way of vaginal administration of progesterone for luteal phase support in IVF cycles.

CONTROLLED TERM: \*ovary hyperstimulation; \*fertilization in vitro; \*progesterone; \*chorionic gonadotropin; luteal phase; drug efficacy; drug bioavailability; drug induced disease; somnolence; drug safety; first pass effect; uterus contraction; gel; human; female; major clinical study; clinical trial; randomized controlled trial; controlled study; adult; article; priority journal; estrogen; estradiol; gonadorelin agonist; gonadorelin antagonist; human menopausal gonadotropin; follitropin; clomifene citrate; utrogest; cetrorelix; gravibinan

CAS REGISTRY NUMBER: (progesterone) 57-83-0; (chorionic gonadotropin) 9002-61-3; (estradiol) 50-28-2; (human menopausal gonadotropin) 61489-71-2; (follitropin) 9002-68-0; (clomifene citrate) 50-41-9; (cetrorelix) 120287-85-6; (gravibinan) 65272-78-8

CHEMICAL NAME: Drug Trade Name: utrogest; crinone; cetrotide; gravibinon

of treatment that has become more established in Western medicine over the last decade. Discussed are the scientific documentation and aspects of acupuncture research, the physiological basis for the use of acupuncture, and evidence for the use of acupuncture in reproductive medicine. We are well aware that there are few well-designed papers on the effectiveness of different treatments in this field. However, we need to adhere to these principles, as we hope, do the readers of the present debate article.

## CONTROLLED TERM:

\*acupuncture; \*infertility therapy; human; clinical trial; nonhuman; safety; infertility; alternative medicine; evidence based medicine; health care cost; physician attitude; medical research; clinical protocol; methodology; needle; psychological aspect; comparative study; validation process; energy; peripheral nervous system function; electrostimulation; analgesia; sympathetic tone; stress; hypothalamus hypophysis adrenal system; sensory nerve; pain; spinal reflex; tranquilizing activity; sensory stimulation; pain threshold; pregnancy; cardiovascular effect; fertilization in vitro; embryo transfer; nidation; anesthesia; oocyte; ovary polycystic disease; disorders of hormone metabolism; anovulation; drug effect; review; opiate; oxytocin; beta endorphin; mu opiate receptor; corticotropin releasing factor; proopiomelanocortin; intermedin; **gonadorelin**; gonadotropin; glutamic acid; aspartic acid; n methyl dextro aspartic acid receptor; substance P; vasoactive intestinal polypeptide; calcitonin gene related peptide; naloxone; cholecystokinin; alfentanil; anesthetic agent; **estradiol valerate**

## CAS REGISTRY NUMBER:

(opiate) 53663-61-9, 8002-76-4, 8008-60-4; (oxytocin) 50-56-6, 54577-94-5; (beta endorphin) 59887-17-1; (corticotropin releasing factor) 9015-71-8; (proopiomelanocortin) 66796-54-1; (intermedin) 9002-79-3, 9046-72-4; (**gonadorelin**) 33515-09-2, **9034-40-6**; (gonadotropin) 63231-54-9; (glutamic acid) 11070-68-1, 138-15-8, 56-86-0, 6899-05-4; (aspartic acid) 56-84-8, 6899-03-2; (substance P) 33507-63-0; (vasoactive intestinal polypeptide) 37221-79-7; (calcitonin gene related peptide) 83652-28-2; (naloxone) 357-08-4, 465-65-6; (cholecystokinin) 9011-97-6, 93443-27-7; (alfentanil) 69049-06-5, 71195-58-9; (**estradiol valerate**) **979-32-8**

L169 ANSWER 22 OF 41 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN  
 ACCESSION NUMBER: 2001:32473055 BIOTECHNO  
 TITLE: Evaluation of an optimal luteal phase support protocol in IVF  
 AUTHOR: Ludwig M.; Diedrich K.  
 CORPORATE SOURCE: Dr. M. Ludwig, Klin. Frauenheilkunde/Geburtshilfe, Universitätsklinikum Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany.  
 SOURCE: Acta Obstetrica et Gynecologica Scandinavica, (2001), 80/5 (452-466), 65 reference(s)  
 CODEN: AOGSAE ISSN: 0001-6349  
 DOCUMENT TYPE: Journal; Article

CONTROLLED TERM: \*uterus myoma; general practitioner; risk factor; menarche; obesity; nullipara; ethnic difference; incidence; disease severity; symptomatology; tumor volume; tumor localization; clinical examination; echography; transvaginal echography; nuclear magnetic resonance imaging; computer assisted tomography; ovary tumor; hysteroscopy; laparoscopic surgery; myomectomy; hysterectomy; uterine artery embolization; endoscopic surgery; safety; drug mechanism; hot flush; osteoporosis; gene therapy; human; female; review; gonadorelin agonist; goserelin; estriol; estradiol valerate; estradiol; mifepristone; interferon; selective estrogen receptor modulator; tamoxifen; raloxifene; cytotoxic agent; menorest 75

CAS REGISTRY NUMBER: (goserelin) 65807-02-5; (estriol) 50-27-1; (estradiol valerate) 979-32-8; (estradiol) 50-28-2; (mifepristone) 84371-65-3; (tamoxifen) 10540-29-1; (raloxifene) 82640-04-8, 84449-90-1

CHEMICAL NAME: Drug Trade Name: zoladex; ru 486; ovestin; progynova; menorest 75

L169 ANSWER 21 OF 41 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN  
ACCESSION NUMBER: 2002:34904784 BIOTECHNO  
TITLE: Alternative treatments in reproductive medicine: Much ado about nothing: Acupuncture - A method of treatment in reproductive medicine: Lack of evidence of an effect does not equal evidence of the lack of an effect

AUTHOR: Stener-Victorin E.; Wikland M.; Waldenstrom U.; Lundeborg T.

CORPORATE SOURCE: E. Stener-Victorin, Dept. of Obstetrics and Gynaecology, Goteborg University, SE-413 45 Goteborg, Sweden.  
E-mail: elisabet.stener-victorin@medstud.gu.se

SOURCE: Human Reproduction, (2002), 17/8 (1942-1946), 47 reference(s)  
CODEN: HUREEE ISSN: 0268-1161

DOCUMENT TYPE: Journal; General Review  
COUNTRY: United Kingdom  
LANGUAGE: English  
SUMMARY LANGUAGE: English

ABSTRACT: The increasing popularity of alternative treatments - methods of treatment that are not generally established in Western medicine - demands a serious debate about scientific documentation, efficacy and safety. It has been argued that there is no alternative medicine. There is only scientifically proven, evidence-based medicine supported by solid data, and we agree. Different methods of treatment, referred to as alternative treatments, are used by millions of patients every day which generates billions of dollars in health care expenditure each year. Therefore, it is important that physicians become more knowledgeable about different methods of treatment and increase their understanding of the possible benefits and limitations of each therapy. This article is intended to illustrate acupuncture in reproductive medicine today, as an example of a method

AE; GOSERELIN \*RN; S.C. \*FT; IMPLANT \*FT;  
 LULIBERIN-AGONIST \*FT; MODE-OF-ACT. \*FT; ZENECA \*FT;  
 INJECTION \*FT; **RELEASING-FACTOR** \*FT;  
**RELEASING-FACTORS** \*FT; LULIBERIN-AGONISTS \*FT; TR  
 \*FT; **AE** \*FT

CAS REGISTRY NO.: 65807-02-5

[02]

**ESTRADIOL-VALERATE** \*TR; ESTRADIOL-VALERATE \*  
**AE**; DIVINA \*TR; DIVINA \*AE; ORION \*FT;  
 HYPOESTROGENIC \*TR; VASOMOTOR \*TR; **FLUSHING** \*TR;  
 SWEATING \*TR; LIBIDO \*TR; BREAKTHROUGH-BLEEDING \*AE  
 ; HEADACHE \*AE; PREMENSTRUAL-TENSION \*AE;  
 SWEAT \*TR; MENSTRUATION \*AE; GYNECOLOGY \*AE  
 ; MENTAL-DISORDER \*AE; MENSTRUATION \*AE;  
 ESTRADIOV \*RN; COMB.PREP. \*FT; ESTROGEN \*FT; ESTROGENS \*FT;  
 TR \*FT; **AE** \*FT

CAS REGISTRY NO.: 979-32-8

[03]

MEDROXYPROGESTERONE-ACETATE \*TR; MEDROXYPROGESTERONE-ACETATE  
 \*AE; DIVINA \*TR; DIVINA \*AE; ORION \*FT;  
 HYPOESTROGENIC \*TR; VASOMOTOR \*TR; **FLUSHING** \*TR;  
 SWEATING \*TR; LIBIDO \*TR; BREAKTHROUGH-BLEEDING \*AE  
 ; HEADACHE \*AE; PREMENSTRUAL-TENSION \*AE;  
 SWEAT \*TR; MENSTRUATION \*AE; GYNECOLOGY \*AE  
 ; MENTAL-DISORDER \*AE; MENSTRUATION \*AE;  
 MEDOXPRAC \*RN; COMB.PREP. \*FT; PROGESTOGEN \*FT; PROGESTOGENS  
 \*FT; TR \*FT; **AE** \*FT

CAS REGISTRY NO.: 71-58-9

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

L169 ANSWER 20 OF 41 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

ACCESSION NUMBER: 2003:36267579 BIOTECHNO

TITLE: Uterine fibroids an update for GPs

AUTHOR: Jones I.

CORPORATE SOURCE: Prof. I. Jones, University of Queensland, Mater  
 Mothers' Hospital, Brisbane, QLD, Australia.

SOURCE: Medicine Today, (01 FEB 2003), 4/2 (16-20), 1  
 reference(s)

CODEN: MTNBCV ISSN: 1443-430X

DOCUMENT TYPE: Journal; General Review

COUNTRY: Australia

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: .bullet. Risk factors for the development of uterine  
 fibroids include an early menarche, obesity,  
 nulliparity and being of Africa origin. .bullet. The  
 incidence and severity of a woman's symptoms depend on  
 the size, number and anatomical location of the  
 fibroids in the uterus. .bullet. Diagnosis of uterine  
 fibroids is by clinical examination, pelvic ultrasound  
 examination (including vaginal ultrasound with or  
 without saline infusion sonography), MRI and CT scan.  
 .bullet. Beware the postmenopausal fibroid - it be an  
 ovarian tumour. .bullet. Management options for  
 symptomatic fibroids include hysteroscopic submucous  
 fibroid resection, laparoscopic and open myomectomy,  
 laparoscopic or open hysterectomy and in some cases  
 uterine artery embolisation. .bullet. The use of GnRH  
 agonists to shrink the size of fibroid before surgery  
 has made both open and endoscopic treatment easier and  
 safer.



23, pp. 607-610. 15 Refs.  
CODEN: DDIPD8; ISSN: 0363-9045.

DOCUMENT TYPE: Journal  
LANGUAGE: English  
ABSTRACT:

One-hundred and six beef cows were included in a study to determine if \*\*\*gonadorelin\*\*\* (gonadotropin releasing hormone) administered via needleless implants would enhance calving rate like conventional gonadorelin administration; all cows were synchronized with the norgestomet and estradiol valerate estrus synchronization procedure and then randomly assigned to 1 of 3 groups: no \*\*\*gonadorelin\*\*\*, gonadorelin via conventional implants, and \*\*\*gonadorelin\*\*\* via needleless implants.

Gonadorelin was administered 30 h after norgestomet implant removal. Needleless implants were administered while cows were restrained. \*\*\*Gonadorelin\*\*\* administered by both methods equally enhanced calving rate and the needleless implant caused minimal response by the cows.

It was concluded that remote administration of gonadorelin may accomplish therapeutic efficacy and reduce the time, labor, stress, and risk of injury associated with providing conventional animal therapy.

M. Therese Gyi

SECTION: 8 Biopharmaceutics; 12 Preliminary Drug Test  
CLASSIFICATION: 68:00 Hormones  
INDEX TERM: Gonadorelin; implants; cows  
INDEX TERM: Norgestomet; concomitant therapy  
INDEX TERM: Estradiol valerate; concomitant therapy  
INDEX TERM: Hormones; gonadorelin; implants  
INDEX TERM: Implants; gonadorelin; administration  
INDEX TERM: Drug administration; gonadorelin; implants  
INDEX TERM: Dosage forms; gonadorelin; implants  
INDEX TERM: Drug administration routes; subdermal; gonadorelin  
CAS REGISTRY NO.: 33515-09-2 (Gonadorelin)  
CAS REGISTRY NO.: 25092-41-5 (Norgestomet)  
CAS REGISTRY NO.: 979-32-8 (Estradiol valerate)  
CHEMICAL NAME: Gonadorelin (Gonadotropin releasing hormone)

L169 ANSWER 26 OF 41 IPA COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 84:10285 IPA  
DOCUMENT NUMBER: 23-03355  
TITLE: Growth and sexual development before and after sex steroid therapy in patients with thalassemia major  
AUTHOR: Landau, H.; Gross, V.; Dagan, I.; Palti, Z.; Spitz, I. M.; et al  
CORPORATE SOURCE: Dept. of Endocrinology and Metabolism, Shaare Zedek Med. Ctr., Jerusalem, Israel  
SOURCE: Archives of Internal Medicine (USA), (Dec 1984) Vol. 144, pp. 2341-2346. 19 Refs.  
CODEN: AIMDAP; ISSN: 0003-9926.  
DOCUMENT TYPE: Journal  
FILE SEGMENT: HUMAN  
LANGUAGE: English  
ABSTRACT:

The effect of sex steroid therapy on growth and sexual development of patients with thalassemia major was studied in 5 female patients (older than 18 yr) treated with low dose Progyluton (estradiol, combination, estradiol \*\*\*valerate\*\*\*, norgestrel) or Microgynon (ethinyl estradiol, combination, levonorgestrel), 9 female patients (younger than 18 yr) treated with \*\*\*gonadorelin\*\*\* (gonadotropin releasing hormone) given as an oral tablet, and 9 male patients (younger than 19 yr) treated

with long acting Durasteron (testosterone enanthate, combination, testosterone propionate, testosterone undecylenate) injection.

The results showed that 4 of the females treated with estrogen-progesterone preparation and 6 of the males treated with testosterone preparations showed satisfactory pubertal progression.

It was concluded that treatment with sex steroids should be considered in both female and male patients with thalassemia major.

Elvira deC. Weiss

SECTION: 6 Drug Evaluations  
 CLASSIFICATION: 68:00 Hormones; 68:00 Hormones; 68:00 Hormones; 68:00 Hormones  
 INDEX TERM: Estradiol; combination, **estradiol valerate**, norgestrel; puberty, thalassemia major  
 INDEX TERM: **Estradiol valerate**; combination, estradiol, norgestrel; puberty, thalassemia major  
 INDEX TERM: Norgestrel; combination, estradiol, **estradiol valerate**; puberty, thalassemia major  
 INDEX TERM: Ethinyl estradiol; combination, levonorgestrel; puberty, thalassemia major  
 INDEX TERM: Levonorgestrel; combination, ethinyl estradiol; puberty, thalassemia major  
 INDEX TERM: **Gonadorelin**; effects; puberty, lack, thalassemia major  
 INDEX TERM: Testosterone enanthate; combination, testosterone propionate, testosterone undecylenate; puberty, thalassemia major  
 INDEX TERM: Testosterone propionate; combination, testosterone enanthate, testosterone undecylenate; puberty, thalassemia major  
 INDEX TERM: Testosterone undecylenate; combination, testosterone enanthate, testosterone propionate; puberty, thalassemia major  
 INDEX TERM: Puberty; estradiol, combination, **estradiol valerate**, norgestrel; thalassemia major  
 INDEX TERM: Puberty; ethinyl estradiol, combination, levonorgestrel; thalassemia major  
 INDEX TERM: Puberty; testosterone enanthate, combination, testosterone propionate, testosterone undecylenate; thalassemia major  
 INDEX TERM: Puberty; **gonadorelin**; thalassemia major  
 INDEX TERM: Thalassemia; estradiol, combination, **estradiol valerate**, norgestrel; effects, puberty  
 INDEX TERM: Thalassemia; ethinyl estradiol, combination, levonorgestrel; effects, puberty  
 INDEX TERM: Thalassemia; testosterone enanthate, combination, testosterone propionate, testosterone undecylenate; effects, puberty  
 INDEX TERM: Thalassemia; **gonadorelin**; effects, puberty  
 INDEX TERM: Hormones; **gonadorelin**; puberty, thalassemia major  
 INDEX TERM: Hormones; estradiol, combination, **estradiol valerate**, norgestrel; puberty, thalassemia major  
 INDEX TERM: Hormones; ethinyl estradiol, combination, levonorgestrel; puberty, thalassemia major  
 INDEX TERM: Hormones; testosterone enanthate, combination, testosterone propionate, testosterone undecylenate; puberty, thalassemia major  
 CAS REGISTRY NO.: 50-28-2 (Estradiol)  
 CAS REGISTRY NO.: 979-32-8 (**Estradiol valerate**)  
 CAS REGISTRY NO.: 6533-00-2 (Norgestrel)  
 CAS REGISTRY NO.: 57-63-6 (Ethinyl estradiol)  
 CAS REGISTRY NO.: 797-63-7 (Levonorgestrel)

CAS REGISTRY NO.: 33515-09-2 (Gonadorelin)  
CAS REGISTRY NO.: 315-37-7 (Testosterone enanthate)  
CAS REGISTRY NO.: 57-85-2 (Testosterone propionate)  
CHEMICAL NAME: Testosterone undecylenate  
CHEMICAL NAME: Gonadorelin, combination, estradiol valerate, norgestrel, combination, levonorgestrel, combination, testosterone propionate, testosterone undecylenate (Gonadotropin releasing hormone); Estradiol, combination, estradiol valerate, norgestrel, combination, levonorgestrel, combination, testosterone propionate, testosterone undecylenate (Progyluton); Ethinyl estradiol, combination, levonorgestrel, combination, testosterone propionate, testosterone undecylenate (Microgynon); Testosterone enanthate, combination, testosterone propionate, testosterone undecylenate (Durasteron)

L169 ANSWER 27 OF 41 IPA COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 81:7560 IPA  
DOCUMENT NUMBER: 20-04450  
TITLE: Danazol: endocrine consequences in healthy women  
AUTHOR: Luciano, A. A.; Hauser, K. S.; Chapler, F. K.; Sherman, B. M.  
CORPORATE SOURCE: Div. of Reproductive Endocrinology, Dept. of Obstet. and Gynecol., Univ. of Iowa, Iowa City, IA 52242  
SOURCE: American Journal of Obstetrics and Gynecology (USA), (Nov 15 1981) Vol. 141, pp. 723-727. 19 Refs.  
CODEN: AJOGAH; ISSN: 0002-9378.  
DOCUMENT TYPE: Journal  
FILE SEGMENT: HUMAN  
LANGUAGE: English  
ABSTRACT:

The effects of danazol (I) on pituitary and gonadal functions were studied in 7 normal women (aged 24-40 yr) given oral I, at a dose of 400 mg 2 times/day, for 2 months.

Circulating levels of sex steroids, gonadotropins, and prolactin on alternate days throughout a control menstrual cycle and during treatment were measured. Danazol inhibited ovulation in all subjects. The amenorrheic state induced by I was characterized by normal basal levels of gonadotropins, prolactin, and estrogen. Serum androgen levels were significantly increased as was the urinary excretion of 17-ketosteroids. The LH and FSH responses to \*\*\*gonadotropin\*\*\* -releasing hormone were enhanced during treatment, and there was a normal LH rise following administration of \*\*\*estradiol\*\*\* valerate, indicative of intact positive feedback. These observations fail to support the contention that I suppresses pituitary gonadotropin secretion or directly inhibits steroidogenesis:

It was concluded that I may have a primary site of action at the ovary by suppressing the normal, orderly process of follicular maturation.

Elvira deC. Weiss

SECTION: 11 Pharmacology  
CLASSIFICATION: 68:08 Androgens  
INDEX TERM: Danazol; effects; pituitary, and gonadal functions, mechanisms, humans  
INDEX TERM: Mechanism of action; danazol; effects, pituitary and gonadal functions, humans  
INDEX TERM: Androgens; danazol; effects, pituitary and gonadal functions, mechanisms, humans  
INDEX TERM: Site of action; danazol; ovary, humans  
CAS REGISTRY NO.: 17230-88-5 (Danazol)

L169 ANSWER 28 OF 41 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2006:145920 BIOSIS

DOCUMENT NUMBER: PREV200600135910

TITLE: Endocrine treatment of male-to-female transsexuals using  
**gonadotropin-releasing hormone**  
agonist.

AUTHOR(S): Dittrich, R.; Binder, H.; Cupisti, S.; Hoffmann, I.;  
Beckmann, M. W.; Mueller, A. [Reprint Author]

CORPORATE SOURCE: Erlangen Univ Hosp, Dept Obstet and Gynaecol, Univ Str  
21-23, D-91054 Erlangen, Germany  
andreas.mueller@gyn.imed.uni-erlangen.de

SOURCE: Experimental and Clinical Endocrinology & Diabetes, (DEC  
2005) Vol. 113, No. 10, pp. 586-592.  
ISSN: 0947-7349.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 22 Feb 2006

Last Updated on STN: 22 Feb 2006

ABSTRACT: in transsexual people; cross-sex hormone therapy is an important component of medical treatment. In male-to-female transsexuals, feminizing effects should be achieved before irreversible sex reassignment surgery (SRS) is considered. The most common treatment regimen in male-to-female transsexuals is a combination of ethinyl oestradiol and cyproterone acetate, with the exception of transdermal oestradiol-17 beta in individuals over the age of 40. The mortality and morbidity rates with this treatment regimen have been reported in more than 800 patients. Typical **side** **\*\*\*effects\*\*\*** include venous thrombosis, elevated liver enzymes, symptomatic gallstones, hyperprolactinaemia and **depression**. Sixty male-to-female transsexuals were treated with monthly injections of **gonadotropin-\*\*\*releasing\*\*\* hormone** agonist (GnRHa) and oral oestradiol-17 beta valerate for 2 years to achieve feminisation until SRS. There was a significant decline in gonadotropins, total testosterone and calculated free testosterone. In general, the treatment regimen was well accepted. An equal increase in breast size was achieved compared to common hormone therapy. Two **\*\*\*side\*\*\* effects** were documented. One, venous thrombosis, occurred in a patient with a homozygous MTHFR mutation. One patient was found to be suffering from symptomatic preexisting gallstones. No other complications were documented. Liver enzymes, lipids, and prolactin levels were unchanged. Significantly increased oestradiol and SHBG serum levels were detectable. In addition, an increase in bone mass density, in the femoral neck and lumbar spine, was recorded. We conclude that cross-sex hormone treatment of male-to-female transsexuals using GnRHa and oestradiol-17 beta valerate is **\*\*\*effective\*\*\***, and **side effects** and complication rates can be reduced using the treatment regimen presented here.

CONCEPT CODE: Genetics - Human 03508  
Pathology - Therapy 12512  
Urinary system - Pathology 15506  
Reproductive system - Pathology 16506  
Endocrine - General 17002  
Nervous system - Physiology and biochemistry 20504  
Pharmacology - General 22002  
Pharmacology - Clinical pharmacology 22005  
Pharmacology - Endocrine system 22016  
Toxicology - Pharmacology 22504

INDEX TERMS: Major Concepts  
Pharmacology; Urology (Human Medicine, Medical Sciences); Gynecology (Human Medicine, Medical Sciences); Clinical Endocrinology (Human Medicine,

Medical Sciences)  
INDEX TERMS: Parts, Structures, & Systems of Organisms  
lumbar spine: nervous system  
INDEX TERMS: Chemicals & Biochemicals  
liver enzyme; SHBG; cyproterone acetate: hormone-drug;  
ethinyl estradiol: hormone-drug, estrogen-drug;  
gonadotropin-releasing hormone  
agonist: hormone-drug, adverse effects  
, drug regimen, efficacy; estradiol-17-beta-valerate:  
hormone-drug, estrogen-drug, adverse  
effects, drug regimen, efficacy  
INDEX TERMS: Methods & Equipment  
cross-sex hormone therapy: therapeutic and prophylactic  
techniques, clinical techniques  
INDEX TERMS: Miscellaneous Descriptors  
morbidity rate; mortality rate; male-to-female  
transsexual  
ORGANISM: Classifier  
Hominidae 86215  
Super Taxa  
Primates; Mammalia; Vertebrata; Chordata; Animalia  
Organism Name  
human (common): female, male  
Taxa Notes  
Animals, Chordates, Humans, Mammals, Primates,  
Vertebrates  
REGISTRY NUMBER: 427-51-0 (cyproterone acetate)  
57-63-6 (ethinyl estradiol)  
979-32-8 (estradiol-17-beta-valerate)  
GENE NAME: human MTHFR gene (Hominidae)

L169 ANSWER 29 OF 41 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 1995:397525 BIOSIS  
DOCUMENT NUMBER: PREV199598411825  
TITLE: Long oestradiol replacement in an oocyte donation  
programme.  
AUTHOR(S): Remohi, Jose; Gutierrez, Antonio; Cano, Fidel; Ruiz,  
Amparo; Simon, Carlos; Pellicer, Antonio [Reprint author]  
CORPORATE SOURCE: Instituto Valenciano de Infertilidad, Guardia Civil 23,  
46020 Valencia, Spain  
SOURCE: Human Reproduction (Oxford), (1995) Vol. 10, No. 6, pp.  
1387-1391.  
CODEN: HUREEE. ISSN: 0268-1161.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 13 Sep 1995  
Last Updated on STN: 13 Sep 1995

ABSTRACT: The objective of this study was to optimize, in terms of endometrial  
receptivity (embryo implantation), the limits of unopposed administration of  
oestrogens beyond 35 days in an in-vitro fertilization (IVF) and ovum donation  
programme. Oocytes donated by 182 women undergoing IVF were distributed among  
186 women treated by ovum donation. Five groups of recipients were established  
according to the duration of oestradiol valerate administration, in a  
'prolonged follicular phase' protocol, before embryo replacement, employing  
oestradiol valerate at increasing doses up to 6 mg/day. Gonadotrophin-  
releasing hormone analogues (GnRHa) were simultaneously administered in  
ovulatory patients. The dosage of oestradiol valerate was maintained until  
oocytes were available for insemination and subsequent transfer. Donors and  
recipients were equally distributed among groups in terms of age and cause of

infertility. There was no difference among groups in serum oestradiol concentration the day in which progesterone was added to obtain a secretory transformation of the endometrium. An analysis of the ovum donation cycles showed no difference among groups in pregnancy and implantation rates after the replacement of a similar number of embryos. Successful implantation was observed even after 100 days of unopposed oestradiol valerate administration. Break-through bleeding increasingly appeared according to the duration of oestrogen replacement. These clinical observations provide evidence that the concept of 'prolonged follicular phase' oestrogen replacement for ovum donation can be maintained, at least as long as 15 weeks. However, because of the high (gt 44%) incidence of break-through bleeding after 9 weeks, it is advisable to stop oestrogen treatment at this point. This protocol enormously facilitates the chances of synchronization between donor and recipient in an anonymous oocyte donation programme.

CONCEPT CODE: Cytology - Human 02508  
 Biochemistry studies - Proteins, peptides and amino acids 10064  
 Biochemistry studies - Sterols and steroids 10067  
 Pathology - Therapy 12512  
 Cardiovascular system - Blood vessel pathology 14508  
 Reproductive system - Physiology and biochemistry 16504  
 Reproductive system - Pathology 16506  
 Endocrine - Gonads and placenta 17006  
 Endocrine - Neuroendocrinology 17020  
 Nervous system - Physiology and biochemistry 20504  
 Pharmacology - Clinical pharmacology 22005  
 Pharmacology - Endocrine system 22016  
 Pharmacology - Reproductive system and implantation studies 22028  
 In vitro cellular and subcellular studies 32600

INDEX TERMS: Major Concepts  
 Cardiovascular Medicine (Human Medicine, Medical Sciences); Cell Biology; Endocrine System (Chemical Coordination and Homeostasis); Nervous System (Neural Coordination); Pharmacology; Reproductive System (Reproduction)

INDEX TERMS: Chemicals & Biochemicals  
 OESTRADIOL; ESTRADIOL VALERATE; PROGESTERONE

INDEX TERMS: Miscellaneous Descriptors  
 BREAK-THROUGH BLEEDING; ENDOMETRIAL RECEPTIVITY; ESTRADIOL VALERATE; GONADOTROPIN-RELEASING HORMONE ANALOG; HORMONE-DRUG; IN-VITRO FERTILIZATION; INFERTILITY; OOCYTE DONATION PROGRAM; PREGNANCY; PROGESTERONE

ORGANISM: Classifier  
 Hominidae 86215  
 Super Taxa  
 Primates; Mammalia; Vertebrata; Chordata; Animalia  
 Organism Name  
 human  
 Taxa Notes  
 Animals, Chordates, Humans, Mammals, Primates, Vertebrates

REGISTRY NUMBER: 50-28-2 (OESTRADIOL)  
 979-32-8 (ESTRADIOL VALERATE)  
 57-83-0 (PROGESTERONE)

L169 ANSWER 30 OF 41 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1982:203875 BIOSIS

Searched by Barb O'Bryen, STIC 2-2518

DOCUMENT NUMBER: PREV198273063859; BA73:63859  
 TITLE: DANAZOL ENDOCRINE CONSEQUENCES IN HEALTHY WOMEN.  
 AUTHOR(S): LUCIANO A A [Reprint author]; HAUSER K S; CHAPLER F K;  
 SHERMAN B M  
 CORPORATE SOURCE: DIV OF REPRODUCTIVE ENDOCRINOLOGY, DEP OF OBSTETRICS AND  
 GYNECOL, UNIV OF IOWA, IOWA CITY, IOWA 52242, USA  
 SOURCE: American Journal of Obstetrics and Gynecology, (1981) Vol.  
 41, No. 6, pp. 723-727.  
 CODEN: AJOGAH. ISSN: 0002-9378.  
 DOCUMENT TYPE: Article  
 FILE SEGMENT: BA  
 LANGUAGE: ENGLISH

ABSTRACT: The effects of danazol on pituitary and gonadal function was studied in 7 normal women who volunteered to take danazol, 400 mg twice daily, for 2 mo. Circulating sex steroids, gonadotropins and prolactin levels were measured on alternate days throughout a control menstrual cycle and during treatment. Danazol inhibited ovulation in all subjects. The amenorrheic state induced by danazol was characterized by normal basal levels on gonadotropins, prolactin and estrogen. Serum androgen levels were significantly increased as was the urinary excretion of 17-ketosteroids. The LH [luteinizing hormone] and FSH responses to gonadotropin-releasing hormone were enhanced during treatment, and there was a normal LH rise following administration of estradiol valerate, indicative of intact positive feedback. These observations fail to support the contention that danazol suppresses pituitary gonadotropin secretion or directly inhibits steroidogenesis. Danazol may have a primary site of action at the ovary by suppressing the normal, orderly process of follicular maturation. [Danazol, a synthetic isoxazol derivative of 17- $\alpha$  ethinyl testosterone, was introduced for the treatment of endometriosis. Since then, danazol has been found to be useful in the therapy of benign fibrocystic disease of the breast, precocious puberty, congenital angioneurotic edema, and as a contraceptive in men and women.]

CONCEPT CODE: Genetics - Human 03508  
 Clinical biochemistry - General methods and applications 10006  
 Biochemistry studies - Proteins, peptides and amino acids 10064  
 Biochemistry studies - Sterols and steroids 10067  
 Biochemistry studies - Carbohydrates 10068  
 Enzymes - Physiological studies 10808  
 Pathology - Comparative 12503  
 Pathology - Inflammation and inflammatory disease 12508  
 Pathology - Therapy 12512  
 Metabolism - Sterols and steroids 13008  
 Metabolism - Metabolic disorders 13020  
 Blood - Other body fluids 15010  
 Reproductive system - Physiology and biochemistry 16504  
 Reproductive system - Pathology 16506  
 Endocrine - Gonads and placenta 17006  
 Endocrine - Pituitary 17014  
 Endocrine - Neuroendocrinology 17020  
 Nervous system - Physiology and biochemistry 20504  
 Pharmacology - Drug metabolism and metabolic stimulators 22003  
 Pharmacology - Clinical pharmacology 22005  
 Pharmacology - Endocrine system 22016  
 Pharmacology - Immunological processes and allergy 22018  
 Pharmacology - Reproductive system and implantation studies 22028  
 Pediatrics - 25000  
 Development and Embryology - Pathology 25503

Development and Embryology - Morphogenesis 25508  
 Immunology - Immunopathology, tissue immunology 34508

INDEX TERMS: Major Concepts  
 Clinical Chemistry (Allied Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Metabolism; Pharmacology; Reproductive System (Reproduction)

INDEX TERMS: Miscellaneous Descriptors  
 ESTRADIOL VALERATE CONTRACEPTIVE-DRUG  
 GONADOTROPIN RELEASING HORMONE  
 HORMONE-DRUG FSH LUTEINIZING HORMONE GONADOTROPINS SEX STEROIDS ENDOMETRIOSIS PRECOCIOUS PUBERTY BENIGN FIBROCYSTIC DISEASE CONGENITAL ANGIO NEUROTIC EDEMA PHARMACODYNAMICS FOLLICULAR MATURATION  
 DEPRESSION

ORGANISM: Classifier  
 Hominidae 86215  
 Super Taxa  
 Primates; Mammalia; Vertebrata; Chordata; Animalia  
 Taxa Notes  
 Animals, Chordates, Humans, Mammals, Primates, Vertebrates

REGISTRY NUMBER: 17230-88-5 (DANAZOL)  
 979-32-8 (ESTRADIOL VALERATE)  
 9002-68-0 (FSH)  
 9002-67-9 (LUTEINIZING HORMONE)  
 33515-09-2Q (GONADOTROPIN RELEASING HORMONE)  
 107950-52-7Q (GONADOTROPIN RELEASING HORMONE)

L169 ANSWER 31 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004220561 EMBASE  
 TITLE: Oestrogen and attacks of migraine with and without aura.  
 AUTHOR: MacGregor E.A.  
 CORPORATE SOURCE: E.A. MacGregor, City of London Migraine Clinic, 22 Charterhouse Square, London, EC1M 6DX, United Kingdom. anne.macgregor@bartsandthelondon.nhs.uk  
 SOURCE: Lancet Neurology, (1 Jun 2004) Vol. 3, No. 6, pp. 354-361.

Refs: 67  
 ISSN: 1474-4422 CODEN: LNAEAM

PUBLISHER IDENT.: S 1474-4422(04)00768-9  
 COUNTRY: United Kingdom  
 DOCUMENT TYPE: Journal; General Review  
 FILE SEGMENT: 008 Neurology and Neurosurgery  
 027 Biophysics, Bioengineering and Medical Instrumentation  
 037 Drug Literature Index  
 038 Adverse Reactions Titles  
 039 Pharmacy

LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 ENTRY DATE: Entered STN: 20040701  
 Last Updated on STN: 20040701

ABSTRACT: During women's reproductive years, migraine is three times more common than in men of a similar age. Although this female preponderance is commonly assumed to be associated with the additional trigger of fluctuating sex hormones of the menstrual cycle, few studies have been done to confirm or



refute this. This review is confined to the relation between oestrogen and attacks of migraine. The evidence for an association between oestrogen "withdrawal" and attacks of migraine without aura is presented, as well as evidence for an association between high oestrogen states and attacks of migraine with aura. Only clinical data are presented here.

CONTROLLED TERM: Medical Descriptors:  
 \*migraine: CO, complication  
 \*migraine: DT, drug therapy  
 \*migraine: ET, etiology  
 \*migraine: SI, side effect  
 \*hallucination  
 disease association  
 drug withdrawal  
 menstruation  
 menstrual cycle  
 ovulation  
 hormonal therapy  
 follicular phase  
 luteal phase  
 bleeding: SI, side effect  
 hormone substitution  
 ovariectomy  
 device  
 gel  
 drug exposure  
 drug efficacy  
 estrogen deficiency: SI, side effect  
 hot flush: SI, side effect  
 bone density  
 side effect: SI, side effect  
 drug use  
 disease exacerbation: SI, side effect  
 stroke: SI, side effect  
 cerebrovascular accident: SI, side effect  
 cardiovascular risk  
 risk factor  
 human  
 clinical trial  
 review  
 priority journal  
 Drug Descriptors:  
 \*estrogen: AE, adverse drug reaction  
 \*estrogen: CT, clinical trial  
 \*estrogen: CB, drug combination  
 \*estrogen: CM, drug comparison  
 \*estrogen: DT, drug therapy  
 \*estrogen: PR, pharmaceuticals  
 progesterone: DT, drug therapy  
 estradiol valerate: DT, drug therapy  
 estradiol valerate: IM, intramuscular drug  
 administration  
 estradiol: AD, drug administration  
 estradiol: PO, oral drug administration  
 gonadorelin: AE, adverse drug reaction  
 gestagen: CB, drug combination  
 oral contraceptive agent: AE, adverse drug reaction  
 oral contraceptive agent: PO, oral drug administration  
 medroxyprogesterone acetate: AE, adverse drug reaction  
 (progesterone) 57-83-0; (estradiol valerate)

CAS REGISTRY NO.:

979-32-8; (estradiol) 50-28-2; (gonadorelin)  
33515-09-2, 9034-40-6; (medroxyprogesterone acetate)  
71-58-9  
NAME OF PRODUCT: Clearplan

L169 ANSWER 32 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004151204 EMBASE

TITLE: Applications of chemically-modified cyclodextrins: Use of hydroxypropyl- $\beta$ -cyclodextrin as an enabling excipient for brain targeting, redox-based derivatives of estradiol: A review of preclinical and clinical findings.

AUTHOR: Brewster M.E.; Loftsson T.; Bodor N.

CORPORATE SOURCE: M.E. Brewster, Dept. of Pharmaceutical Sciences, J./Johnson Pharmaceut. Res./Devt., Beerse, Belgium.  
mbrewste@prdbe.jnj.com

SOURCE: Journal of Drug Delivery Science and Technology, (2004)  
Vol. 14, No. 1, pp. 21-34. .  
Refs: 96  
ISSN: 1157-1489 CODEN: JDD SAL

COUNTRY: France

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 010 Obstetrics and Gynecology  
030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20040513  
Last Updated on STN: 20040513

ABSTRACT: Estrogen depletion associated with the menopause produces a constellation of debilitating symptoms which range the gamut from vasomotor complaints which severely affect over one-third of all climacteric women to cognitive deficits. While many of these complications can be alleviated with traditional hormone replacement therapy (HRT), fear of cancer, cardiovascular problems and other metabolic diseases prompt many women to avoid treatment. Surveys suggest that over 30% of all prescriptions written for HRT are never filled due to these concerns and recent findings from Woman's Health Initiative trials have only added to these trepidations. Selective brain delivery of estrogens, in general, and estradiol, in particular, may address these items. One approach to accomplish CNS deposition is the use of a chemical delivery system for estradiol that selectively targets the central nervous system and may, therefore, reduce the incidence or severity of peripherally manifested side-effects. Owing to the very poor water solubility and limited stability of these derivatives, hydroxypropyl- $\beta$ -cyclodextrin has proved to be enabling excipients in the development of these drug candidates. Various preclinical evaluations have demonstrated the organ-targeting potential of an estradiol-chemical delivery systems (E2-CDS) and therefore its potential usefulness as a therapeutic adjunct in certain subpopulations of menopausal women including those at risk to breast carcinomas. A very exciting potential use of the E2-CDS is in neurodegenerative diseases. Data suggest that estrogens may improve the mental performance of elderly patents suspected of having Alzheimer's disease.

CONTROLLED TERM: Medical Descriptors:  
\*chemical modification  
\*drug targeting  
\*brain  
\*oxidation reduction reaction

menopause  
menopausal syndrome: DI, diagnosis  
menopausal syndrome: DT, drug therapy  
menopausal syndrome: ET, etiology  
estrogen therapy  
    **breast carcinoma: SI, side effect**  
    **cardiovascular disease: SI, side effect**  
    **metabolic disorder: SI, side effect**  
clinical trial  
Woman Health Initiative  
drug delivery system  
chemical delivery system  
solubility  
molecular stability  
degenerative disease: DI, diagnosis  
degenerative disease: DT, drug therapy  
Alzheimer disease: DI, diagnosis  
Alzheimer disease: DT, drug therapy  
drug effect  
treatment indication  
drug formulation  
in vitro study  
drug half life  
drug distribution  
drug release  
area under the curve  
drug brain level  
drug elimination  
mean residence time  
drug protein binding  
luteinizing hormone release  
gonadorelin release  
dose response  
drug synthesis  
sexual behavior  
drug solubility  
body weight  
human  
nonhuman  
male  
female  
review  
Drug Descriptors:  
\*cyclodextrin derivative  
\*2 hydroxypropyl beta cyclodextrin  
\*excipient  
\*estradiol: AE, adverse drug reaction  
\*estradiol: CT, clinical trial  
\*estradiol: AD, drug administration  
\*estradiol: CR, drug concentration  
\*estradiol: DO, drug dose  
\*estradiol: DT, drug therapy  
    **\*estradiol: TO, drug toxicity**  
\*estradiol: PR, pharmaceuticals  
\*estradiol: PK, pharmacokinetics  
\*estradiol: PD, pharmacology  
\*estradiol: BD, buccal drug administration  
\*estradiol: IV, intravenous drug administration  
\*estradiol: PO, oral drug administration  
\*estradiol: RC, rectal drug administration

\*estradiol: TD, transdermal drug administration  
 estrogen: AE, adverse drug reaction  
 estrogen: CT, clinical trial  
 estrogen: DO, drug dose  
 estrogen: DT, drug therapy  
 estrogen: PR, pharmaceuticals  
 estrogen: PK, pharmacokinetics  
 estrogen: PD, pharmacology  
 estrogen: BD, buccal drug administration  
 estrogen: IV, intravenous drug administration  
 estrogen: PO, oral drug administration  
 estrogen: RC, rectal drug administration  
 estrogen: TD, transdermal drug administration  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: AD, drug  
 administration  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: DV, drug  
 development  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: DO, drug dose  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: TO, drug toxicity  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: PR, pharmaceuticals  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: PK,  
 pharmacokinetics  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: PD, pharmacology  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: BD, buccal drug  
 administration  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: IV, intravenous  
 drug administration  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: PO, oral drug  
 administration  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: RC, rectal drug  
 administration  
 3 hydroxy 17beta [[[1 methyl 1,4 dihydropyridin 3  
 yl)carbonyl]oxy]estra 1,3,5(10) triene: TD, transdermal  
 drug administration  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 yl)oxy]carbonyl]pyridinium iodide: AD, drug administration  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 yl)oxy]carbonyl]pyridinium iodide: DV, drug development  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 yl)oxy]carbonyl]pyridinium iodide: DO, drug dose  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 yl)oxy]carbonyl]pyridinium iodide: TO, drug toxicity  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 yl)oxy]carbonyl]pyridinium iodide: PR, pharmaceuticals  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 yl)oxy]carbonyl]pyridinium iodide: PK, pharmacokinetics  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 yl)oxy]carbonyl]pyridinium iodide: PD, pharmacology  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta

ylloxy]carbonyl]pyridinium iodide: BD, buccal drug administration  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 ylloxy]carbonyl]pyridinium iodide: IV, intravenous drug administration  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 ylloxy]carbonyl]pyridinium iodide: PO, oral drug administration  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 ylloxy]carbonyl]pyridinium iodide: RC, rectal drug administration  
 1 methyl 3 [[[3 hydroxyestra 1,3,5(10)trien 17beta  
 ylloxy]carbonyl]pyridinium iodide: TD, transdermal drug administration  
 estradiol nicotinate: AD, drug administration  
 estradiol nicotinate: DV, drug development  
 estradiol nicotinate: DO, drug dose  
 estradiol nicotinate: TO, drug toxicity  
 estradiol nicotinate: PR, pharmaceuticals  
 estradiol nicotinate: PK, pharmacokinetics  
 estradiol nicotinate: PD, pharmacology  
 estradiol nicotinate: BD, buccal drug administration  
 estradiol nicotinate: IV, intravenous drug administration  
 estradiol nicotinate: PO, oral drug administration  
 estradiol nicotinate: RC, rectal drug administration  
 estradiol nicotinate: TD, transdermal drug administration  
 estradiol bisnicotinate: AD, drug administration  
 estradiol bisnicotinate: DV, drug development  
 estradiol bisnicotinate: DO, drug dose  
 estradiol bisnicotinate: TO, drug toxicity

## CONTROLLED TERM:

Drug Descriptors:  
 estradiol bisnicotinate: PR, pharmaceuticals  
 estradiol bisnicotinate: PK, pharmacokinetics  
 estradiol bisnicotinate: PD, pharmacology  
 estradiol bisnicotinate: BD, buccal drug administration  
 estradiol bisnicotinate: IV, intravenous drug administration  
 estradiol bisnicotinate: PO, oral drug administration  
 estradiol bisnicotinate: RC, rectal drug administration  
 estradiol bisnicotinate: TD, transdermal drug administration  
 luteinizing hormone  
 gonadorelin  
 testosterone  
 androgen  
 prolactin  
 growth hormone  
 liothyronine  
 drug vehicle  
 unclassified drug  
 estradiol valerate

## CAS REGISTRY NO.:

(2 hydroxypropyl beta cyclodextrin) 94035-02-6; (estradiol) 50-28-2; (luteinizing hormone) 39341-83-8, 9002-67-9; (gonadorelin) 33515-09-2, 9034-40-6; (testosterone) 58-22-0; (prolactin) 12585-34-1, 50647-00-2, 9002-62-4; (growth hormone) 36992-73-1, 37267-05-3, 66419-50-9, 9002-72-6; (liothyronine) 6138-47-2, 6893-02-3; (estradiol valerate) 979-32-8

## CHEMICAL NAME:

Progynova

L169 ANSWER 33 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003385827 EMBASE  
 TITLE: Sex steroid replacement during and after the induction of puberty.  
 AUTHOR: Peter F.  
 CORPORATE SOURCE: F. Peter, Buda Children's Hospital, Bolyai-u. 5-7, 1023 Budapest, Hungary. peter\_f@elender.hu  
 SOURCE: Growth Hormone and IGF Research, (2003) Vol. 13, No. SUPPL. A, pp. S136-S142. .  
 Refs: 46  
 ISSN: 1096-6374 CODEN: GHIRF  
 COUNTRY: United Kingdom  
 DOCUMENT TYPE: Journal; Article  
 FILE SEGMENT: 003 Endocrinology  
 007 Pediatrics and Pediatric Surgery  
 030 Pharmacology  
 037 Drug Literature Index  
 038 Adverse Reactions Titles  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 ENTRY DATE: Entered STN: 20031009  
 Last Updated on STN: 20031009

ABSTRACT: The main aim of sex steroid replacement during induction of puberty is to obtain a balance between healthy psychological and somatic development and optimal final height and peak bone mass (PBM). At present, the age at which it is considered appropriate to begin inducing puberty is younger than it was in the past. This trend aims for optimisation of prepubertal and pubertal growth through earlier onset of growth hormone (GH) therapy and administration of higher doses during puberty as necessary. Adequate initiation of puberty should ensure not only optimal final height and psychological balance, but also normal body proportions, appropriate bone formation and preservation of fertility for children with GH and gonadotropin deficiencies. .COPYRG. 2003 Elsevier Science Ltd. All rights reserved.

CONTROLLED TERM: Medical Descriptors:  
 \*puberty  
 \*hormone substitution  
 mental development  
 physical development  
 body height  
 bone mass  
 age distribution  
 prepuberty  
 dose response  
 ossification  
 fertility  
 growth hormone deficiency: DT, drug therapy  
 gonadotropin deficiency: DT, drug therapy  
 bone density  
 bone mineral  
 drug activity  
 precocious puberty: DT, drug therapy  
 drug metabolism  
 hypertension: SI, side effect  
 drug blood level  
 multiple pregnancy: SI, side effect  
 ovary hyperstimulation: SI, side effect  
 liver toxicity: SI, side effect  
 pain: SI, side effect

gynecomastia: SI, side effect  
fluid retention  
human  
male  
female  
adolescent  
school child  
article  
priority journal  
Drug Descriptors:  
\*sex hormone: AE, adverse drug reaction  
\*sex hormone: CB, drug combination  
\*sex hormone: CR, drug concentration  
\*sex hormone: DT, drug therapy  
\*sex hormone: EC, endogenous compound  
\*sex hormone: PK, pharmacokinetics  
\*sex hormone: PD, pharmacology  
\*sex hormone: PO, oral drug administration  
\*sex hormone: TD, transdermal drug administration  
growth hormone: DO, drug dose  
gonadotropin: EC, endogenous compound  
estrogen: AE, adverse drug reaction  
estrogen: CB, drug combination  
estrogen: CR, drug concentration  
estrogen: DT, drug therapy  
estrogen: EC, endogenous compound  
estrogen: PK, pharmacokinetics  
estrogen: PD, pharmacology  
estrogen: TD, transdermal drug administration  
gonadorelin derivative: DT, drug therapy  
ethinylestradiol: AE, adverse drug reaction  
ethinylestradiol: CB, drug combination  
ethinylestradiol: DT, drug therapy  
ethinylestradiol: PK, pharmacokinetics  
ethinylestradiol: PD, pharmacology  
ethinylestradiol: TD, transdermal drug administration  
estradiol: CR, drug concentration  
estradiol: DT, drug therapy  
estradiol: PK, pharmacokinetics  
    estradiol valerate: CB, drug combination  
    estradiol valerate: CR, drug concentration  
    estradiol valerate: DT, drug therapy  
    estradiol valerate: PK, pharmacokinetics  
    estradiol valerate: TD, transdermal drug  
administration  
gestagen: CB, drug combination  
gestagen: DT, drug therapy  
luteinizing hormone: AE, adverse drug reaction  
luteinizing hormone: CB, drug combination  
luteinizing hormone: DT, drug therapy  
luteinizing hormone: IM, intramuscular drug administration  
follitropin: AE, adverse drug reaction  
follitropin: CB, drug combination  
follitropin: DT, drug therapy  
follitropin: IM, intramuscular drug administration  
methyltestosterone: AE, adverse drug reaction  
methyltestosterone: DT, drug therapy  
methyltestosterone: PO, oral drug administration  
oxymetholone: AE, adverse drug reaction  
oxymetholone: DT, drug therapy

oxymetholone: PO, oral drug administration  
 testosterone undecanoate: DT, drug therapy  
 testosterone undecanoate: PK, pharmacokinetics  
 testosterone undecanoate: PO, oral drug administration  
 testosterone enantate: DT, drug therapy  
 testosterone enantate: IM, intramuscular drug  
 administration  
 testosterone: AE, adverse drug reaction  
 testosterone: CR, drug concentration  
 testosterone: DT, drug therapy  
 testosterone: PK, pharmacokinetics  
 testosterone: IM, intramuscular drug administration  
 testosterone: PO, oral drug administration  
 gonadorelin: DT, drug therapy  
 gonadorelin: PD, pharmacology

CAS REGISTRY NO.: (growth hormone) 36992-73-1, 37267-05-3, 66419-50-9,  
 9002-72-6; (gonadotropin) 63231-54-9; (ethinylestradiol)  
 57-63-6; (estradiol) 50-28-2; (estradiol valerate)  
 979-32-8; (luteinizing hormone) 39341-83-8,  
 9002-67-9; (follitropin) 9002-68-0; (methyltestosterone)  
 58-18-4; (oxymetholone) 434-07-1; (testosterone  
 undecanoate) 5949-44-0; (testosterone enantate) 315-37-7;  
 (testosterone) 58-22-0; (gonadorelin) 33515-09-2, 9034-40-6

L169 ANSWER 34 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights  
 reserved on STN

ACCESSION NUMBER: 2000038275 EMBASE  
 TITLE: Use of androgens and oestrogens in adolescents - A review  
 of hormone replacement treatment.  
 AUTHOR: Zacharin M.  
 CORPORATE SOURCE: M. Zacharin, Dept. of Endocrinology and Diabetes, Royal  
 Children's Hospital, Parkville, Vic. 3052, Australia  
 SOURCE: Journal of Pediatric Endocrinology and Metabolism, (2000)  
 Vol. 13, No. 1, pp. 3-11. .  
 Refs: 75  
 ISSN: 0334-018X CODEN: JPEMFT  
 COUNTRY: Israel  
 DOCUMENT TYPE: Journal; General Review  
 FILE SEGMENT: 003 Endocrinology  
 007 Pediatrics and Pediatric Surgery  
 037 Drug Literature Index  
 038 Adverse Reactions Titles  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 20000203  
 Last Updated on STN: 20000203  
 CONTROLLED TERM: Medical Descriptors:  
 \*hormone substitution  
 \*puberty  
 \*hypogonadism  
 hypertension: SI, side effect  
 skin defect: SI, side effect  
 virilization  
 feminization  
 comorbidity  
 chronic disease  
 drug mixture  
 drug elimination  
 Turner syndrome: CN, congenital disorder  
 risk factor  
 child development



bone mass  
 child growth  
 sexual maturation  
 dose response  
 long term care  
 treatment indication  
 human  
 male  
 female  
 adolescent  
 review

## Drug Descriptors:

\*androgen: AE, adverse drug reaction  
 \*androgen: CB, drug combination  
 \*androgen: DO, drug dose  
 \*androgen: PD, pharmacology  
 \*androgen: IM, intramuscular drug administration  
 \*androgen: SC, subcutaneous drug administration  
 \*androgen: DL, intradermal drug administration  
 \*estrogen: AE, adverse drug reaction  
 \*estrogen: CB, drug combination  
 \*estrogen: DO, drug dose  
 \*estrogen: PD, pharmacology  
 \*estrogen: PO, oral drug administration  
 \*estrogen: DL, intradermal drug administration  
 growth hormone  
 ethinylestradiol: AE, adverse drug reaction  
 ethinylestradiol: DO, drug dose  
 ethinylestradiol: PK, pharmacokinetics  
 ethinylestradiol: PD, pharmacology  
 sex hormone binding globulin: EC, endogenous compound  
 conjugated estrogen: AE, adverse drug reaction

**estradiol valerate**

piperazine estrone sulfate  
 gestagen: CB, drug combination  
 medroxyprogesterone acetate: CB, drug combination  
 norethisterone acetate: CB, drug combination  
 testosterone undecanoate: DO, drug dose  
 testosterone undecanoate: PD, pharmacology  
 testosterone enantate: DO, drug dose  
 testosterone enantate: PD, pharmacology  
 chorionic gonadotropin: CB, drug combination  
 chorionic gonadotropin: PD, pharmacology  
**gonadorelin: CB, drug combination**  
**gonadorelin: PD, pharmacology**

CAS REGISTRY NO.: (growth hormone) 36992-73-1, 37267-05-3, 66419-50-9,  
 9002-72-6; (ethinylestradiol) 57-63-6; (estradiol valerate)  
 979-32-8; (piperazine estrone sulfate) 7280-37-7;  
 (medroxyprogesterone acetate) 71-58-9; (norethisterone  
 acetate) 51-98-9; (testosterone undecanoate) 5949-44-0;  
 (testosterone enantate) 315-37-7; (chorionic gonadotropin)  
 9002-61-3; (gonadorelin) 33515-09-2, 9034-40-6

L169 ANSWER 35 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 93078418 EMBASE

DOCUMENT NUMBER: 1993078418

TITLE: Sex hormones and headache.

AUTHOR: Silberstein S.D.; Merriam G.R.

CORPORATE SOURCE: One Penn Boulevard, Philadelphia, PA 19144, United States

SOURCE: Journal of Pain and Symptom Management, (1993) Vol. 8, No. 2, pp. 98-114. .  
ISSN: 0885-3924 CODEN: JPSMEU  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Conference Article  
FILE SEGMENT: 003 Endocrinology  
008 Neurology and Neurosurgery  
010 Obstetrics and Gynecology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 930418  
Last Updated on STN: 930418

ABSTRACT: A variety of evidence suggests a link between migraine and the female sex hormones. Women with migraine outnumber men by at least a 2:1 ratio and definite patterns of development and attacks are noted at menarche and throughout the period of menses, related to trimester of pregnancy, and again at menopause, although it may also regress. Hormonal replacement with estrogens can exacerbate migraine; oral contraceptives can change the character and frequency of migraine headache. This article will cover approaches to the therapy of hormone-related headaches associated with the menstrual cycle, menopause, and oral contraceptives.

CONTROLLED TERM: Medical Descriptors:  
\*estrogen therapy  
\*headache: DT, drug therapy  
\*headache: ET, etiology  
\*headache: SI, side effect  
\*hormone action  
\*menstrual cycle  
\*oral contraception  
cluster headache: ET, etiology  
cluster headache: DT, drug therapy  
conference paper  
hormone substitution  
human  
intravaginal drug administration  
menarche  
menopause  
migraine: DT, drug therapy  
migraine: PC, prevention  
migraine: ET, etiology  
neuroendocrine system  
nonhuman  
oral drug administration  
ovary function  
pregnancy  
prophylaxis  
steroidogenesis  
transdermal drug administration  
Drug Descriptors:  
\*conjugated estrogen: PD, pharmacology  
\*conjugated estrogen: DT, drug therapy  
\*ergotamine: DT, drug therapy  
\*estrogen derivative: PD, pharmacology  
\*estrogen derivative: DT, drug therapy  
\*nonsteroid antiinflammatory agent: PD, pharmacology  
\*nonsteroid antiinflammatory agent: DT, drug therapy  
\*oral contraceptive agent: PD, pharmacology

\*oral contraceptive agent: AE, adverse drug reaction  
\*sex hormone  
antidepressant agent: DT, drug therapy  
beta adrenergic receptor blocking agent: DT, drug therapy  
bromocriptine mesilate: DT, drug therapy  
calcium channel blocking agent: DT, drug therapy  
corticosteroid: DT, drug therapy  
danazol: DT, drug therapy  
    **estradiol valerate: DT, drug therapy**  
ethinylestradiol: DT, drug therapy  
follitropin  
    **gonadorelin**  
luteinizing hormone  
methysergide: DT, drug therapy  
opiate peptide: PD, pharmacology  
piperazine estrone sulfate: DT, drug therapy  
progesterone  
prolactin  
prostaglandin: PD, pharmacology  
quinestrol: DT, drug therapy  
tamoxifen citrate: DT, drug therapy

CAS REGISTRY NO.: (ergotamine) 113-15-5, 52949-35-6; (bromocriptine mesilate) 22260-51-1; (danazol) 17230-88-5; (estradiol valerate) 979-32-8; (ethinylestradiol) 57-63-6; (follitropin) 9002-68-0; (gonadorelin) 33515-09-2, 9034-40-6; (luteinizing hormone) 39341-83-8, 9002-67-9; (methysergide) 16509-15-2, 361-37-5, 62288-72-6; (piperazine estrone sulfate) 7280-37-7; (progesterone) 57-83-0; (prolactin) 12585-34-1, 50647-00-2, 9002-62-4; (quinestrol) 152-43-2; (tamoxifen citrate) 54965-24-1

CHEMICAL NAME: Danocrine; Nolvadex; Parlodel; Premarin; Ogen; Estraval; Estinyl; Estrovis

L169 ANSWER 36 OF 41 TOXCENTER COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:34866 TOXCENTER

COPYRIGHT: Copyright 2006 ACS

DOCUMENT NUMBER: CA14410177480Z

TITLE: Pharmaceutical-encapsulated nanoparticles for transmucosal absorption

AUTHOR(S): Mizushima, Hiroshi; Ueno, Yukio; Udagawa, Masae; Kameyama, Mieko; Suzuki, Yoshiki; Sekine, Junzo

CORPORATE SOURCE: ASSIGNEE: Ltt Biopharma Co., Ltd.

PATENT INFORMATION: JP 200628031 A2 2 Feb 2006

SOURCE: (2006) Jpn. Kokai Tokkyo Koho, 19 pp.  
CODEN: JKXXAF.

COUNTRY: JAPAN

DOCUMENT TYPE: Patent

FILE SEGMENT: CAPLUS

OTHER SOURCE: CAPLUS 2006:99929

LANGUAGE: Japanese

ENTRY DATE: Entered STN: 20060207

Last Updated on STN: 20060228

ABSTRACT:

Title nanoparticles contain divalent metal salts, hydrophobic substances, and/or sugars, and pharmaceuticals encapsulated in cores having CO<sub>2</sub>H on the surface. Thus, rhodamine-encapsulated, carboxylated polystyrene nanoparticles were treated with CaCl<sub>2</sub> to give secondary nanoparticles with particle size 50 nm, which were almost completely absorbed from jejunum in mice.

CLASSIFICATION CODE: 63-6

SUPPLEMENTARY TERMS: Miscellaneous Descriptors

## REGISTRY NUMBER:

carboxylated polystyrene nanoparticle transmucosal drug  
bioavailability; calcium chloride nanoparticle  
transmucosal drug bioavailability; divalent metal salt  
hydrophobic substance sugar nanoparticle drug  
bioavailability

9004-10-8 (Insulin)  
50-21-5 (Lactic acid)  
50-28-2 (Estradiol)  
50-50-0 (Estradiol benzoate)  
50-53-3 (Chlorpromazine)  
52-21-1 (Prednisolone acetate)  
57-85-2 (Testosterone propionate)  
58-22-0 (Testosterone)  
59-05-2 (Methotrexate)  
68-26-8 (Retinol)  
69-93-2 (Uric acid)  
143-19-1 (Sodium oleate)  
144-62-7 (Oxalic acid)  
302-79-4 (Retinoic acid)  
315-37-7 (Testosterone enanthate)  
363-24-6 (Dinoprostone)  
378-44-9 (Betamethasone)  
389-08-2 (Nalidixic acid)  
439-14-5 (Diazepam)  
497-19-8 (Sodium carbonate)  
544-63-8 (Myristic acid)  
745-65-3 (Alprostadil)  
979-32-8 (Estradiol valerate)  
1177-87-3 (Dexamethasone acetate)  
1406-16-2 (Vitamin D)  
1406-18-4 (Vitamin E)  
2152-44-5 (Betamethasone valerate)  
5104-49-4 (Flurbiprofen)  
5536-17-4 (Vidarabine)  
5593-20-4 (Betamethasone dipropionate)  
7439-95-4Q (Magnesium, salts)  
7440-50-8Q (Copper, salts)  
7646-85-7 (Zinc chloride)  
7705-08-0 (Ferric chloride)  
9002-60-2 (ACTH)  
9002-64-6 (Parathyroid hormone)  
9002-72-6 (Somatotropin)  
9003-53-6Q (Polystyrene, carboxylated)  
9003-70-7Q (Divinylbenzene-styrene copolymer,  
carboxylated)  
9004-96-0 (Polyethylene glycol oleate)  
9007-12-9 (Calcitonin)  
9010-92-8Q (Methacrylic acid-styrene copolymer,  
carboxylated)  
9014-42-0 (Thrombopoietin)  
9034-40-6 (Luteinizing hormone-releasing  
hormone)  
9039-53-6 (Urokinase)  
9054-89-1 (Superoxide dismutase)  
9061-61-4 (Nerve growth factor)  
10043-52-4 (Calcium chloride)  
11000-17-2 (Vasopressin)  
11096-26-7 (Erythropoietin)  
11103-57-4 (Vitamin A)  
12001-79-5 (Vitamin K)

15663-27-1 (Cisplatin)  
17902-23-7 (Tegafur)  
21829-25-4 (Nifedipine)  
22071-15-4 (Ketoprofen)  
23214-92-8 (Doxorubicin)  
24305-27-9 (Thyrotropin-releasing hormone)  
26023-30-3 (Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)])  
26100-51-6 (Lactic acid homopolymer)  
33069-62-4 (Paclitaxel)  
34346-01-5 (Lactic acid-glycolic acid copolymer)  
54527-84-3 (Nicardipine hydrochloride)  
59277-89-3 (Acyclovir)  
59865-13-3 (Ciclosporin)  
61422-45-5 (Carmofur)  
62031-54-3 (Fibroblast growth factor)  
62229-50-9 (Epidermal growth factor)  
70458-96-7 (Norfloxacin)  
78110-38-0 (Aztreonam)  
81103-11-9 (Clarithromycin)  
82419-36-1 (Ofloxacin)  
83869-56-1 (Granulocyte macrophage colony-stimulating factor)  
91503-79-6 (Flurbiprofen axetil)  
91832-40-5 (Cefdinir)  
100286-90-6 (Irinotecan hydrochloride)  
104987-11-3 (Tacrolimus)  
130939-66-1 (Neurotrophin 3)  
139639-23-9 (Tissue plasminogen activator)  
143011-72-7 (Granulocyte colony-stimulating factor)  
145040-37-5 (Candesartan cilexetil)  
154598-52-4 (Efavirenz)  
169494-85-3 (Leptin)  
170277-31-3 (Infliximab)  
185243-69-0 (Etanercept)  
REGISTRY NUMBER: 111470-99-6

L169 ANSWER 37 OF 41 TOXCENTER COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1994:187800 TOXCENTER  
COPYRIGHT: Copyright 2006 ACS  
DOCUMENT NUMBER: CA12124286617V  
TITLE: Permeation enhancement of topical pharmaceuticals by inducing phase separation of epithelial lipid bilayers  
AUTHOR(S): Elias, Peter M.; Thornfeldt, Carl R.; Feingold, Kenneth R.; Holleran, Walter M.  
CORPORATE SOURCE: ASSIGNEE: Regents of the University of California  
PATENT INFORMATION: WO 9421271 A1 29 Sep 1994  
SOURCE: (1994) PCT Int. Appl., 29 pp.  
CODEN: PIXXD2.  
COUNTRY: UNITED STATES  
DOCUMENT TYPE: Patent  
FILE SEGMENT: CAPLUS  
OTHER SOURCE: CAPLUS 1994:686617  
LANGUAGE: English  
ENTRY DATE: Entered STN: 20011116  
Last Updated on STN: 20020917

ABSTRACT:  
Topical compns. containing  $\geq 1$  intercellular phase-separating agent, such as epicholesterol (I), are used for inducing phase separation of the epithelial multilayered lipid bilayers within the intercellular spaces of the stratum corneum in a host in need of the topical administration of a physiol. active

substance. Combination of I with transvaccenic acid in propylene glycol/EtOH delivered LHRH at 4.7 times the amount delivered by the vehicle. A lotion contained estradiol valerate 1-10, cetyl alc. 200, propylene glycol 100, Na lauryl sulfate 15, I 10 g, and water 400mL.

CLASSIFICATION CODE: 63-6

SUPPLEMENTARY TERMS: Miscellaneous Descriptors

permeation phase sepn epithelial lipid bilayer; topical  
permeation enhancer epithelial lipid bilayer;  
transvaccenic acid epicholesterol estradiol lotion

REGISTRY NUMBER: 53-86-1 (Indomethacin)  
54-05-7 (Chloroquine)  
57-55-6 (Propylene glycol)  
57-88-5 (Cholesterol)  
58-08-2 (Caffeine)  
67-68-5 (DmsO)  
76-41-5 (Oxymorphone)  
77-86-1 (Tris)  
79-63-0 (Lanosterol)  
111-02-4 (Squalene)  
124-30-1 (Stearylamine)  
128-33-6 (Zymosterol)  
128-53-0 (n-Ethylmaleimide)  
137-58-6 (Lidocaine)  
143-28-2 (Oleyl alcohol)  
303-43-5 (Cholesterol oleate)  
313-04-2 (Desmosterol)  
404-86-4 (Capsaicin)  
434-16-2 (7-Dehydrocholesterol)  
474-77-1 (Epicholesterol)  
601-34-3 (Cholesterol palmitate)  
693-72-1 (Trans-Vaccenic acid)  
979-32-8 (Estradiol valerate)  
1256-86-6 (Cholesterol sulfate)  
1393-88-0 (Gramicidin d)  
1908-11-8 (Cholesterol laurate)  
1989-52-2 (Cholesterol myristate)  
2001-95-8 (Valinomycin)  
2387-23-7 (Dicyclohexylcarbodiimide)  
2573-03-7 (Cholesterol arachidate)  
7365-45-9 (Hepes)  
9034-40-6 (Lhrh)  
11000-17-2 (Vasopressin)  
11054-70-9 (Lasalocid)  
17090-79-8 (Monesin)  
20350-15-6 (Brefeldin a)  
28380-24-7 (Nigericin)  
33507-63-0 (Substance p)  
35602-69-8 (Cholesterol stearate)  
51013-18-4 (Methyl pyrrolidone)  
53003-10-4 (Salinomycin)  
59227-89-3 (1-Dodecylazacycloheptan-2-one)  
60299-11-8 (Nifedipine hydrochloride)  
88899-55-2 (Bafilomycin a1)  
88899-56-3 (Bafilomycin b1)

L169 ANSWER 38 OF 41 TOXCENTER COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2002:567563 TOXCENTER  
DOCUMENT NUMBER: DART-TER-93001533  
TITLE: Hormones and hormonal antagonists.  
AUTHOR(S): Schardein J L

CORPORATE SOURCE: International Research and Development Corporation,  
Mattawan, MI.

SOURCE: Chemically Induced Birth Defects, (1993) 2 271-339. Ref:  
687.  
ISBN: 0-8247-8775-7.

DOCUMENT TYPE: (CHAPTER)  
(REVIEW, ACADEMIC)  
General Review; (REVIEW)

FILE SEGMENT: DART

LANGUAGE: English

ENTRY DATE: Entered STN: 20040203  
Last Updated on STN: 20040203

CONTROLLED TERM: Check Tags: Animal; Human; Female  
Pregnancy  
\*Abnormalities, Drug-Induced  
Androgens: TO, TOXICITY  
Estrogens: TO, TOXICITY  
Progestational Hormones: TO, TOXICITY  
\*Androgen Antagonists: TO, TOXICITY  
\*Estrogen Antagonists: TO, TOXICITY  
\*Adrenal Cortex Hormones: TO, TOXICITY  
\*Sex Hormones: TO, TOXICITY

REGISTRY NUMBER: 2363-58-8 (2-alpha,3-alpha-Epithio-5-alpha-androstan-17-  
beta-ol)  
2529-46-6 (17-alpha-(2-Methallyl)-19-nortestosterone)  
434-22-0 (Nandrolone)  
5630-53-5 (Tibolone)  
17924-92-4 (Zearalenone)  
57-85-2 (Testosterone)  
521-10-8 (Methandriol)  
58-18-4 (Methyltestosterone)  
17230-88-5 (Danazol)  
57-83-0 (Progesterone)  
56-53-1 (Diethylstilbestrol)  
50-50-0 (Estradiol benzoate)  
113-38-2 (Estradiol dipropionate)  
979-32-8 (Estradiol valerate)  
57-63-6 (Ethinyl estradiol)  
53-16-7 (Estrone)  
50-27-1 (Estriol)  
1169-79-5 (Quinestradiol)  
2624-43-3 (Cyclofenil)  
84-17-3 (Dienestrol)  
53-03-2 (Prednisone)  
124-94-7 (Triamcinolone)  
84-16-2 (Hexestrol)  
302-22-7 (Chlormadinone acetate)  
297-76-7 (Ethinodiol diacetate)  
52-76-6 (Lynestrenol)  
71-58-9 (Medroxyprogesterone acetate)  
68-22-4 (Norethindrone)  
68-23-5 (Norethynodrel)  
1477-57-2 (Fertilysin)  
926-93-2 (Methallibure)  
434-03-7 (Ethisterone)  
152-62-5 (Dydrogesterone)  
432-60-0 (Allylestrenol)  
38673-38-0 (Norethindrone acetate)  
68-96-2 (Hydroxyprogesterone)  
520-85-4 (Medroxyprogesterone)

79-64-1 (Dimethisterone)  
302-23-8 (Hydroxyprogesterone acetate)  
630-56-8 (Hydroxyprogesterone caproate)  
797-63-7 (Norgestrel)  
2098-66-0 (Cyproterone)  
911-45-5 (Clomiphene)  
67-98-1 (Ethamoxytriphetol)  
10448-84-7 (Nitromifene)  
9002-60-2 (Corticotropin)  
9002-61-3 (Human chorionic gonadotropin)  
9002-70-4 (Pregnant mare's serum gonadotropin)  
9002-71-5 (Thyrotropin)  
11000-17-2 (Vasopressin)  
61489-71-2 (Human menopausal gonadotropin)  
378-44-9 (Betamethasone)  
4419-39-0 (Beclomethasone)  
50-22-6 (Corticosterone)  
51333-22-3 (Budesonide)  
54063-32-0 (Clobetasone)  
53-06-5 (Cortisone)  
382-67-2 (Desoxymetasone)  
64-85-7 (Desoxycorticosterone)  
50-02-2 (Dexamethasone)  
2607-06-9 (Diflucortolone)  
152-97-6 (Fluocortolone)  
3385-03-3 (Flunisolide)  
50-23-7 (Hydrocortisone)  
6000-74-4 (Hydrocortisone sodium phosphate)  
2668-66-8 (Medrysone)  
83-43-2 (Methylprednisolone)  
50-24-8 (Prednisolone)  
72-33-3 (Mestranol)  
11085-36-2 (Human placental lactogen)  
9034-40-6 (Gonadotropin-releasing hormone)  
125-04-2 (Hydrocortisone sodium succinate)  
13609-67-1 (Hydrocortisone 17-alpha-butyrate)  
897-06-3 (delta-1,4-Androstadiene-3,17-dione)  
1852-53-5 (Androstenediol, 3alpha,17beta-)  
846-46-8 (Androstenedione)  
633-35-2 (1,4,6-Androstatriene-3,17-dione)  
521-17-5 (Androstenediol)  
63-05-8 (Androstenedione)  
53-41-8 (Androsterone)  
17021-26-0 (Calusterone)  
248-66-2 (2alpha-Cyano-4,4,17alpha-trimethylandrosterone-5-en-17beta-ol-3-one)  
53-43-0 (Dehydroepiandrosterone)  
521-18-6 (Dihydrotestosterone)  
965-90-2 (Ethylestrenol)  
20799-24-0 (17alpha-Ethynyl-17beta-acetoxy-19-norandrost-4-en-3-one oxime)  
98319-26-7 (Finasteride)  
76-43-7 (Fluoxymesterone)  
1424-00-6 (Mesterolone)  
3704-09-4 (Mibolerone)  
797-58-0 (Norbolethone)  
52-78-8 (Norethandrolone)  
434-07-1 (Oxymetholone)  
10418-03-8 (Stanozolol)  
26538-44-3 (Zeranol)



57-91-0 (Estradiol, alpha-)  
50-28-2 (Estradiol, 17beta-)  
7642-52-6 (17-Ethynyl-7alpha-methyl-19-nortestosterone)  
21327-74-2 (F 6103)  
152-43-2 (Quinestrol)  
43085-16-1 (STS 153)  
65928-58-7 (STS 557)  
24356-94-3 (Algestone acetophenide)  
1961-77-9 (Chlormadinone)  
427-51-0 (6-Chloro-delta6-1,2alpha-methylene-17alpha-hydroxyprogesterone acetate)  
2529-45-5 (Flurogestone acetate)  
145-15-3 (20beta-Hydroxy-pregn-4-en-3-one)  
595-33-5 (Megestrol acetate)  
2919-66-6 (Melengestrol acetate)  
128-20-1 (Pregnanolone)  
2755-10-4 (Retroprogesterone)  
8056-92-6 (Ethynodiol diacetate-mestranol)  
8015-14-3 (Lynestrenol-mestranol)  
8015-29-0 (Norethindrone-mestranol)  
8015-30-3 (Norethynodrel-mestranol)  
8056-51-7 (Norgestrel-ethinyl estradiol)  
79-01-6 (TRI)  
31477-60-8 (Centchroman)  
34616-48-3 (5-((2-Chlorobenzylidene)-amino)-isoquinoline)  
38641-70-2 (N-(2-Chloro-1-naphthylidene)-3-amino-2:6-lutidine)  
64959-26-8 (N-(2-Chloro-1-naphthylidene)aniline)  
40226-25-3 (N-(2-Chloro-1-naphthylidene)-o-anisidine)  
40226-23-1 (N-(2-Chloro-1-naphthylidene)-o-toluidine)  
40226-24-2 (N-(2-Chloro-1-naphthylidene)-p-toluidine)  
38641-71-3 (N-(2-Chloro-1-naphthyl)-N-phenylmethylaniline)  
33204-76-1 (2,6-cis-Diphenylhexamethyl-cyclotetrasiloxane)  
467-77-6 (Coronaridine)  
71743-82-3 (1,2-Diethyl-1,3-bis-p-hydroxyphenyl-1-propene)  
1945-67-1 (Dimethylglyoxal-bis-(guanylhydrazone))  
1945-68-2 (Ethylglyoxal-bis-guanylhydrazone)  
595-57-3 (9alpha-Fluoro-11beta,17-dihydroxy-3-oxo-4-androstene-17alpha-propionic acid)  
76430-81-4 (Glyoxal-bis(guanylhydrazone) diacetate)  
109-56-8 (2-Isopropylamino ethanol)  
1945-62-6 (Malonaldehyde-bis-guanylhydrazone)  
21658-26-4 (p-Nitrophenyl-p'-guanidino benzoate)  
7698-97-7 (ORF-3858)  
16550-39-3 (ORF-4563)  
27953-80-6 (ORF-5656)  
76584-58-2 (2-Oxophenylacetaldehyde-1-guanylhydrazone)  
53305-31-0 (DL-6-(N-alpha-Pipecolinomethyl)-5-hydroxyindane maleate)  
6237-78-1 (Pyruvic acid guanylhydrazone)  
76567-36-7 (Quinone oxime guanylhydrazone)  
1238-54-6 (SCH 10015)  
20835-91-0 (5-alpha-Stigmastane-3beta-5,6beta-triol-3-monobenzoate)  
13073-86-4 (SU-13320)  
3646-61-5 (U-10293)  
3414-47-9 (U-11634)  
24543-59-7 (6alpha-Bromo-17beta-methyl-4-oxa-5alpha-androstan-3-one)  
39962-28-2 (N-3,5-Dimethyl-4-isoxazolyl-methyl

phthalimide)  
 13311-84-7 (Flutamide)  
 65121-68-8 (1-(p-(2-N,N-Diethylaminoethoxy)phenyl)-1,2-di-(p-methoxyphenyl)-but-1-ene)  
 21708-94-1 (1-[p-(beta-Diethylaminoethoxy)phenyl]-2-nitro-1,2-diphenyl ethylene)  
 6732-77-0 (1[p-(beta-Diethylaminoethoxy)phenyl]-1-phenyl-2-(p-methoxyphenyl)-ethane)  
 37820-57-8 (1-[p-(beta-Dimethylaminoethoxy)phenyl]-2-nitro-1,2-diphenyl ethylene)  
 1845-11-0 (Nafoxidine)  
 10540-29-1 (Tamoxifen)  
 89778-26-7 (Toremifene)  
 9002-72-6 (Anterior pituitary hormone)  
 33515-09-2 (Gonadorelin)  
 9034-42-8 (beta-Melanotropin)  
 9002-64-6 (Parathormone)  
 9002-62-4 (Prolactin)  
 24305-27-9 (Thyrotropin-releasing hormone)  
 66734-13-2 (Alclometasone)  
 52-39-1 (Aldosterone)  
 2135-17-3 (Flumethasone)  
 145-13-1 (Pregnenolone)  
 0 (Androgens); 0 (Estrogens); 0 (Progestational hormones);  
 0 (Androgen antagonists); 0 (Estrogen antagonists); 0  
 (Adrenal cortex hormones); 0 (Sex hormones); 0 (Oral  
 contraceptives); 0 (Menotropins); 0 (Conjugated  
 estrogens); 0 (16beta-Bromo-3beta,17-hydroxy-5alpha-  
 pregnane-11,20-dione); 0 (Dihydroisoandrosterone); 0  
 (Hydroxymethylandrosterone); 0 (2,3-Diphenyl-6-methoxy-1-  
 (N-methyl-N-propargyl) aminoindene); 0  
 (2,3-Diphenyl-1-(N-methyl-N-propargyl) aminoindene); 0  
 (Ethylene-bis-guanide copper sulfate); 0  
 (Phenylglyoxal-bis(guanylhydrazone)); 0  
 (o-Phthalaldehyde-bis-(guanylhydrazone)); 0  
 (Succinaldehyde-bis(guanylhydrazone)); 0  
 (1-(p-(2-N,N-Diethylaminoethoxy)phenyl)-1,2-di-(p-  
 methoxyphenyl)-3-methyl-but-1-ene); 0  
 (1-(p-(beta-Diethylaminoethoxy)phenyl)-1,2-diphenyl  
 ethylene); 0 (2-[p-(6-Methoxy-2-phenyliden-3-  
 ly)phenoxy]triethylamine); 0 (Menotropins)

## CHEMICAL NAME:

L169 ANSWER 39 OF 41 TOXCENTER COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1985:74669 TOXCENTER  
 COPYRIGHT: Copyright (c) 2006 The Thomson Corporation  
 DOCUMENT NUMBER: PREV198579030165  
 TITLE: POLYCYSTIC OVARIAN CONDITION IN ESTRADIOL VALERATE-TREATED  
 RATS SPONTANEOUS CHANGES IN CHARACTERISTIC ENDOCRINE  
 FEATURES  
 AUTHOR(S): SCHULSTER A [Reprint author]; FAROOKHI R; BRAWER J R  
 CORPORATE SOURCE: DEP OF OBSTET AND GYNECOL, F3 WOMEN'S PAVILION, ROYAL  
 VICTORIA HOSP, 687 PINE AVE WEST, MONTREAL, QUEBEC, H3A  
 1A1, CANADA  
 SOURCE: Biology of Reproduction, (1984) Vol. 31, No. 3, pp.  
 587-594.  
 CODEN: BIREBV. ISSN: 0006-3363.  
 DOCUMENT TYPE: Article  
 FILE SEGMENT: BIOSIS  
 OTHER SOURCE: BIOSIS 1985:250169  
 LANGUAGE: ENGLISH

ENTRY DATE: Entered STN: 20011116  
Last Updated on STN: 20011116

## ABSTRACT:

A chronic anovulatory polycystic ovarian (PCO) condition can be induced in rats with estradiol valerate (EV). The early stages (8-10 wk after EV treatment) of the condition are characterized by low basal plasma luteinizing hormone (LH) and estradiol concentrations, as well as poor LH responsiveness to LHRH. Alterations in pituitary LH secretory activity may be involved in induction and maintenance of the PCO condition. To examine this possibility basal plasma LH and FSH concentrations were measured at various times (6, 15, 20 and 22 wk) after treatment with EV. At 22 wk, animals were subjected to a double LHRH pulse or equivalent treatment with saline. Basal plasma LH concentrations in EV-treated animals doubled between 6 and 22 wk. Despite this sharp increase, basal plasma LH concentrations at 22 wk were still significantly lower in EV-treated animals compared to proestrous controls. Basal FSH in EV-treated animals remained in the proestrous range throughout the 22-wk period. Pituitary FSH and LH secretions in response to the LHRH challenge were significantly greater in EV-treated animals compared to proestrous controls. Plasma estradiol was significantly greater at 22 wk post-EV treatment than at 9 wk and this difference was reflected in the histology of the endometrium. A PCO condition is compatible with radical alterations in basal LH, and responsiveness to LHRH. Aberrations in the ability to secrete LH do not appear to be causal in maintaining the condition.

CLASSIFICATION CODE: Microscopy - Histology and histochemistry 01056  
Cytology - Animal 02506  
Circadian rhythms and other periodic cycles 07200  
Biochemistry studies - Proteins, peptides and amino acids 10064  
Biochemistry studies - Sterols and steroids 10067  
Biochemistry studies - Carbohydrates 10068  
Anatomy and Histology - Microscopic and ultramicroscopic anatomy 11108  
Metabolism - Carbohydrates 13004  
Metabolism - Sterols and steroids 13008  
Metabolism - Proteins, peptides and amino acids 13012  
Blood - Blood and lymph studies 15002  
Reproductive system - General and methods 16501  
Reproductive system - Pathology 16506  
Endocrine - Gonads and placenta 17006  
Endocrine - Pituitary 17014  
Endocrine - Neuroendocrinology 17020  
Nervous system - Physiology and biochemistry 20504  
Pharmacology - Drug metabolism and metabolic stimulators 22003  
Pharmacology - Endocrine system 22016  
Pharmacology - Reproductive system and implantation studies 22028  
Toxicology - Pharmacology 22504  
Development and Embryology - Descriptive teratology and teratogenesis 25552

SUPPLEMENTARY TERMS: Major Concepts  
Cell Biology; Endocrine System (Chemical Coordination and Homeostasis); Metabolism; Morphology; Pharmacology; Reproductive System (Reproduction); Toxicology

SUPPLEMENTARY TERMS: Miscellaneous Descriptors  
ENDOMETRIUM PITUITARY ALTERATION LUTEINIZING HORMONE LHRH FSH

ORGANISM: Classifier  
Muridae 86375  
Super Taxa

Rodentia; Mammalia; Vertebrata; Chordata; Animalia  
Taxa Notes

Animals, Chordates, Mammals, Nonhuman Vertebrates,  
Nonhuman Mammals, Rodents, Vertebrates

REGISTRY NUMBER: 979-32-8 (ESTRADIOL VALERATE)  
9002-67-9 (LUTEINIZING HORMONE)  
9034-40-6 (LHRH)  
9002-68-0 (FSH)

L169 ANSWER 40 OF 41 TOXCENTER COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1980:63320 TOXCENTER  
COPYRIGHT: Copyright (c) 2006 The Thomson Corporation  
DOCUMENT NUMBER: PREV198069071126  
TITLE: EFFECTS OF ESTRADIOL INDUCED LESIONS OF THE ARCUATE  
NUCLEUS ON GONADOTROPIN RELEASE IN RESPONSE TO PREOPTIC  
STIMULATION IN THE RAT  
AUTHOR(S): BRAWER J R [Reprint author]; RUF K B; NAFTOLIN F  
CORPORATE SOURCE: DEP OBSTET GYNECOL, R VICTORIA HOSP, WOMENS PAVILLON, 687  
PINE AVE W, MONTREAL, QUE H3A 1A1, CAN  
SOURCE: Neuroendocrinology, (1980) Vol. 30, No. 3, pp. 144-149.  
CODEN: NUNDAJ. ISSN: 0028-3835.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BIOSIS  
OTHER SOURCE: BIOSIS 1980:196130  
LANGUAGE: ENGLISH  
ENTRY DATE: Entered STN: 20011116  
Last Updated on STN: 20011116

ABSTRACT:

Female Wistar rats treated with a single s.c. injection of 2 mg estradiol valerate (EV) develop gradually progressive, multifocal lesions of the arcuate nucleus. They also exhibit persistent vaginal estrus and endocrine profiles characteristic of animals sustaining anterior hypothalamic deafferentiation. In this study, EV-treated females with the arcuate lesions released significantly less LH [lutropin] 1 h following electrochemical stimulation of the medial preoptic area (MPOA) than did normally cycling controls in proestrus. FSH [follitropin] release in response to MPOA stimulation was the same for both groups. As plasma LH concentrations were not significantly different between EV-treated and control animals 1 h after the injection of a potent LHRH [luliberin] analog, the reduced LH response to MPOA stimulation appears to reflect a primarily hypothalamic defect. However, the EV treatment also affected pituitary responsiveness to long-term stimulation as evidenced by reduced LH responses to the LHRH analog after 2 and 3 h. No such differences were seen in the FSH response.

CLASSIFICATION CODE: Circadian rhythms and other periodic cycles 07200  
Biochemistry studies - Proteins, peptides and amino acids 10064  
Biochemistry studies - Sterols and steroids 10067  
Biochemistry studies - Carbohydrates 10068  
External effects - Electric, magnetic and gravitational phenomena 10610  
Metabolism - Carbohydrates 13004  
Metabolism - Sterols and steroids 13008  
Metabolism - Proteins, peptides and amino acids 13012  
Reproductive system - Physiology and biochemistry 16504  
Reproductive system - Pathology 16506  
Endocrine - Gonads and placenta 17006  
Endocrine - Pituitary 17014  
Endocrine - Neuroendocrinology 17020  
Integumentary system - General and methods 18501  
Nervous system - General and methods 20501

Nervous system - Physiology and biochemistry 20504  
 Pharmacology - Drug metabolism and metabolic stimulators  
 22003  
 Pharmacology - Endocrine system 22016  
 Routes of immunization, infection and therapy 22100  
 Toxicology - Pharmacology 22504

## SUPPLEMENTARY TERMS: Major Concepts

Endocrine System (Chemical Coordination and Homeostasis);  
 Nervous System (Neural Coordination); Pharmacology;  
 Reproductive System (Reproduction)

## SUPPLEMENTARY TERMS: Miscellaneous Descriptors

LULIBERIN HORMONE-DRUG ESTRADIOL VALERATE LUTROPIN  
 FOLLITROPIN

## ORGANISM:

Classifier

Muridae 86375

Super Taxa

Rodentia; Mammalia; Vertebrata; Chordata; Animalia

Taxa Notes

Animals, Chordates, Mammals, Nonhuman Vertebrates,  
 Nonhuman Mammals, Rodents, Vertebrates

## REGISTRY NUMBER:

50-28-2 (ESTRADIOL)

9034-40-6 (LULIBERIN)

979-32-8 (ESTRADIOL VALERATE)

152923-57-4 (LUTROPIN)

9002-68-0 (FOLLITROPIN)

9002-67-9 (LUTROPIN)

L169 ANSWER 41 OF 41 ADISINSIGHT COPYRIGHT (C) 2006 Adis Data Information BV  
 on STN

ACCESSION NUMBER: 1998:7442 ADISINSIGHT

SOURCE: Adis R&amp;D Insight

DOCUMENT NO: 008188

CHANGE DATE: Feb 16, 2006

GENERIC NAME: Tibolone

SYNONYM: KB 889; ORG OD 14; ORG OD14

CHEMICAL NAME: 19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-,  
 (7alpha, 17alpha)-


TRADE NAME: Boltin(R); Livial(R); Liviella(R); Livifem(R);  
 Paraclim(R); Xyvion(TM)

MOLECULAR FORMULA: C21 H28 O2

CAS REGISTRY NO.: 5630-53-5

STRUCTURE:

Absolute stereochemistry.



EPHRA ATC CODE: G3 Sex Hormones and Products with Similar Desired Effects, Systemic Action Only; G3B Androgens, Excluding G3E, G3F; G3H Other Sex Hormones and Similar Products; L2A Cytostatic Hormones; M5X All Other Musculoskeletal Products

WHO ATC CODE: G03 Sex Hormones and Modulators of the Genital System; G03C-B Synthetic estrogens, plain; G03X Other Sex Hormones and Modulators of the Genital System; G03X-C Selective estrogen receptor modulators; L02A Hormones and Related Agents; M05B-X Other drugs affecting bone structure and mineralization

HIGHEST DEV. PHASE: Launched

## CURRENT DEVELOPMENT STATUS:

Launched, Asia, Menopausal syndrome  
 Launched, Australia, Menopausal syndrome  
 Launched, Europe, Menopausal syndrome  
 Launched, France, Menopausal syndrome  
 Launched, Latin America, Menopausal syndrome  
 Launched, Norway, Menopausal syndrome  
 Launched, World, Menopausal syndrome  
 Launched, Argentina, Postmenopausal osteoporosis prevention  
 Launched, Asia, Postmenopausal osteoporosis prevention  
 Launched, Europe, Postmenopausal osteoporosis prevention  
 Launched, Latin America, Postmenopausal osteoporosis prevention  
 Launched, Scandinavia, Postmenopausal osteoporosis prevention  
 Registered, United States, Postmenopausal osteoporosis prevention  
 Preregistration, Canada, Menopausal syndrome  
 Preregistration, United States, Menopausal syndrome  
 Preregistration, Canada, Postmenopausal osteoporosis prevention  
 Preregistration, Japan, Postmenopausal osteoporosis treatment  
 Phase III, Europe, Breast cancer  
 Phase III, Japan, Menopausal syndrome  
 Clinical (Phase Unknown), Australia, Female sexual dysfunction  
 Clinical (Phase Unknown), Europe, Female sexual dysfunction  
 Clinical (Phase Unknown), United States, Female sexual dysfunction

## COMPANY INFORMATION

ORIGINATOR: Nourypharma (Germany)  
 PARENT: Akzo Nobel  
 LICENSEE: Elea; Nippon Organon; Organon

OTHER SOURCES: 809022484; 809037749; 809033241; 800708242; 800742374;  
 800855632; 800714153; 800933006; 800540966; 800521913;  
 800551086; 807120199; 800748139; 800672800; 800720849;  
 800465194; 807201067; 800494778; 800916727; 800443030;  
 800691857; 800698900; 800673840; 807172782; 800779944;  
 807200205; 800738134; 800818370; 800833752; 800809422;  
 800810917; 800671375; 800924592; 807162624; 800833829;  
 800917174; 800797271; 800494741

WORD COUNT: 5323

## TEXT

## Introduction:

Tibolone (ORG OD 14, ORG OD14, KB 889, Livial sup((R)), Liviella sup((R)), Livifem sup((R)), Boltin sup((R)), Xyvion(TM), Paraclim sup((R))) is a synthetic steroid belonging to a class of menopausal drugs known as selective tissue estrogenic activity regulator (STEAR), which does not contain estrogen or progestogen. It has estrogenic, progestogenic as well as androgenic properties. Tibolone is indicated for menopausal symptoms associated with

hormone deficiency and osteoporosis. Its action is mainly facilitated by the tissue-specific effects of its three metabolites, which activates specific receptors; the 3alpha-OH and 3beta-OH metabolites display their activity via the estrogen receptor, while the Delta4 metabolite has affinity for the androgen and progesterone receptors/1/.

Tibolone is a tissue-selective estrogen agonist, acting as an estrogen in some tissues including the brain, bone, vaginal tissue and blood vessels, but not acting as an estrogen on the endometrium or breast tissue. In addition, tibolone is mildly androgenic and increases free testosterone among women. Since several motivational aspects of sexual functioning are androgen-dependent, this steroid could also be beneficial in the management of sexual dysfunction in postmenopausal women. The product is available as a 2.5mg daily dose in more than 80 countries worldwide for a variety of indications.

#### Company agreements

Tibolone is in development with Organon and Nourypharma (both subsidiaries of Akzo Nobel) and is licensed to Nippon Organon in Japan. Donmed, the South African agent of Organon, markets Livifem sup((R)) in South Africa.

#### Key development milestones

Osteoporosis and menopausal disorders: tibolone has been launched as a hormonal replacement therapy (HRT) for the treatment of menopausal disorders and for the prevention of postmenopausal osteoporosis in more than 70 countries worldwide, including most Asian, European and Latin American countries, but excluding the US, Canada and Japan. The product is marketed as Livifem sup((R)) in South Africa, Boltin sup((R)) in Spain, Paraclim in Argentina (by ELEA pharmaceuticals) and Livial sup((R)) in other countries.

Studies in the US were conducted at different dosages (1.25 and 0.625mg) from those in other markets (2.5mg) and an application for approval as therapy for the prevention of postmenopausal osteoporosis and as HRT has been made with the FDA. Subsequently, following a request for further information, the FDA has approved tibolone for use in postmenopausal osteoporosis. However, the product will not be launched in the US because labelling is still under FDA review. Additional studies are ongoing in US to address the FDA's labelling concerns. Tibolone is forecasted for launch in the US by the end of 2006, following completion of additional phase III trials in 2005.

Tibolone is also awaiting approval in Canada for the treatment of menopausal disorders and for the prevention of postmenopausal osteoporosis. It is undergoing phase III trials for menopausal syndrome and is awaiting approval for treatment of postmenopausal osteoporosis in Japan; regulatory authorities there have delayed approval of the drug.

In February 2006, Organon announced its decision to close the LIFT ("Long term Intervention on Fractures and other endpoints Trial") study earlier than scheduled, based on the recommendation from the independent study Data & Safety Monitoring Board (DSMB) and Steering Committee. According to interim results, tibolone did decrease the incidence of vertebral fractures, but this was also associated with more strokes versus controls; further DSMB's analysis in January 2006 revealed that such findings had persisted. Consequently, trial investigators and patients have been informed and treatment halted to conduct final assessments. Following full data analysis, Organon will reconsider clinical activities of tibolone for this indication/2/. LIFT was a global, 5-year, randomised, double-blind study investigating tibolone 1.25mg among elderly patients at high risk of osteoporotic fractures. The trial was initiated in July 2001 and completed enrolment in June 2003 with 4538 subjects at > 50 sites located worldwide, including Argentina, Australia, Belgium, Brazil, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Mexico, the

Netherlands, Norway, Poland, Slovakia, Spain, the UK, Venezuela and the US/3/.

Breast cancer: tibolone is in clinical development for the treatment of breast cancer. The LIBERATE (Livial sup((R)) Intervention following Breast cancer Efficacy, Recurrence And Tolerability Endpoints) trial is ongoing among women with a history of breast cancer afflicted by the climacteric symptoms of menopause; patients will be followed for 5 years. Recruitment for the LIBERATE trial started in 2002 and aims to enrol 2600 women in 26 countries, including the Netherlands; other countries have not been specified. In July 2004, Organon announced that > 2200 women have been enrolled in the study involving 260 clinical centres; preliminary data are anticipated in July 2006/4/. LIBERATE trial completion is forecasted in 2008.

In vitro studies have shown that tibolone induces apoptosis in breast cancer cells. Tibolone has also demonstrated anti-ischaemic properties similar to estrogen and may have potential in the prevention of primary and secondary coronary artery disease.

Female sexual dysfunction: Organon is sponsoring a major international study, called LISA (Livial International Study in sexual Arousal disorders) to investigate tibolone 2.5mg for the management of sexual dysfunction among healthy postmenopausal women with an intact uterus. This 6-month, double-blind, double-dummy, randomised trial has been designed to compare tibolone with transdermal estrogen and progestogen therapy. The primary objective of LISA is to evaluate the effects of tibolone on sexual functioning over and above its established ability to relieve climacteric symptoms among this patient population. Only subjects with sexual dysfunction caused by personal distress and not considered to be caused by relationship/partner problems will be eligible to participate/5/. A total of 360 women being recruited at = 25 clinical centres in Europe, the US and Australia; trial enrolment commenced in March 2004 with availability of initial results anticipated by the end of 2005.

Tibolone potentially provides postmenopausal women experiencing sexual dysfunction and impaired well-being with an effective treatment option. It has been shown to improve the mental and sexual well-being of postmenopausal via the drug's effects in influencing libido, arousal and satisfaction. In addition, randomised studies indicate that tibolone improves libido and sexual responsiveness to a greater extent than the conventional estrogen-progestogen therapies/6/.

Product manufacturing: in November 2003, Organon Pharmaceutical announced the official opening of its extended and upgraded factory in Nanjing, China. The factory is fully upgraded for the GMP (Good Manufacturing Practice) production and packaging of pharmaceutical tablets for the local market, which includes Livial sup((R)). This investment confirms the growing importance of the pharmaceutical market in China for Organon.

#### EVALUATION:

Menopausal syndrome 74 (PO).

Postmenopausal osteoporosis prevention 74 (PO).

Postmenopausal osteoporosis treatment 74 (PO).

#### COMMERCIAL SUMMARY:

Osteoporosis + menopause / Steroid

Company	Region	Launch Date	Peak Sales	Patent Expiry
Akzo Nobel	Eur	Feb-1997	\$200m	2010
Akzo Nobel	Japan	2008	\$50m	2010
Akzo Nobel	US	2007	\$300m	



-----  
Copyright (C) Lehman Brothers International. All rights reserved.

#### PHARMACOLOGY OVERVIEW:

##### Pharmacodynamics:

Significant inhibitory effect in human breast cancer cells; inhibits local production of estradiol in breast tissue; increases loss of trabecular but not cortical bone density

##### Mechanism of action:

Androgen agonists

Progesterone agonists

Selective tissue estrogenic activity regulators

#### CLINICAL OVERVIEW:

Route(s) of Administration: PO

Administration Freq. (per day):

##### Adverse events:

most frequent: Vaginal bleeding.

occasional: Breast pain, Dizziness, Headache, Migraine, Nausea, Skin disorders, Weight gain.

rare: Hirsutism, Nervousness, Oedema.

##### Drug Interactions:

Moderate. Tibolone may interact with liver enzyme-inducing drugs and with anticoagulants

#### Adverse Events:

The adverse reaction profile of tibolone is similar to other hormone replacement therapies. The adverse reactions of tibolone reported most commonly to the UK Committee on Safety of Medicines and Medicines Control Agency include headache, dizziness, nausea, rash, pruritus and weight gain. Other adverse effects of tibolone are vaginal bleeding, migraine and visual disturbances. Vaginal bleeding can occur in 8-9% of tibolone recipients/7/.

A UK study found that younger women, women who are recently menopausal and those who have detectable estradiol levels are more likely to report vaginal bleeding while taking tibolone. They also report that even if women do bleed, there is no evidence of endometrial stimulation, or hyperplasia. The researchers compared the incidence of vaginal bleeding in 59 recently menopausal women who received tibolone 2.5mg daily (treatment group), with 53 similar women who received no medication (control group). In the treatment group, 12 women (20%) reported vaginal bleeding. In those who bled, the age of menopause, and the months since last menstrual period were significantly lower, compared to those who did not bleed. In true postmenopausal (12 months after the last menstrual period) the incidence of bleeding was 12%. The number of women who bled in the treatment group who had detectable estradiol levels > 70 pmol/L, was significantly higher, compared to the control group. Only 17% of those who bled in the treatment group had any bleeding after the first 3 months of tibolone treatment. In the control group 75 women (9.4%) reported bleeding. Those who bled in this group were closer to their last menstrual period than those who did not bleed, and the number who had detectable estradiol levels was significantly higher in those who bled than in those who did not. In truly menopausal women the incidence of bleeding was 2.3%/8/.

In a 48-week study in 423 women with menopausal symptoms, vaginal bleeding occurred significantly less often with tibolone than with estradiol/norethisterone. In addition, amenorrhoea was achieved more quickly with tibolone than with estradiol/norethisterone. There were also significantly fewer reports of breast tenderness with tibolone therapy compared with estradiol/norethisterone/9/. However, a study in 235 patients randomised to treatment with tibolone or **estradiol valerate** /norethisterone for 12 months found the incidence of the main adverse events of bleeding, breast tenderness and headache to be comparable between the 2

treatment groups/10/.

Tibolone (2.5 mg/day) and estradiol (50 microg/day) had comparable tolerability in a trial in 76 women with surgical menopause. No adverse events were reported in 23/32 (72%) of patients in the tibolone group and 24/34 (71%) in the estradiol group. Adverse events associated with tibolone included nausea (12%) and weight gain, oedema, facial hair, endometriosis and nervousness (1 patient each). Events reported in the estradiol group were nausea (3%), skin irritation from patches (12%), breast tenderness (9%), weight gain (6%), oedema (3%) and headache (3%)/11/.

88 women with symptomatic osteoporosis were randomised to receive oral tibolone 2.5 mg/day (n = 45), or placebo (43), for 2 years. All patients also received calcium 800 mg/day. 14/88 (15.9%) women discontinued therapy because of adverse events including breast tenderness, increased bodyweight and nausea. 60% of tibolone recipients and 54% of placebo recipients experienced  $\geq 1$  adverse event, while vaginal bleeding or spotting was reported by 31 and 12.2% of patients in the respective treatment groups/12/.

In April 2002, Organon reported that tibolone is significantly better tolerated than conventional hormone replacement therapy (continuous combined estradiol plus norethindrone acetate), according to results from the first study (n = 225) to compare these therapies' tolerability and efficacy on postmenopausal bone loss. The study showed that while both therapies are equally effective, tibolone is markedly less likely to cause vaginal bleeding and breast pain, and therefore provides postmenopausal women with a more acceptable first-line therapy for the protection of bone health/13/.

The most common events in women receiving tibolone or no treatment for the prevention of postmenopausal osteoporosis for 10 years were menopausal vaginal bleeding (34 vs 14%), hypertension (15 vs 22%) and weight increase (15 vs 0%)/14/.

#### Drug Interactions:

Phenytoin, carbamazepine, rifampicin and other drugs which induce liver enzymes can reduce the effectiveness of tibolone by accelerating its metabolism. Tibolone may increase the effect of anticoagulants.

#### PHARMACOLOGY:

##### Pharmacokinetics:

Tibolone is rapidly and almost completely absorbed after oral administration. Peak plasma levels are reached after 1.5-4h and are 2.3-7.8% of the dose administered/litre. Cumulative excretion in the urine is = 30% of the tibolone dose/15/.

There are 3 primary metabolites of tibolone: the delta sup(4)-isomer, the 3alpha-hydroxy metabolite and the 3beta-hydroxy metabolite. All 3 of these metabolites and tibolone itself are pharmacologically active. The main binding affinities of tibolone and the delta sup(4)-isomer are progestogenic and androgenic, whereas the main affinity for the hydroxy metabolites is estrogenic/15/.

96.3% of tibolone is bound to protein in human female serum in vitro. In animal studies, tibolone and its derivatives are widely distributed in tissues after oral administration. Most is found in the liver, and high levels are also found in the kidneys. After repeated dosing, tibolone and its derivatives did not accumulate in tissues/15/.

Tibolone is metabolised by a first-pass effect. It is mainly metabolised in the liver, but metabolism may also occur in the intestine. 60-65% of the drug and its metabolites is excreted in the faeces. In humans, the elimination half-life of tibolone is = 45 hours. After a single dose, the elimination half-life of the hydroxy metabolites is = 6 hours/15/.

##### Pharmacodynamics (Cancer):

Preclinical studies: a study compared the dose-response effect ( $5 \times 10^{-8}$  to  $5 \times 10^{-5}$  mol/L) of tibolone and its metabolites (Org OM38, Org 4094, and Org 30,126) on the sulfatase pathway of 2 hormone-dependent human breast cancer cells MCF-7 and T-47D. After 24h incubation with estrone sulfate  $5 \times 10^{-8}$

sup(-9) mol/L and high doses (5 x 10 sup(-5) and 5 x 10 sup(-6) mol/L) of the different compounds, the conversion of estrone sulfate to estradiol was strongly inhibited by all 5 substances tested. When low doses (5 x 10 sup(-8) and 5 x 10 sup(-7) mol/L) were used, tibolone and the metabolites Org 4094 and Org 30,126 still potently inhibited the conversion of estrone sulfate to estradiol in both cells, but the effect was less intense with Org OM38. Norethisterone was the least potent anti-sulfatase agent tested/16/.

Pharmacodynamics (Ischaemic Heart Disease):

Clinical studies: tibolone 1.25 or 2.5 mg/day significantly decreased serum levels of high density lipoprotein cholesterol, apolipoprotein AI and total cholesterol vs placebo. Serum triglyceride levels were also significantly lowered vs placebo. Levels of plasminogen activator inhibitor antigen and tissue plasminogen activator, and plasminogen activator inhibitor activity were significantly decreased vs placebo/17/. In another study, tibolone significantly decreased triglyceride, lipoprotein(a), plasminogen and plasminogen activator inhibitor-1 levels/18/.

No significant associations were observed between either aortic compliance or blood pressure-corrected aortic compliance values, and body mass index, time since menopause or family history of cardiovascular disease/19/.

Pharmacodynamics (Musculoskeletal Disorders):

Clinical studies: administration of tibolone (1.25 or 2.5mg for 24 months) resulted in a significant placebo-adjusted increase from baseline of trabecular and phalangeal bone density, vs placebo. Both doses of tibolone significantly decreased the levels of alkaline phosphatase and phosphorus from baseline vs placebo. The 2.5mg dose of tibolone significantly decreased the hydroxyproline/creatinine and calcium/creatinine ratios vs placebo/20/. In the first year after discontinuation of tibolone treatment in these patients, there was an increased loss of trabecular bone density compared with placebo/21/.

Pharmacodynamics (Women's Health):

Effects on the breast: in postmenopausal women, treatment with tibolone 2.5 mg/day for up to 24 months resulted in minimal mammographic changes. However, women with no mammographic changes had a significantly higher increase in serum dehydroepiandrosterone (DHEAS) levels than in women with mammographic changes/22/. Another study also showed no significant changes in breast density after treatment with tibolone for >= 12 months, compared with estradiol/nomegestrol/23/.

Effects on bone density: loss of trabecular bone density was significantly greater 1 year after discontinuation of treatment with tibolone in patients treated with either 1.25 or 2.5 mg/day doses of tibolone compared with placebo. However, loss of cortical bone density did not increase in this study of postmenopausal women/21/.

Effects on endometrium: endometrial features were examined in patients with vaginal bleeding during tibolone therapy. In 42/43 patients, the endometrium was atrophic. 16/17 patients with intracavitary lesions (polyps, fibroids, congenital abnormalities) experienced bleeding during tibolone treatment. One patient had endometrial hyperplasia/24/.

Tibolone relieved symptoms of urogenital atrophy and was not associated with endometrial proliferation in women with symptoms of vaginal atrophy. Similar results were also reported after administration of conjugated estrogens/25/.

Uterine bleeding: 28% of postmenopausal women experienced uterine bleeding during treatment with tibolone for 1 year, compared with 59% of women being treated with estradiol/norethisterone/26/.

Other effects: tibolone 2.5 mg/day od for 1 year was associated with a significant reduction in HDL and a significant elevation in serum ApoB in 41 menopausal osteoporotic women. However, total cholesterol values did not change. An increase in body mass index was statistically significant/27/.

Tibolone significantly decreased the levels of triglycerides and fasting glucose from baseline in a study involving 11 healthy postmenopausal women/28/.

Treatment with tibolone increased beta-endorphine levels in menopausal women to premenopausal values, and improved parameters of mood/15/.

In a comparative phase II study in 62 postmenopausal women of mean age 50 years, oral tibolone 2.5mg for 6 months did not significantly affect concentrations of plasma homocysteine, which is an independent risk factor for cardiovascular diseases/29/.

Tibolone and its metabolites enhanced prolactin expression in human endometrial stromal cells/30/.

#### THERAPEUTIC TRIALS:

##### Cancer:

Breast cancer: one patient in a study involving 14 patients with breast cancer showed a partial response to treatment with tibolone. The response duration in this patient was seen in an axillary soft tissue mass and lasted for 24 weeks/31/.

Treatment of the hypoestrogenic state in patients with uterine leiomyoma: in patients with uterine leiomyoma, treatment with a **gonadotropin-releasing hormone** agonist frequently causes unpleasant adverse events because of the hypoestrogenic state induced. In 50 women with uterine leiomyoma, randomised to receive leuprorelin depot (3.75 mg/dose) monthly for 6 months +/- tibolone, the administration of tibolone did not compromise the therapeutic efficacy of leuprorelin. Vasomotor symptoms were significantly reduced and bone loss prevented in recipients of combination therapy vs leuprorelin monotherapy/32/.

In postmenopausal women with uterine leiomyoma, tibolone treatment significantly decreased the incidence of irregular spotting and irregular bleeding vs treatment with conjugated estrogens and medroxyprogesterone acetate. However, the incidence of amenorrhoea was higher in the tibolone group, but the difference did not reach significance. Endometrial thickness in all patients after 12 months' treatment was similar to that at baseline/33/.

##### Ischaemic Heart Disease:

An open-label study involving 10 postmenopausal women with chronic stable angina pectoris and confirmed coronary artery disease found that tibolone appears to have anti-ischaemic properties that are similar to those of estrogen. The women had not taken hormone replacement therapy for the past 3 months. Baseline exercise tests were conducted and the women then received oral tibolone 2.5mg, followed by exercise tests 24 hours later. 30 minutes' rest preceded each exercise test. Tibolone administration was associated with a significant improvement in time to onset of myocardial ischaemia (as defined by ST segment depression); the median time to onset was increased by 102 seconds, compared with baseline. The researchers concluded that a placebo-controlled study in a larger population is warranted/34/.

##### Musculoskeletal Disorders:

Dosage and administration: tibolone is administered as an oral dose once daily. The optimal dose for tolerability and efficacy is 2.5 mg/day.

Treatment of postmenopausal osteoporosis: tibolone 2.5 mg/day bid for 2 years significantly increased trabecular and cortical bone mineral density in 107 postmenopausal osteoporotic women. Lumbar spine bone mineral density increased by an average of 7.2% in tibolone recipients compared with 0.9% in placebo recipients, and by 8.9% in tibolone recipients with previous fractures. Femoral neck bone mineral density increased by 2.6% in tibolone recipients and 1.1% in tibolone recipients with previous fractures, and decreased by 1.6% in placebo recipients/35/. Eighty-eight women with symptomatic osteoporosis were randomised to receive oral tibolone 2.5 mg/day or placebo for 2 years in a double-blind study. After 24 months' therapy, the bone mineral density of the lumbar spine and the femoral neck had increased significantly from baseline in

tibolone, compared with placebo, recipients. The urinary calcium:creatinine ratio and the hydroxyproline:creatinine ratio decreased among tibolone recipients, indicating inhibition of bone resorption. Serum alkaline phosphatase and serum phosphate levels, both markers of bone formation, were also significantly reduced among tibolone, compared with placebo, recipients/12/.

In an open-label study, 47 postmenopausal women with normal mineral bone density (BMD) of the lumbar spine and femur were randomised to receive oral tibolone 2.5 mg/day (n = 26), or no treatment, for 96 weeks. BMD at the neck of the femur and Ward's triangle in tibolone-treated recipients did not significantly change from baseline over the entire study period. However, significant increases from baseline were recorded in the BMD of the lumbar spine from week 24 (+2.34% increasing to +3.67% at week 96), and of the trochanter at week 72 (+3.83%) and week 96 (+3.67%); these differences were significant compared with untreated controls/36/.

A study involving 94 women with postmenopausal osteoporosis, found that fluoride + tibolone was significantly more effective at increasing bone mineral density at the lumbar spine than fluoride + placebo. Lumbar spine bone mineral density increased without concurrent loss of cortical bone/37/.

Prevention of osteoporosis in postmenopausal women: both tibolone and estradiol/norethisterone increased the change in lumbar bone mineral density in postmenopausal women, compared with placebo. 81% of tibolone recipients were still compliant with treatment at 1 year, compared with 65% of patients in the estradiol/norethisterone group/38/. After 1 year, tibolone significantly increased bone mineral density compared with baseline and controls. Similar results were achieved with estradiol or estradiol + androgens/39/.

In a study involving 222 postmenopausal women that received treatment with tibolone or estradiol/norethisterone, bone mineral density increased in the lumbar spine and femur in all treatment groups/40/.

A meta-analysis of 2 phase III studies investigating the efficacy and tolerability of tibolone for the prevention of postmenopausal women found that tibolone 1.25 or 2.5mg increased spine and femur bone mineral density. Biochemical markers of bone turnover decreased at all time points in all treatment groups, and were significantly different from placebo after 2 years/41/.

In March 2002, research presented during an international expert meeting confirmed tibolone's (Livial sup((R))'s) advantages over conventional estrogen-containing hormone replacement therapies. Tibolone is licensed for the treatment of climacteric complaints and the prevention of osteoporosis in postmenopausal women. Clinical trials have confirmed that it is as effective as conventional treatment in alleviating climacteric complaints and may preserve bone mass to the same extent, however, tibolone has shown a number of important differences compared with conventional HRT. Clinical studies have shown that it has superior effects on women's mood and sexual well being. New results from a comparative study involving >500 women showed a significantly lower incidence of breast pain and vaginal bleeding and lower discontinuation rates, than treatment with continuous combined estrogen/progestogen. Results from another study showed that almost 60% of women continued tibolone treatment for at least 8 years - an unprecedented adherence rate that contrasts with that seen with conventional therapies. Observations that tibolone did not increase breast density were also confirmed by results from a double-blind, randomized controlled study. Tibolone did not reduce the sensitivity of mammography screening and is an important advantage compared to conventional HRT/42/.

Long-term treatment: in a randomised study involving 110 postmenopausal women with raised gonadotropin levels, open-label treatment with tibolone 2.5 mg/day for 10 years increased mean bone mineral density in treated women, compared with untreated control patients. Tibolone was associated with a significant improvement in mean lumbar spine and femoral neck bone mineral density at 10 years in postmenopausal women (+4.8 and +3.7%, respectively, vs baseline),

while untreated controls had significant reductions (-8.5 and -8.9%;  $p < 0.001$ ). Tibolone was also associated with a reduced incidence and intensity of hot flushes/14/.

Pharmacoeconomic studies: a Markov model using previously published clinical data, healthcare resource-use estimates provided by an expert panel, and national cost data, was used to compare the costs and outcomes associated with the first 48 weeks of treatment with tibolone and estradiol/norethisterone in postmenopausal women with climacteric symptoms. It was found that for a mean additional cost of Lstg 21/patient, tibolone treatment (total cost Lstg 260/patient) was as effective as estradiol/norethisterone (Lstg 239/patient) at relieving climacteric symptoms in postmenopausal women. In addition, significant reductions in vaginal bleeding (-36%) and breast tenderness (-57%) were reported following tibolone use, compared with estradiol/norethisterone treatment. The comparatively high acquisition cost of tibolone, compared with estradiol/norethisterone (Lstg 140 vs Lstg 85 per patient), was offset by the higher incidence of estradiol/norethisterone-related adverse events, which in turn resulted in a higher HRT continuation rate among tibolone recipients/43/.

Postmenopausal osteoporosis in patients with rheumatoid arthritis: in a study involving 65 patients with rheumatoid arthritis and reduced bone mineral density, tibolone significantly increase bone mineral density at the femoral neck but not at the lumbar spine vs controls. Etidronic acid did significantly increase bone mineral density at the lumbar spine vs controls/44/.

#### Women's Health:

Dosage and administration: tibolone is administered as an oral dose once daily. The optimal dose for tolerability and efficacy is 2.5 mg/day/45/.

Premenstrual syndrome: treatment with tibolone 2.5 mg/day PO for 3 months significantly improved visual linear analogue scale scores and improved beta-endorphin concentrations versus placebo, in a study in 18 patients/46/.

Menopausal syndrome: in a study in 235 patients randomised to treatment with tibolone or **estradiol valerate**/norethisterone for 12 months, both treatments were found to have similar efficacy for relieving menopausal symptoms. However, **estradiol valerate**/norethisterone improved the high density lipoprotein to low density lipoprotein (HDL/LDL) cholesterol ratio, whereas tibolone significantly reduced HDL cholesterol but had no significant effect on the reduction of LDL cholesterol/10/. In a 48-week study in 423 women with menopausal symptoms, tibolone was associated with fewer adverse events than a combination of estradiol/norethisterone. Vaginal bleeding occurred significantly less often with tibolone than with estradiol/norethisterone. In addition, amenorrhoea was achieved more quickly with tibolone than with estradiol/norethisterone. The mean reduction from baseline in the score rating hot flushes among 423 evaluable women with menopausal symptoms was slightly but significantly greater with estradiol/norethisterone 2mg/1mg than with tibolone 2.5 mg/day/9/.

In a study in 210 postmenopausal women, tibolone was effective in relieving menopausal symptoms, particularly mood disorders and loss of libido, in most patients/47/.

Tibolone (2.5 mg/day) was at least as effective as estradiol (50 microg/day) in alleviating menopausal symptoms in a study in 76 women with surgical menopause. Vasomotor symptoms were reduced in 22/23 tibolone recipients and 26/29 receiving estradiol. Backache and arthralgia were reduced in 10/19 tibolone recipients and 9/26 in the estradiol group. Both psychological problems and sexual behaviour were improved in significantly more patients in the tibolone group (13/17 and 10/11, respectively) than in the estradiol group (9/21 and 7/15, respectively). Improvements in total cholesterol and triglyceride levels were also significantly greater in tibolone recipients/11/.

Both tibolone and continuous combined hormone replacement therapy improved

overall quality of life and wellbeing among postmenopausal women, according to results of an international study of 501 such women aged < 65 years who had not undergone hysterectomy and who were randomised to receive oral tibolone 2.5mg (n = 250) or oral conjugated estrogens (Premarin) 0.625mg plus oral medroxyprogesterone (Provera) 5mg for a 12-month period. Tibolone was associated with significantly less vaginal bleeding during cycles four-six than conjugated estrogens/medroxyprogesterone. However, tibolone and conjugated estrogens/medroxyprogesterone both improved quality of life, climacteric symptoms and urogenital symptoms in postmenopausal women/48/.

Female sexual dysfunction: in a study in 120 patients randomised to treatment with tibolone, estradiol or **estradiol valerate** + androgens, the frequency of sexual interest, frequency of orgasm, frequency of dyspareunia, general sexual satisfaction and sexual responsiveness were all significantly improved compared with untreated controls. The frequency of orgasm and sexual responsiveness were improved to a significantly greater extent in patients who received **estradiol valerate** + androgens or tibolone, compared with estradiol alone/39/.

Pharmacoeconomic studies: an economic appraisal found that tibolone improves quality of life for women with menopausal symptoms at 'reasonable cost', according to a UK study. Based on data from published studies over a 5-year period, the researcher estimated that tibolone generates 0.05-0.11 quality-adjusted life-years (QALYs) in women with mild symptoms and 0.11-0.25 QALYs in those with severe symptoms, compared with continuous combined hormone replacement therapy. The cost/QALY gained was estimated to be Lstg 1180-6500 (discounted values). Compared with no hormone replacement therapy, the cost-QALY gained using tibolone also falls within an acceptable range. These cost values are based on the alleviation of menopausal symptoms and do not take into account the reduced risk of hip fracture, which would produce further QALY gains/49/.

Treatment of postmenopausal osteoporosis: tibolone 2.5 mg/day bid for 2 years: significantly increased trabecular and cortical bone mineral density in 107 postmenopausal osteoporotic women. Lumbar spine bone mineral density increased by an average of 7.2% in tibolone recipients compared with 0.9% in placebo recipients, and by 8.9% in tibolone recipients with previous fractures. Femoral neck bone mineral density increased by 2.6% in tibolone recipients and 1.1% in tibolone recipients with previous fractures, and decreased by 1.6% in placebo recipients/35/. Eighty-eight women with symptomatic osteoporosis were randomised to receive oral tibolone 2.5 mg/day or placebo for 2 years in a double-blind study. After 24 months' therapy, the bone mineral density of the lumbar spine and the femoral neck had increased significantly from baseline in tibolone, compared with placebo, recipients. The urinary calcium:creatinine ratio and the hydroxyproline:creatinine ratio decreased among tibolone recipients, indicating inhibition of bone resorption. Serum alkaline phosphatase and serum phosphate levels, both markers of bone formation, were also significantly reduced among tibolone, compared with placebo, recipients/12/.

In an open-label study, 47 postmenopausal women with normal mineral bone density (BMD) of the lumbar spine and femur were randomised to receive oral tibolone 2.5 mg/day (n = 26), or no treatment, for 96 weeks. BMD at the neck of the femur and Ward's triangle in tibolone-treated recipients did not significantly change from baseline over the entire study period. However, significant increases from baseline were recorded in the BMD of the lumbar spine from week 24 (+2.34% increasing to +3.67% at week 96), and of the trochanter at week 72 (+3.83%) and week 96 (+3.67%); these differences were significant compared with untreated controls/36/.

In March 2002, research presented during an international expert meeting confirmed tibolone's (Livial sup(R))'s advantages over conventional



estrogen-containing hormone replacement therapies. Tibolone is licensed for the treatment of climacteric complaints and the prevention of osteoporosis in postmenopausal women. Clinical trials have confirmed that it is as effective as conventional treatment in alleviating climacteric complaints and may preserve bone mass to the same extent, however; tibolone has shown a number of important differences compared with conventional HRT. Clinical studies have shown that it has superior effects on women's mood and sexual well being. New results from a comparative study involving >500 women showed a significantly lower incidence of breast pain and vaginal bleeding and lower discontinuation rates, than treatment with continuous combined estrogen/progestogen. Results from another study showed that almost 60% of women continued tibolone treatment for at least eight years - an unprecedented adherence rate that contrasts with that seen with conventional therapies. Observations that tibolone did not increase breast density were also confirmed by results from a double-blind, randomized controlled study. Tibolone did not reduce the sensitivity of mammography screening and is an important advantage compared to conventional HRT/42/.

Long-term treatment: in a randomised study involving 110 postmenopausal women with raised gonadotropin levels, open-label treatment with tibolone 2.5 mg/day for 10 years increased mean bone mineral density in treated women, compared with untreated control patients. Tibolone was associated with a significant improvement in mean lumbar spine and femoral neck bone mineral density at 10 years in postmenopausal women (+4.8 and +3.7%, respectively, vs baseline), while untreated controls had significant reductions (-8.5 and -8.9%;  $p < 0.001$ ). Tibolone was also associated with a reduced incidence and intensity of hot flushes/14/.

Treatment of endometriosis: tibolone may be a therapeutic option for patients with residual endometriosis after undergoing bilateral oophorectomy with or without hysterectomy according to the results of a study conducted in Italy. In the study, 21 such patients were randomised to receive transdermal estradiol 0.05 mg/day, plus medroxyprogesterone 10 mg/day for 12 days per month, if they had not undergone hysterectomy (10), or tibolone 2.5 mg/day. Patients were followed-up for 12 months. Moderate pelvic pain was experienced by 4 estradiol recipients and 1 tibolone recipient during treatment. No patients experienced severe pelvic pain. One estradiol recipient reported severe dyspareunia; 2 patients in each treatment group experienced mild dyspareunia during treatment/50/.

In a Turkish study, tibolone ameliorated hypoestrogenic symptoms induced by goserelin therapy in women with endometriosis. Women with endometriosis who were receiving SC depot injections of goserelin 3.6mg every 4 weeks for 6 months were randomised to receive oral tibolone 2.5 mg/day ( $n = 15$ ) or an iron pill (14). Treatment with tibolone or iron commenced at the beginning of the third menstrual cycle after starting goserelin therapy. After 3 months' therapy with goserelin alone, both treatment groups reported an increased frequency of vasomotor symptoms such as hot flushes, sweating and nervousness. After the addition of tibolone or iron, the incidence and severity of these symptoms was significantly reduced in tibolone, compared with iron, recipients. Similarly, while the urinary calcium:creatinine ratio increased during therapy with goserelin alone, tibolone recipients demonstrated a significant reduction in the urinary calcium:creatinine ration, compared with iron recipients/51/

#### DEVELOPMENT HISTORY:

27 Feb 2001	A study has been added to the adverse events and Women's Health therapeutic trials sections (855632)
31 Jan 2001	A pharmacoeconomic study has been added to the Musculoskeletal Disorders therapeutic trials section (810917)
08 Jan 2001	Preregistration for Postmenopausal osteoporosis treatment in Japan (PO)
08 Jan 2001	Profile reviewed by Akzo Nobel
28 Jul 2000	Registered for Menopausal syndrome in Australia (PO)



28 Jul 2000 Registered for Menopausal syndrome in France (PO)  
 16 Feb 2000 Launched for Menopausal syndrome in Asia (PO)  
 16 Feb 2000 Launched for Menopausal syndrome in Latin America (PO)  
 16 Feb 2000 Launched for Postmenopausal osteoporosis prevention in Europe (PO)  
 16 Feb 2000 Launched for Postmenopausal osteoporosis prevention in Latin America (PO)  
 25 Jan 2000 Launched for Postmenopausal osteoporosis prevention in Asia (PO)  
 25 Jan 2000 Launched for Postmenopausal osteoporosis prevention in Brazil (PO)  
 25 Jan 2000 Launched for Postmenopausal osteoporosis prevention in Italy (PO)  
 25 Jan 2000 Launched for Postmenopausal osteoporosis prevention in Netherlands (PO)  
 25 Jan 2000 Launched for Postmenopausal osteoporosis prevention in Scandinavia (PO)  
 25 Jan 2000 Launched for Postmenopausal osteoporosis prevention in South Africa (PO)  
 25 Jan 2000 Launched for Postmenopausal osteoporosis prevention in South America (PO)  
 25 Jan 2000 Launched for Postmenopausal osteoporosis prevention in Spain (PO)  
 25 Jan 2000 Launched for Postmenopausal osteoporosis prevention in United Kingdom (PO)  
 25 Jan 2000 Phase-III clinical trials for Postmenopausal osteoporosis treatment in Japan (PO)  
 25 Jan 2000 Preregistration for Menopausal syndrome in Canada (PO)  
 25 Jan 2000 Preregistration for Postmenopausal osteoporosis prevention in Canada (PO)  
 25 Jan 2000 Preregistration for Postmenopausal osteoporosis prevention in Europe (PO)  
 25 Jan 2000 Preregistration for Postmenopausal osteoporosis prevention in USA (PO)  
 18 Nov 1999 Launched for Menopausal syndrome in Germany (PO)  
 18 Nov 1999 Launched for Menopausal syndrome in World (PO)  
 18 Nov 1999 Launched for Postmenopausal osteoporosis in World (PO)  
 18 Nov 1999 Phase-III clinical trials for Menopausal syndrome in Japan (PO)  
 18 Nov 1999 Preregistration for Menopausal syndrome in USA (PO)  
 16 Nov 1999 Kanebo's pharmaceutical business has been merged with Organon's Japanese operations to form Nippon Organon  
 29 Oct 1999 A study in patients with residual endometriosis has been added to the Women's Health therapeutic trials section (797271)  
 29 Oct 1999 Investigation in Endometriosis in Italy (PO)  
 11 Oct 1999 Launched for Postmenopausal osteoporosis in Asia (PO)  
 11 Oct 1999 Launched for Postmenopausal osteoporosis in South America (PO)  
 21 Sep 1999 Launched for Menopausal syndrome in Scandinavia (PO)  
 21 Sep 1999 Launched for Postmenopausal osteoporosis in Scandinavia (PO)  
 09 Sep 1999 Launched for Postmenopausal osteoporosis in Europe (PO)  
 09 Sep 1999 Preregistration for Postmenopausal osteoporosis in Canada (PO)  
 09 Sep 1999 Preregistration for Postmenopausal osteoporosis in USA (PO)  
 06 Sep 1999 A study in postmenopausal women with osteoporosis has been added to the Musculoskeletal Disorders and Women's Health therapeutic trials sections (779944)  
 30 Apr 1999 A clinical study of bone density loss has been added to the Women's Health pharmacodynamics section (748139)  
 29 Oct 1998 A study in women with osteoporosis has been added to the adverse events and the Musculoskeletal Disorders and Women's Health therapeutic trials sections (714153)  
 15 Sep 1998 A study has been added to the Women's Health therapeutic trials section (698900)  
 18 Aug 1998 A study has been added to the Women's Health therapeutic trials section (691857)

- 15 Jul 1998 Launched for Menopausal syndrome in Brazil (PO)
- 30 Jun 1998 Phase-III clinical trials for Postmenopausal osteoporosis in Japan (PO)
- 30 Jun 1998 Profile reviewed by Kanebo
- 22 Jun 1998 A clinical study has been added to the Women's Health pharmacodynamics section (672800)
- 04 Jun 1998 Launched for Menopausal syndrome in Spain (PO)
- 02 Dec 1997 Phase-III clinical trials for Postmenopausal osteoporosis in USA (PO)
- 23 Jun 1997 Preclinical development for Breast cancer in France (PO)
- 23 Jun 1997 Preclinical development for Breast cancer in Netherlands (PO)
- 25 Feb 1997 Launched for Menopausal syndrome in Italy (PO)
- 25 Feb 1997 Launched for Menopausal syndrome in South Africa (PO)
- 25 Feb 1997 Phase-III clinical trials for Postmenopausal osteoporosis in Europe (PO)
- 20 Feb 1997 Launched for Menopausal syndrome in Europe (PO)
- 20 Feb 1997 Launched for Menopausal syndrome in Netherlands (PO)
- 20 Feb 1997 New profile
- 20 Feb 1997 Phase-II clinical trials for Postmenopausal osteoporosis in Japan (PO)
- 20 Feb 1997 Phase-II clinical trials for Postmenopausal osteoporosis in USA (PO)

#### REFERENCES

1. Vogelvang TE, van der Mooren MJ, et al. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. *Treatments in Endocrinology*. 3: 105-115, No. 2, 2004. (English).
2. Organon. Organon to close the LIFT study. Media Release. : 16 Feb 2006. Available from: URL: <http://www.organon.com>. (English).
3. Organon NV. Organon's 'Pivotal' Lift Study completes enrollment. Media Release. : 16 Jun 2003. Available from: URL: <http://www.organon.com>. (English). 809022484
4. Organon. Women with breast cancer history prove eager to take part in Organon's LIBERATE trial. Media Release. : 20 Jul 2004. Available from: URL: <http://www.organon.com>. (English). 809037749
5. Organon. Organon announces research study to investigate Livial(R) in postmenopausal women with sexual dysfunction. Media Release. : 1 Apr 2004. Available from: URL: <http://www.organon.com>. (English). 809033241
6. Organon. Tibolone, the unique menopausal therapy for improvement of sexual life in postmenopausal women. Media Release. : 12 Jun 2004. Available from: URL: <http://www.organon.com>. (English).
7. Tibolone (Livial). *Current Problems in Pharmacovigilance*. 20: 14, Nov 1994. (English).
8. Rymer J, Fogelman I, et al. The incidence of vaginal bleeding with tibolone treatment. *British Journal of Obstetrics and Gynaecology*. 101: 53-56, Jan 1994. (English).
9. Hammar M, Christau S, et al. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. *British Journal of Obstetrics and Gynaecology*. 105: 904-911, Aug 1998. (English). 800708242
10. Al-Azzawi F, Wahab M, et al. Continuous combined hormone replacement therapy compared with tibolone. *Obstetrics and Gynecology*. 93: 258-264, Feb 1999. (English). 800742374
11. Mendoza N, Suarez AM, et al. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17-beta-estradiol for hormonal replacement therapy in women with surgical menopause. *Maturitas*. 37: 37-43, 30 Nov 2000. (English). 800855632
12. Studd J, Arnala I, et al. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures.

- Obstetrics and Gynecology. 92: 574-579, Part 1, Oct 1998. (English). 800714153
13. Organon. Livial(R) offers important tolerability advantages over conventional hormone replacement therapy increasing its long-term acceptability. Media Release. : 24 Apr 2002. Available from: URL: <http://www.organon.com>. (English).
  14. Rymer J, Robinson J, et al. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric. 5: 390-398, Dec 2002. (English). 800933006
  15. NV Organon. Livial (Rm) scientific information: tissue-specific therapy for the menopause. Company Communication. : (72 pages), Aug 2000. Available from: URL: <http://www.organon.com>. (English).
  16. Chetrite G, Kloosterboer HJ, et al. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Research. 17: 135-140, Jan-Feb 1997. (English).
  17. Bjarnason NH, Bjarnason K, et al. Tibolone: influence on markers of cardiovascular disease. Journal of Clinical Endocrinology and Metabolism. 82: 1752-1756, Jun 1997. (English). 800540966
  18. Rosati D, Micheli S, et al. Changes in lipidic and hemostatic parameters induced by tibolone treatment. Thrombosis Research. 85: 273-278, 1 Feb 1997. (English). 800521913
  19. Ross JR, Hopkins KD, et al. Treatment with hormone replacement therapy (tibolone) affects the relationship between serum lipids and aortic distensibility. Journal of Vascular Investigation. 3: 87-93, Jun 1997. (English). 800551086
  20. Berning B, Kuijk CV, et al. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone. 19: 395-399, Oct 1996. (English). 807120199
  21. Berning B, v Kuijk C, et al. Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 years hormone replacement therapy with Tibolone. Maturitas. 31: 151-159, 4 Jan 1999. (English). 800748139
  22. Tamer Erel C, Elter K, et al. Mammographic changes in women receiving tibolone therapy. Fertility and Sterility. 69: 870-875, May 1998. (English). 800672800
  23. Colacurci N, Mele D, et al. Effects of tibolone on the breast. European Journal of Obstetrics & Gynecology and Reproductive Biology. 80: 235-238, Oct 1998. (English). 800720849
  24. Habiba M, Ramsay J, et al. Immunohistochemical and hysteroscopic assessment of postmenopausal women with uterine bleeding whilst taking tibolone. European Journal of Obstetrics & Gynecology and Reproductive Biology. 66: 45-49, 1996. (English). 800465194
  25. Hao R, Pfeiffer RF. Effect of pramipexole on mesencephalic dopaminergic neurons in culture. Annals of Neurology. 44: 454, Sep 1998. (English).
  26. Doren M, Rubig A, et al. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause. 6: 299-306, No. 4, 1999. (English). 807201067
  27. Haddad J, Delaroudis S, et al. The effects of tibolone on the lipid profile of postmenopausal women with osteoporosis. 66th Congress of the European Atherosclerosis Society. : 55, 13 Jul 1996. (English).
  28. Cagnacci A, Mallus E, et al. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. Journal of Clinical Endocrinology and Metabolism. 82: 251-253, Jan 1997. (English). 800494778
  29. Celik H, Ayar A, et al. Effects of tibolone on plasma homocysteine levels in postmenopausal women. Fertility and Sterility. 78: 347-350, Aug 2002. (English). 800916727
  30. Schatz F, Kuczynski E, et al. Tibolone and its metabolites enhance prolactin expression in human endometrial stromal cells. 16th Annual Meeting of the North American Menopause Society. : abstr. S-12, 28 Sep 2005.

Available from: URL: <http://www.menopause.org>. (English).

31. O'Brien MER, Montes A, et al. Hormone replacement therapy as treatment of breast cancer - a phase II study of Org OD 14 (tibolone). *British Journal of Cancer*. 73: 1086-1088, May 1996. (English). 800443030
32. Palomba S, Affinito P, et al. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. *Fertility and Sterility*. 70: 111-118, Jul 1998. (English). 800691857
33. de Aloysio D, Altieri P, et al. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. *Maturitas*. 29: 261-264, 17 Jun 1998. (English). 800698900
34. Lloyd GWL, Patel NR, et al. Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina. *International Journal of Clinical Practice*. 52: 155-157, Apr-May 1998. (English). 800673840
35. Pavlov PW, Ginsburg J, et al. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. *Gynecological Endocrinology*. 13: 230-237, Aug 1999. (English). 807172782
36. Beardsworth SA, Kearney CE, et al. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. *British Journal of Obstetrics and Gynaecology*. 106: 678-683, Jul 1999. (English). 800779944
37. Reginster JY, Agnusdei D, et al. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. *Gynecological Endocrinology*. 13: 361-368, Oct 1999. (English). 807200205
38. Donhauser P, Hartard M, et al. Better tolerability and compliance of tibolone (Livial R) vs. estradiol (KLIOGEST R) for prevention of postmenopausal osteoporosis after 1 year of treatment in ORG OD 14 study. *Bone*. 23 (Suppl.): 388, No. 5, 1998. (English). 800738134
39. Castelo-Branco C, Vicente JJ, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. *Maturitas*. 34: 161-168, 15 Feb 2000. (English). 800818370
40. Roux C, Pelissier C, et al. Tibolone and cc. E2/NETA are effective in the prevention of postmenopausal bone loss. *Maturitas*. 35 (Suppl. 1): 28, Jun 2000. (English). 800833752
41. Gallagher JC, Freeman R, et al. Tibolone prevents postmenopausal bone loss and is well-tolerated: phase III trial results. *Journal of Bone and Mineral Research*. 14 (Suppl. 1): 158, Sep 1999. (English). 800809422
42. Organon. Latest results confirm Livial(R)'s advantages over conventional hormone replacement therapy as research efforts continue. Media Release. : 22 Mar 2002. Available from: URL: <http://www.organon.com>. (English).
43. Plumb JM, Guest JF. Economic impact of tibolone compared with continuous-combined hormone replacement therapy: in the management of postmenopausal women with climacteric symptoms in the UK. *PharmacoEconomics*. 18: 477-486, Nov 2000. (English). 800810917
44. Morrison E, Paterson A, et al. Change in bone mineral density over 1 year in postmenopausal women with rheumatoid arthritis treated with either tibolone or cyclical etidronate and calcium compared to controls. *British Journal of Rheumatology*. 37 (Suppl. 1): 140, 1998. (English). 800671375
45. Landgren MB, Coelingh Bennink HJT, et al. Dose-response analysis of effects of tibolone on climacteric symptoms. *BJOG: An International Journal of Obstetrics and Gynaecology*. 109: 1109-1114, Oct 2002. (English). 800924592
46. Taskin O, Gokdeniz R, et al. Placebo-controlled cross-over study of effects of tibolone on premenstrual symptoms and peripheral beta-endorphin concentrations in premenstrual syndrome. *Human Reproduction*. 13: 2402-2405, Sep 1998. (English). 807162624
47. Gokmen O, Moroy P, et al. Hormone replacement therapy with tibolone. *Maturitas*. 35 (Suppl. 1): 82, Jun 2000. (English). 800833829

48. Huber J, Palacios S, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. *BJOG: An International Journal of Obstetrics and Gynaecology*. 109: 886-893, Aug 2002. (English). 800917174
49. Phillips CJ. Livial: an economic appraisal. *British Journal of Obstetrics and Gynaecology*. 106 (Suppl. 19): 22-28, Mar 1999. (English).
50. Fedele L, Bianchi S, et al. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. *Maturitas*. 32: 189-193, 16 Aug 1999. (English). 800797271
51. Taskin O, Yalcinoglu AI, et al. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. *Fertility and Sterility*. 67: 40-45, Jan 1997. (English). 800494741

=> fil capl; d que nos l34; s l34 not l166  
FILE 'CAPLUS' ENTERED AT 12:11:23 ON 02 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Mar 2006 VOL 144 ISS 10  
FILE LAST UPDATED: 1 Mar 2006 (20060301/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L2 1 SEA FILE=REGISTRY ABB=ON 979-32-8  
L3 STR  
L5 29 SEA FILE=REGISTRY FAM FUL L3  
L6 SEL L2 1- RN : 1 TERM  
L7 25 SEA FILE=REGISTRY ABB=ON L6/CRN  
L9 4 SEA FILE=REGISTRY ABB=ON L5 NOT L7  
L11 2 SEA FILE=REGISTRY ABB=ON L9 AND A  
L12 27 SEA FILE=REGISTRY ABB=ON L5 NOT L11  
L14 1074 SEA FILE=CAPLUS ABB=ON L12  
L20 406 SEA FILE=CAPLUS ABB=ON L14 (L) USES/RL  
L21 499 SEA FILE=CAPLUS ABB=ON RETENTION/OBI (L) FLUID#/OBI  
L22 661 SEA FILE=CAPLUS ABB=ON HOT/OBI (L) FL!SH#/OBI  
L23 5507 SEA FILE=CAPLUS ABB=ON HEADACHE#/OBI  
L24 2103 SEA FILE=CAPLUS ABB=ON NAUSEA/OBI  
L25 11069 SEA FILE=CAPLUS ABB=ON DEPRESSION/OBI (L) MENTAL/OBI  
L26 40 SEA FILE=CAPLUS ABB=ON (MAMMARY/OBI OR BREAST#/OBI) (L) TENDER?/  
OBI  
L27 50049 SEA FILE=CAPLUS ABB=ON CARDIOVASCULAR/OBI  
L28 294 SEA FILE=CAPLUS ABB=ON GYNECOMASTI?/OBI  
L29 56 SEA FILE=CAPLUS ABB=ON PROSTAT?/OBI (L) ENLARG?/OBI  
L31 37 SEA FILE=CAPLUS ABB=ON L20 AND (L21 OR L22 OR L23 OR L24 OR  
L25 OR L26 OR L27 OR L28 OR L29)  
L32 506947 SEA FILE=CAPLUS ABB=ON ADV/RL  
L33 14986 SEA FILE=CAPLUS ABB=ON (SIDE/OBI OR ADVERSE/OBI) (L) (EFFECT?/OB  
I OR EVENT?/OBI)  
L34 12 SEA FILE=CAPLUS ABB=ON L31 AND (L32 OR L33)

L170 10 L34 NOT L166  
=> d ibib ed abs hitstr l170 1-10; fil hom

L170 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:978863 CAPLUS

DOCUMENT NUMBER: 144:143261

TITLE: A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17 $\beta$ -estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period

AUTHOR(S): Pornel, B.; Spielmann, D.

CORPORATE SOURCE: The Trimegestone 302 Study Group, Brussels Menopause Center, Brussels, Belg.

SOURCE: Gynecological Endocrinology (2005), 21(2), 74-81

CODEN: GYENER; ISSN: 0951-3590

PUBLISHER: Taylor & Francis Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 08 Sep 2005

AB Objective: To compare the efficacy of two sequential 17 $\beta$ -estradiol (17 $\beta$ -E2)/trimegestone (TMG) combinations with the sequential estradiol valerate (E2V)/norethisterone (NET) regimen in relieving climacteric symptoms. Study design: This was a double-blind, randomized, multicenter study conducted among 1218 Caucasian (99%) postmenopausal women with an intact uterus in seven European countries and Israel, over 13 cycles (each of 28 days). Study duration was extended further for 13 cycles, with 531 women receiving treatment for up to 26 cycles. Treatments consisted of 1 mg 17 $\beta$ -E2 on days 1-14 and 1 mg 17 $\beta$ -E2/0.125 mg TMG or 0.25 mg TMG on days 15-28, and 1 mg E2V on days 1-16 and 1 mg E2V/1 mg NET on days 17-28. Results: Rapid and significant redns. in the mean daily number and severity of hot flushes and in the mean daily number of nocturnal sweats were established in most women with 1 mg 17 $\beta$ -E2/0.25 mg TMG and E2V/NET. These treatments also induced a significant improvement in the quality-of-life assessments. Conclusion: The 1 mg 17 $\beta$ -E2/0.25 mg TMG regimen provides rapid and effective relief of menopausal symptoms, with a reduction in the number of hot flushes at least as good as that of the E2V/NET comparator.

IT 979-32-8, Estradiol valerate


RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination therapy of 17 $\beta$ -estradiol and trimegestone reduced number and severity of hot flushes as good as E2V/NET treatment and reduced number of nocturnal sweats, improved kupperman index and quality of life in postmenopausal woman)

RN 979-32-8 CAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L170 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1022315 CAPLUS

DOCUMENT NUMBER: 142:191433

TITLE: Smoking reduces **breast tenderness** during oral estrogen-progestogen therapy

AUTHOR(S): Bjarnason, Nh; Jorgensen, C.; Kremmer, H.; Alexandersen, P.; Christiansen, C.

CORPORATE SOURCE: Center for Clinical & Basic Research, Ballerup, 2750, Den.

SOURCE: Climacteric (2004), 7(4), 390-396

CODEN: CLIMFC; ISSN: 1369-7137

PUBLISHER: Taylor & Francis Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 29 Nov 2004

AB The authors wished to study the influence of smoking upon the occurrence of breast tenderness during oral estrogen-progestogen therapy (EPT). Data from 626 healthy postmenopausal women participating in three double-blind, randomized, controlled long-term trials of EPT vs. placebo were included. The studies covered sequential, continuous and interrupted regimens of estradiol opposed by a selection of progestins. All studies were mono-center studies and performed in the period 1988-1997. Data on breast tenderness were collected from adverse event reporting and information on smoking status was obtained by interview. Smoking was associated with an earlier age at menopause (difference: 1.3 years) and a slightly lower body mass index (difference: 0.8 kg/m<sup>2</sup>). Smoking women in the EPT groups had significantly lower on-treatment estradiol levels compared to non-smoking women, whereas no differences were observed in the placebo group. In parallel, the incidence of breast tenderness during EPT was reduced by about one-half in smokers compared to non-smokers, whereas no differences were seen on placebo. Thus, current smoking reduces the incidence of breast tenderness in women receiving oral EPT. This may be caused by the increased degradation of estradiol during smoking.

IT 60513-93-1, Estradiol valerate-levonorgestrel mixture

64368-84-9, Estradiol valerate-medroxyprogesterone acetate mixture

108116-22-9, Estradiol valerate-cyproterone acetate mixture

RL: ADV (Adverse effect, including toxicity); PAC

(Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(smoking reduction of **breast tenderness** during oral estrogen-progestogen therapy in postmenopausal women)




RN 60513-93-1 CAPLUS  
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 $\alpha$ )-, mixt. with (17 $\beta$ )-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate (9CI) (CA INDEX NAME)

CM 1

CRN 979-32-8  
 CMF C23 H32 O3


Absolute stereochemistry.



CM 2

CRN 797-63-7  
 CMF C21 H28 O2

Absolute stereochemistry.




RN 64368-84-9 CAPLUS  
 CN Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6 $\alpha$ )-, mixt. with (17 $\beta$ )-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate (9CI) (CA INDEX NAME)

CM 1

CRN 979-32-8  
 CMF C23 H32 O3

Absolute stereochemistry.




CM 2

CRN 71-58-9

CMF C24 H34 O4

Absolute stereochemistry.



RN 108116-22-9 CAPLUS


CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 $\beta$ ,2 $\beta$ )-, mixt. with (17 $\beta$ )-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate (9CI) (CA INDEX NAME)

CM 1

CRN 979-32-8

CMF C23 H32 O3

Absolute stereochemistry.




CM 2

CRN 427-51-0

CMF C24 H29 Cl O4

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L170 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:830564 CAPLUS

DOCUMENT NUMBER: 142:980

TITLE: Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone

AUTHOR(S): Andreen, Lotta; Sundstroem-Poromaa, Inger; Bixo, Marie; Andersson, Agneta; Nyberg, Sigrid; Baeckstroem, Torbjorn

CORPORATE SOURCE: Umea Neurosteroid Research Center, Department of Clinical Science, Obstetrics and Gynecology, Norrlands University Hospital, Umea, SE-901 85, Swed.

SOURCE: Psychoneuroendocrinology (2004), Volume Date 2005, 30(2), 212-224

CODEN: PSYCDE; ISSN: 0306-4530

PUBLISHER: Elsevier B.V.


DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 12 Oct 2004

- AB Objective: To compare severity of neg. mood and phys. symptoms between women with different progesterone, allopregnanolone, and pregnanolone plasma concns. during sequential Hormone Replacement Therapy (HRT) with vaginal progesterone suppositories. Design: A randomized, placebo-controlled, double-blind, crossover study. Postmenopausal women (n=36) with climacteric symptoms were treated with 2 mg estradiol daily during 3 28-day cycles. Vaginal progesterone suppositories with 400, 800 mg/day or placebo were added sequentially for 14 days per cycle. Daily symptom ratings using a validated rating scale were kept. Blood samples for progesterone, allopregnanolone, and pregnanolone RIAs were collected during each treatment cycle. Women were divided into 3 groups (low, medium, and high) based on plasma allopregnanolone concentration during progesterone treatment. The concentration of allopregnanolone in the medium group corresponds to the concentration seen during the mid luteal phase of the menstrual cycle. Within women with medium allopregnanolone concentration significantly more neg. mood and phys. symptoms were rated during progesterone treatment compared to treatment with unopposed estrogen or placebo. Between women significantly more neg. mood symptoms were seen during progesterone treatment cycles with medium allopregnanolone concentration compared to cycles with low concentration Plasma progesterone, allopregnanolone, and pregnanolone concns. increased with increasing progesterone dose. Progesterone and allopregnanolone plasma concns. increased 2 h after vaginal administration of progesterone at 400 and 800 mg/day. Vaginal progesterone in sequential HRT causes neg. mood, most likely mediated via allopregnanolone.
- IT 979-32-8, Estradiol valerate  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (relationship between allopregnanolone and neg. mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone)
- RN 979-32-8 CAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L170 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:770465 CAPLUS  
 DOCUMENT NUMBER: 141:420546

TITLE: Influence of a continuous combined HRT (2 mg estradiol valerate and 2 mg dienogest) on postmenopausal depression

AUTHOR(S): Rudolph, I.; Palombo-Kinne, E.; Kirsch, B.; Mellinger, U.; Breitbarth, H.; Graeser, T.

CORPORATE SOURCE: Jenapharm GmbH & Co. KG, Jena, Germany

SOURCE: Climacteric (2004), 7(3), 301-311  
CODEN: CLIMFC; ISSN: 1369-7137

PUBLISHER: Taylor & Francis Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 22 Sep 2004

AB Objective: This randomized, double-blind, placebo-controlled study was planned to investigate the effects of continuous combined hormone replacement therapy (HRT) with 2 mg estradiol valerate and 2 mg dienogest (Climodien/Lafamme) over 24 wk on postmenopausal depression. Method: A total of 129 patients with a mild to moderate depressive episode according to ICD-10: F32.0, F32.1 in the context of a postmenopausal syndrome (ICD-10: N95.1) and a baseline score in the Hamilton depression scale (HAMD)  $\geq 16$  were included in the study. The primary target variable was depression severity as measured by the HAMD after 24 wk of treatment. A four-point difference between HRT and placebo at the end of the study and, in addition, a final score  $\leq 8$  (corresponding to an improvement of  $\geq 50\%$  as compared to baseline) for the individual patient (responders anal.) were considered clin. relevant. Clin. global impression (CGI) of investigators (therapeutic and side-effects) at the end of the study was investigated. Secondary effects of HRT on depression severity caused by its effect on vasomotor symptoms or sleep disturbances (domino hypothesis) were taken into consideration. Also, the study addressed the question of whether the effect of HRT on depression severity depends on a history of premenstrual syndrome (PMS) or postnatal depression (PND). Results: The results showed a clear and clin. relevant reduction of depression severity under HRT after 24 wk of treatment and superiority over placebo ( $p < 0.0005$ ) in spite of a strong placebo effect. The effects of the estrogen-progestin combination thereby seemed only partially to be dependent on the improvement of vasomotor symptoms and sleep disturbances. Also, the effects of HRT could not be shown to be dependent on a history of PMS and/or PND, even though women with and without this history clearly differed in baseline depression scores ( $p < 0.0001$ ). The assessment of CGI was pos.: whereas HRT was clearly superior to placebo with regard to therapeutic effects ( $p = 0.0014$ ), there were no differences with regard to side-effects ( $p = 0.35$ ). Conclusion: The combination of 2 mg estradiol valerate and 2 mg dienogest can be regarded as an effective and safe treatment option for women with mild to moderate depression in the context of postmenopausal syndrome.

IT 307334-58-3, Climodien

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(influence of a continuous combined hormone replacement therapy (2 mg estradiol valerate and 2 mg dienogest) on postmenopausal depression)

RN 307334-58-3 CAPLUS


CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 $\alpha$ )-, mixt. with (17 $\beta$ )-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate (9CI) (CA INDEX NAME)

CM 1

CRN 65928-58-7

CMF C20 H25 N O2

Absolute stereochemistry.




CM 2

CRN 979-32-8

CMF C23 H32 O3

Absolute stereochemistry.



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L170 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:967688 CAPLUS

DOCUMENT NUMBER: 140:229672

TITLE: Clinical experience with trimegestone as a new progestin in HRT

AUTHOR(S): Grubb, Gary; Spielmann, Daniele; Pickar, James; Constantine, Ginger

CORPORATE SOURCE: Women's Health Clinical Research and Development, Collegeville, PA, 19426, USA

SOURCE: Steroids (2003), 68(10-13), 921-926  
CODEN: STEDAM; ISSN: 0039-128X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 11 Dec 2003

AB Trimegestone (TMG) is a novel, 19-norpregnane progestin, which demonstrates endometrial selectivity with a reduced progestin-related side effect profile when compared to several other currently marketed

progestins. TMG has been studied in combination with  $17\beta$ -estradiol ( $17\beta$ -E2) and conjugated equine estrogens (CEE). TMG-containing HRT agents were effective in relieving vasomotor symptoms and providing protection from endometrial hyperplasia with  $\leq 1\%$  hyperplasia. In clin. trials with sequential regimens, TMG provided predictable withdrawal bleeding associated with a low incidence of irregular and prolonged bleeding. Clin. studies of continuous combined regimens of estrogen/TMG combinations demonstrated high levels of amenorrhea. Both  $17\beta$ -E2 and CEE/TMG combinations have shown improved bone mineral d. and quality-of-life assessments. Both continuous combined and sequential regimens of  $17\beta$ -E2/TMG and CEE/TMG have a favorable clin. profile. TMG provides an important new option for the treatment of postmenopausal symptoms and the prevention of osteoporosis.

IT 979-32-8, Estradiol valerate 282089-44-5, Cyclocur


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comparison with trimegestone treatment; clin. experience with trimegestone as a new progestin in hormone replacement therapies)

RN 979-32-8 CAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol ( $17\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282089-44-5 CAPLUS


CN Estra-4,9-dien-3-one, 17-[(2S)-2-hydroxy-1-oxopropyl]-17-methyl-, ( $17\beta$ )-, mixt. with ( $17\beta$ )-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate (9CI) (CA INDEX NAME)

CM 1

CRN 74513-62-5

CMF C22 H30 O3


Absolute stereochemistry.



CM 2

CRN 979-32-8  
CMF C23 H32 O3

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L170 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:808004 CAPLUS

DOCUMENT NUMBER: 140:175349

TITLE: Vaginal administration of allopregnanolone to postmenopausal women undergoing estrogen replacement therapy: preliminary results

AUTHOR(S): Navarro, Paula Andrea de A. S.; Kaddouz, Delphine; De Ziegler, Dominique; Silva De Sa, Marcos Felipe; Ferriani, Rui Alberto

CORPORATE SOURCE: Faculty of Medicine of Ribeirao Preto, Department of Gynecology and Obstetrics, University of Sao Paulo, Ribeirao Preto, Brazil

SOURCE: Maturitas (2003), 46(2), 147-152

CODEN: MATUDK; ISSN: 0378-5122

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 15 Oct 2003



AB Objective: To assess the tolerability and endometrial effects of vaginal administration of an allopregnanolone gel to postmenopausal women undergoing estrogen therapy. Methods: Thirteen postmenopausal women included in the study were divided into two groups and submitted to two consecutive cycles of 28 days during which they received 2 mg oral estradiol valerate daily and vaginally administered allopregnanolone gel during the last 10 days of the second cycle (group 1) or during the last 10 days of each cycle (group 2). Systemic adverse effects, vaginal bleeding and endometrial histol. were characterized, with group 1 patients being submitted to two endometrial biopsies (days 28 and 56) and group 2 patients to one biopsy (day 56). Results: Five patients did not show any adverse effect. Mastalgia was the most frequently reported adverse effect (four cases), followed by headache and abdominal pain (two cases each). The adverse effects were mild and did not interfere with the adequate use of the medication prescribed. Vaginal bleeding due to deprivation was observed in three of the seven patients submitted to one treatment cycle with allopregnanolone (group 1) and in two of six patients submitted to two treatment cycles (group 2). Endometrial biopsy findings did not suggest any secretory action after exposure to allopregnanolone. Conclusions: Tolerability of vaginal administration of allopregnanolone gel was good. Studies employing a larger series and longer time of follow-up are necessary to determine the endometrial effects of this drug.

IT 979-32-8, Estradiol valerate

RL: ADV (Adverse effect, including toxicity); PAC


(Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preliminary clin. study for vaginal administration of allopregnanolone to postmenopausal women undergoing estrogen replacement therapy)

RN 979-32-8 CAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L170 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:463622 CAPLUS

DOCUMENT NUMBER: 137:57759

TITLE: Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations

AUTHOR(S): Skouby, Sven O.; Gram, Jorgen; Andersen, Lars F.; Sidelmann, Johannes; Petersen, Kresten R.; Jespersen, Jorgen

CORPORATE SOURCE: Department of Obstetrics and Gynecology, Frederiksberg Hospital, Copenhagen, DK 2000, Den.

SOURCE: American Journal of Obstetrics and Gynecology (2002), 186(5), 969-977

CODEN: AJOGAH; ISSN: 0002-9378

PUBLISHER: Mosby, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 21 Jun 2002

AB Our purpose was to assess the effect of hormone replacement therapy (HRT) on C-reactive protein blood concns. with special reference to the progestin component. Changes from baseline and between groups in blood concns. of C-reactive protein were determined during 12-mo periods in 6 groups of postmenopausal women. Group A (the reference group) received no HRT; group B received 2 mg of estradiol valerate (E2V) daily combined with 1 mg of cyproterone acetate (CPA) for 10 days (28/10 days); group C received 2 mg of E2V plus 1 mg of CPA sequentially (21/10 days); group D received a combination of 2 mg of E2V and 1 mg of norethindrone acetate continuously; group E received 2 mg of E2V in combination with local delivery of levonorgestrel (20 µg/24 h); and group F received a long-cycle regimen consisting of 2 mg of E2V (84/91 days) plus 20 mg of medroxyprogesterone (14/91 days). No significant variation in CRP levels was observed in the reference group. HRT resulted in a significant increase in CRP concns. in the women receiving the continuous combination of E2V plus norethindrone acetate and the continuous regimen of E2V plus local delivery of levonorgestrel. Cyclic or continuous intake of E2V plus CPA did not change CRP levels significantly. During the long-cycle regimen, the concns. of CRP showed a significant variance over time. The concns. increased during the estrogen phase but were modulated by the progestin intake throughout the study period. HRT can increase CRP levels in healthy women, and both the estrogen and the progestin component are of importance for the change. Whether the increase in CRP levels only reflects a changed steady-state metabolism is unknown. However, the clin. significance should be viewed from the perspective of changes in other inflammatory risk markers of importance for the evolution of cardiovascular disease.

IT 979-32-8, Estradiol valerate


RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of estrogen and progestin replacement therapy on plasma C-reactive protein concns. in postmenopausal women)

RN 979-32-8 CAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17β)-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L170 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:59967 CAPLUS

DOCUMENT NUMBER: 136:257440

TITLE: Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints

AUTHOR(S): Graser, T.; Romer, T.; Wiedey, K. D.; Janaud, A.

CORPORATE SOURCE: Department of Drug Safety, Jenapharm GmbH and Co. KG, Jena, D-07745, Germany

SOURCE: Climacteric (2001), 4(4), 332-342

CODEN: CLIMFC; ISSN: 1369-7137

PUBLISHER: Parthenon Publishing Group Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 23 Jan 2002

AB Objective: To evaluate the efficacy, safety and tolerability of continuous combined hormone replacement therapy (HRT) with Climodien (estradiol valerate 2 mg plus dienogest 2 mg). Design: Open, multinational, multicenter, non-controlled phase III study. Participants: A total of 1501 women aged 52-65 yr with postmenopausal symptoms of sufficient severity to require treatment. Eligible patients were treated with Climodien for 12 treatment cycles (48 wk), with assessments of efficacy, safety and tolerability (adverse events) at 8, 24 and 48 wk. Efficacy was assessed using the Kupperman index. Safety assessments included endovaginal sonog., safety endometrial biopsies, mammog., phys. and gynecol. examination, vital signs, prothrombotic factors and routine laboratory safety parameters. The Kupperman index improved with increasing duration of treatment, accompanied by an improvement in self-reported patient well-being. Individual climacteric symptoms such as hot flushes and psychonervous disorders also improved. The most pronounced improvement was seen in women who had not previously used HRT. The incidence of breakthrough bleeding declined over time, resulting in complete amenorrhea in 86.2% of the patients after 12 cycles of treatment. Furthermore, total and low-d. lipoprotein (LDL) cholesterol levels decreased and high-d. lipoprotein (HDL) cholesterol levels increased. Decreases in alkaline phosphatase, pyridinoline and deoxypyridinoline demonstrated the inhibitory action of estradiol on bone resorption. Endometrial thickness remained almost constant, and the incidence of serious endometrial findings was similar to that in untreated women. Continuous combined estrogen-progestin therapy with Climodien is effective, safe and well tolerated in postmenopausal women, with a profile and incidence of adverse

events consistent with those of existing HRT preps.

IT 307334-58-3, Climodien

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(climodien is safe and effective in treatment of postmenopausal complaints)

RN 307334-58-3 CAPLUS


CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 $\alpha$ )-, mixt. with (17 $\beta$ )-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate (9CI) (CA INDEX NAME)

CM 1

CRN 65928-58-7

CMF C20 H25 N O2

Absolute stereochemistry.




CM 2

CRN 979-32-8

CMF C23 H32 O3

Absolute stereochemistry.



REFERENCE COUNT:

29

THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L170 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:887821 CAPLUS

DOCUMENT NUMBER: 136:194384  
TITLE: Low-dose estrogen supplementation improves vascular function in hypogonadal men  
AUTHOR(S): Komesaroff, Paul A.; Fullerton, Meryl; Esler, Murray D.; Dart, Anthony; Jennings, Garry; Sudhir, Krishnankutty  
CORPORATE SOURCE: Hormones and Vasculature Laboratory and Alfred and Baker Medical Unit, Baker Medical Research Institute and Alfred Hospital, Melbourne, Australia  
SOURCE: Hypertension (2001), 38(5), 1011-1016  
CODEN: HPRTDN; ISSN: 0194-911X  
PUBLISHER: Lippincott Williams & Wilkins  
DOCUMENT TYPE: Journal  
LANGUAGE: English

ED Entered STN: 09 Dec 2001

AB It is widely accepted that in women, estrogens provide protection against the development of cardiovascular disease. However, the cardiovascular role of estrogens in men remains uncertain, despite preliminary evidence that endogenous estrogens produced by aromatization of androgenic precursors are of physiologic importance. Hypogonadal men have very low levels of circulating estrogen. The authors studied the responsiveness of forearm resistance arteries to vasoconstrictor and vasodilator agents in 12 men (mean±SEM age, 68.7±2.6 yr) rendered hypogonadal as a result of treatment for prostatic cancer, before and after 8 wk of estrogen supplementation (estradiol valerate 1 mg daily; n=7) or placebo (n=5). Forearm blood flow was measured by venous occlusion plethysmography, and vasoactive agents were infused through a brachial artery cannula in doses that did not affect blood pressure or heart rate. Estrogen supplementation was well tolerated, with no adverse effects. After estrogen treatment, mean estradiol levels increased from <30 to 308±65 pmol/L, and both systolic and diastolic blood pressures were reduced. HDL cholesterol levels increased significantly, and vasoconstrictor responses to the NO synthase inhibitor NG-monomethyl-L-arginine (1, 2, 4 µmol/min) were enhanced. Vasoconstrictor responses to angiotensin II (8, 16, 32 ng/min) were markedly attenuated by estrogen treatment, as were vasoconstrictor responses to norepinephrine (25, 50, 100 ng/min). Estrogen did not alter the vasodilator responses to acetylcholine (9.25, 18.5, 37 µg/min) or to the endothelium-independent agent sodium nitroprusside (1.6 µg/min). Responses to all vasoactive agents were unchanged after administration of placebo. The authors conclude that low-dose estrogen supplementation in hypogonadal men is well tolerated, lowers blood pressure, and may affect vascular reactivity in a manner that is potentially beneficial, through several mechanisms, including enhancement of basal NO release and attenuation of vasoconstrictor responses to angiotensin II and norepinephrine. These findings suggest the need to consider a possible clinical role for estrogenic compounds in cardiovascular risk reduction in some groups of men.

IT 979-32-8, Estradiol valerate


RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(low-dose estrogen supplementation improves vascular function and reactivity to vasoactive agents in hypogonadal men)

RN 979-32-8 CAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17β)-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L170 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:862323 CAPLUS

DOCUMENT NUMBER: 136:194378

TITLE: Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease

AUTHOR(S): Vitale, Cristiana; Fini, Massimo; Leonardo, Filippo; Rossini, Paola; Cerquetani, Elena; Onorati, Daniela; Rosano, Giuseppe M. C.

CORPORATE SOURCE: Cardiovascular Research Unit, Department of Internal Medicine, San Raffaele-TOSINVEST SANITA, Rome, 00163, Italy

SOURCE: Maturitas (2001), 40(3), 239-245

CODEN: MATUDK; ISSN: 0378-5122

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 29 Nov 2001

AB A large body of evidence has been accumulated suggesting that impairment of vascular endothelial function is an initial step in the development of atherosclerosis. Recent studies have shown that estrogen replacement therapy in postmenopausal women (PMW) improves endothelium-dependent, flow-mediated dilatation (FMD) while the cyclical adjunct of a progestin may reverse this effect. The purpose of this study was to evaluate endothelium-dependent, FMD in the brachial artery and the plasma levels of Endothelin-1 in menopausal females treated with estradiol valerate with and without cyclical cyproterone acetate in 20 PMW (mean age 64 yr) with more than one risk factor for coronary artery disease. After a baseline evaluation, PMW entered a double-blinded, placebo controlled single cross-over study and were randomized to receive either estradiol valerate (2 mg) for 21 days or estradiol valerate (2 mg) for 11 days and estradiol valerate (2 mg) and cyproterone acetate (1 mg) for 10 days. Patients were crossed-over the complementary treatment 7 days after completing the first treatment phase. The study of forearm blood flow was repeated at the end of each treatment period. Estradiol valerate significantly increased FMD as compared with baseline (12 vs. 7%) the adjunct of cyproterone acetate did not affect the effect of estradiol valerate upon FMD (12 vs. 11%, P=NS). Similarly reactive hyperemic flow increased after estradiol valerate alone (24%) or in association with cyproterone acetate (24%) compared with baseline. Plasma levels of Endothelin-1 were significantly reduced by

estradiol valerate alone or in association with cyproterone acetate. In conclusion hormone replacement therapy with estradiol valerate and cyproterone acetate improves endothelial function and reduces plasma levels of Endothelin-1 in PMW at risk of coronary artery disease. These effects may be relevant for cardioprotection.


IT 979-32-8, Estradiol valerate

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease)

RN 979-32-8 CAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 17-pentanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

25

THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


FILE 'HOME' ENTERED AT 12:11:37 ON 02 MAR 2006

=>





```
=> d stat que l12; d his nofile
L2      1 SEA FILE=REGISTRY ABB=ON  979-32-8
L3      STR
```



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE

```
L5      29 SEA FILE=REGISTRY FAM FUL L3
L6      SEL L2 1- RN :      1 TERM
L7      25 SEA FILE=REGISTRY ABB=ON  L6/CRN
L9      4 SEA FILE=REGISTRY ABB=ON  L5 NOT L7
L11     2 SEA FILE=REGISTRY ABB=ON  L9 AND A
L12     27 SEA FILE=REGISTRY ABB=ON  L5 NOT L11
```

(FILE 'HOME' ENTERED AT 10:43:25 ON 02 MAR 2006)

FILE 'CAPLUS' ENTERED AT 10:43:36 ON 02 MAR 2006

```
SET LINE 250
SET DETAIL OFF
E US2003-729487/AP, PRN 25
SET NOTICE 1000 SEARCH
L1      2 SEA ABB=ON  US2003-729487/AP
SET NOTICE LOGIN SEARCH
SET LINE LOGIN
SET DETAIL LOGIN
D SCAN
```

FILE 'REGISTRY' ENTERED AT 10:45:16 ON 02 MAR 2006

```
L2      1 SEA ABB=ON  979-32-8
D SCAN
```

FILE 'REGISTRY' ENTERED AT 10:45:36 ON 02 MAR 2006

```
D IDE
L3      STR  979-32-8
```

L4 0 SEA FAM SAM L3  
L5 29 SEA FAM FUL L3  
SAVE TEMP L5 QAZ487FAM/A  
SET SMARTSELECT ON  
L6 SEL L2 1- RN : 1 TERM  
SET SMARTSELECT OFF  
L7 25 SEA ABB=ON L6/CRN  
L8 0 SEA ABB=ON L7 NOT L5  
L9 4 SEA ABB=ON L5 NOT L7  
D SCAN  
L10 16 SEA ABB=ON L5 NOT A  
L11 2 SEA ABB=ON L9 AND A  
L12 27 SEA ABB=ON L5 NOT L11  
L13 ANALYZE L12 1- LC : 43 TERMS  
D 1-43

FILE 'STNGUIDE' ENTERED AT 10:51:08 ON 02 MAR 2006

FILE 'CAPLUS' ENTERED AT 10:58:06 ON 02 MAR 2006

L14 1074 SEA ABB=ON L12

FILE 'REGISTRY' ENTERED AT 10:58:14 ON 02 MAR 2006

L15 1 SEA ABB=ON 9034-40-6  
D IDE

FILE 'CAPLUS' ENTERED AT 10:58:59 ON 02 MAR 2006

L16 16360 SEA ABB=ON L15  
L17 209 SEA ABB=ON L16 (L) ADV/RL  
L18 1 SEA ABB=ON L17 AND L14  
L19 23 SEA ABB=ON L16 AND L14  
D SCAN TI  
L20 406 SEA ABB=ON L14 (L) USES/RL  
D SCAN L18  
L21 499 SEA ABB=ON RETENTION/OBI (L) FLUID#/OBI  
L22 661 SEA ABB=ON HOT/OBI (L) FL!SH?/OBI  
L23 5507 SEA ABB=ON HEADACHE#/OBI  
L24 2103 SEA ABB=ON NAUSEA/OBI  
L25 11069 SEA ABB=ON DEPRESSION/OBI (L) MENTAL/OBI  
L26 40 SEA ABB=ON (MAMMARY/OBI OR BREAST#/OBI) (L) TENDER?/OBI  
L27 50049 SEA ABB=ON CARDIOVASCULAR/OBI  
L28 294 SEA ABB=ON GYNECOMASTI?/OBI  
L29 56 SEA ABB=ON PROSTAT?/OBI (L) ENLARG?/OBI  
L30 3 SEA ABB=ON L16 AND L14 AND (L21 OR L22 OR L23 OR L24 OR L25  
OR L26 OR L27 OR L28 OR L29)  
D SCAN  
L31 37 SEA ABB=ON L20 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR  
L27 OR L28 OR L29)  
L32 506947 SEA ABB=ON ADV/RL  
L33 14986 SEA ABB=ON (SIDE/OBI OR ADVERSE/OBI) (L) (EFFECT?/OBI OR  
EVENT?/OBI)  
L34 12 SEA ABB=ON L31 AND (L32 OR L33)  
D QUE NOS  
D QUE NOS L30

FILE 'TOXCENTER' ENTERED AT 11:20:13 ON 02 MAR 2006

L35 558 SEA ABB=ON L12  
L36 3200 SEA ABB=ON L15  
L37 7 SEA ABB=ON L35 AND L36  
D SCAN  
L38 1414 SEA ABB=ON (RETENTION OR RETAIN?) (2A) FLUID#

L39 1575 SEA ABB=ON HOT FL!SH?  
 L40 20188 SEA ABB=ON HEADACHE#  
 L41 36314 SEA ABB=ON NAUSEA  
 L42 71854 SEA ABB=ON DEPRESSION  
 L43 358 SEA ABB=ON (MAMMARY OR BREAST#) (2A)TENDER?  
 L44 213083 SEA ABB=ON CARDIOVASCULAR  
 L45 1510 SEA ABB=ON GYNECOMASTI?  
 L46 183 SEA ABB=ON PROSTAT? (2A)ENLARG?  
 L47 808206 SEA ABB=ON (SIDE OR ADVERSE) (2A) (EFFECT? OR EVENT?)  
 L48 210 SEA ABB=ON L35 AND (L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR  
 L44 OR L45 OR L46 OR L47)  
 L49 57 SEA ABB=ON L35 AND (L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR  
 L44 OR L45 OR L46) AND L47

FILE 'BIOSIS' ENTERED AT 11:23:24 ON 02 MAR 2006

L50 1002 SEA ABB=ON L12  
 L51 13923 SEA ABB=ON L15  
 L52 21 SEA ABB=ON L50 AND L51  
 L53 1583 SEA ABB=ON (RETENTION OR RETAIN?) (2A)FLUID#  
 L54 1296 SEA ABB=ON HOT FL!SH?  
 L55 24834 SEA ABB=ON HEADACHE#  
 L56 20197 SEA ABB=ON NAUSEA  
 L57 119520 SEA ABB=ON DEPRESSION  
 L58 262 SEA ABB=ON (MAMMARY OR BREAST#) (2A)TENDER?  
 L59 1807338 SEA ABB=ON CARDIOVASCULAR  
 L60 1659 SEA ABB=ON GYNECOMASTI?  
 L61 652 SEA ABB=ON PROSTAT? (2A)ENLARG?  
 L62 185953 SEA ABB=ON (SIDE OR ADVERSE) (2A) (EFFECT? OR EVENT?)  
 L63 0 SEA ABB=ON L50 AND L51 AND (L53 OR L54 OR L55 OR L56 OR L57  
 OR L58 OR L59 OR L60 OR L61 OR L62)  
 L64 153 SEA ABB=ON L50 AND (L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR  
 L59 OR L60 OR L61 OR L62)  
 L65 21420 SEA ABB=ON (LUTEINIZING OR GONADOTROPIN) (1W)RELEASING  
 HORMONE#  
 L66 3 SEA ABB=ON L50 AND (L51 OR L65) AND (L53 OR L54 OR L55 OR L56  
 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62)

FILE 'USPATFULL' ENTERED AT 11:27:50 ON 02 MAR 2006

L67 117 SEA ABB=ON L12  
 L68 1036 SEA ABB=ON L15  
 L69 5 SEA ABB=ON L67 AND L68  
 D SCAN TI

FILE 'EMBASE' ENTERED AT 11:28:44 ON 02 MAR 2006

L70 2369 SEA ABB=ON L12  
 D TRIAL 100-105  
 L71 2157 SEA ABB=ON ESTRADIOL VALERATE/CT  
 E GONADOTROPIN RE/CT  
 E E18+ALL  
 E E2+ALL  
 L72 20312 SEA ABB=ON GONADORELIN/CT  
 L73 67 SEA ABB=ON (L70 OR L71) AND L72  
 L74 197 SEA ABB=ON L72 (L) AE/CT  
 L75 1 SEA ABB=ON L74 AND (L70 OR L71)  
 D TRIAL  
 L76 0 SEA ABB=ON L72 (L) SI/CT  
 L77 363126 SEA ABB=ON SIDE EFFECT/CT  
 L78 5 SEA ABB=ON L73 AND L77  
 D TRIAL 1-5

FILE 'BIOTECHNO' ENTERED AT 11:34:41 ON 02 MAR 2006

L79 357 SEA ABB=ON L12  
L80 385 SEA ABB=ON ESTRADIOL VALERATE  
L81 5768 SEA ABB=ON L15  
L82 9488 SEA ABB=ON GONADORELIN OR ((LUTEINIZING OR GONADOTROPIN) (1W) RE  
LEASING(W) (FACTOR# OR HORMONE#))  
L83 48 SEA ABB=ON (L79 OR L80) AND (L81 OR L82)  
L84 279 SEA ABB=ON (RETENTION OR RETAIN?) (2A) FLUID#  
L85 287 SEA ABB=ON HOT FL!SH?  
L86 2536 SEA ABB=ON HEADACHE#  
L87 3002 SEA ABB=ON NAUSEA  
L88 5916 SEA ABB=ON DEPRESSION  
L89 17 SEA ABB=ON (MAMMARY OR BREAST#) (2A) TENDER?  
L90 9915 SEA ABB=ON CARDIOVASCULAR  
L91 187 SEA ABB=ON GYNECOMASTI?  
L92 43 SEA ABB=ON PROSTAT? (2A) ENLARG?  
L93 14495 SEA ABB=ON (SIDE OR ADVERSE) (2A) (EFFECT? OR EVENT?)  
L94 5 SEA ABB=ON L83 AND (L84 OR L85 OR L86 OR L87 OR L88 OR L89 OR  
L90 OR L91 OR L92 OR L93)  
D TRIAL 1-5

FILE 'MEDLINE' ENTERED AT 11:36:51 ON 02 MAR 2006

L95 655 SEA ABB=ON L12  
D TRIAL 100-105  
L96 4412 SEA ABB=ON ESTRADIOL/CT(L) AA/CT  
E GONADORELIN+ALL/CT  
L97 22442 SEA ABB=ON GONADORELIN+NT/CT  
D PY 22442  
L98 132 SEA ABB=ON (L95 OR L96) AND L97  
L99 966 SEA ABB=ON L97(L) AE/CT  
L100 7 SEA ABB=ON L99 AND (L95 OR L96)  
D TRIAL 1-7

FILE 'AGRICOLA' ENTERED AT 11:40:11 ON 02 MAR 2006

L101 111 SEA ABB=ON L12  
D TRIAL 100-105  
L102 60 SEA ABB=ON ESTRADIOL VALERATE  
L103 1744 SEA ABB=ON L15  
L104 1358 SEA ABB=ON GONADORELIN OR ((LUTEINIZING OR GONADOTROPIN) (1W) RE  
LEASING(W) (FACTOR# OR HORMONE#))  
L105 7 SEA ABB=ON (L101 OR L102) AND (L103 OR L104)  
D TRIAL 1-7  
L106 53 SEA ABB=ON (RETENTION OR RETAIN?) (2A) FLUID#  
L107 16 SEA ABB=ON HOT FL!SH?  
L108 206 SEA ABB=ON HEADACHE#  
L109 221 SEA ABB=ON NAUSEA  
L110 3636 SEA ABB=ON DEPRESSION  
L111 36 SEA ABB=ON (MAMMARY OR BREAST#) (2A) TENDER?  
L112 6079 SEA ABB=ON CARDIOVASCULAR  
L113 5 SEA ABB=ON GYNECOMASTI?  
L114 5 SEA ABB=ON PROSTAT? (2A) ENLARG?  
L115 7300 SEA ABB=ON (SIDE OR ADVERSE) (2A) (EFFECT? OR EVENT?)  
L116 0 SEA ABB=ON L105 AND (L106 OR L107 OR L108 OR L109 OR L110 OR  
L111 OR L112 OR L113 OR L114 OR L115)  
E HUMAN/CT  
E HUMANS/CT  
E E3+ALL  
L117 7071 SEA ABB=ON MAN/CT  
E WOMAN/CT  
L118 10394 SEA ABB=ON WOMEN/CT

L119 0 SEA ABB=ON L105 AND (L117 OR L118)

FILE 'DRUGU' ENTERED AT 11:44:46 ON 02 MAR 2006

L120 371 SEA ABB=ON L12  
L121 816 SEA ABB=ON ESTRADIOL VALERATE  
L122 0 SEA ABB=ON L15  
L123 2266 SEA ABB=ON GONADORELIN OR ((LUTEINIZING OR GONADOTROPIN) (1W) RE  
LEASING(W) (FACTOR# OR HORMONE#))  
D TRIAL 100-105  
L124 14 SEA ABB=ON (L120 OR L121) AND L123  
D TRIAL 1-14

FILE 'STNGUIDE' ENTERED AT 11:46:33 ON 02 MAR 2006

FILE 'DRUGU' ENTERED AT 11:52:25 ON 02 MAR 2006

L125 765 SEA ABB=ON ESTRADIOL-VALERATE/CT  
L126 12 SEA ABB=ON (L120 OR L125) AND L123  
D TRIAL 1-12  
L127 8458 SEA ABB=ON RELEASING-FACTOR#/CT  
L128 0 SEA ABB=ON RELEASING-FACTOR \*AE/CT OR RELEASING-FACTORS  
\*AE/CT  
L129 33 SEA ABB=ON (L120 OR L125) AND L127  
L130 10 SEA ABB=ON (L120 OR L125) AND L127 AND L123  
L131 311308 SEA ABB=ON AE  
D TRIAL  
L132 6 SEA ABB=ON L130 AND L131  
D TRIAL 1-6  
L133 0 SEA ABB=ON ADVERSE REACTIONS/CT  
L134 240306 SEA ABB=ON ADVERSE REACTIONS/CC  
L135 6 SEA ABB=ON L130 AND (L131 OR L134)  
L136 6084 SEA ABB=ON FLUSHING/CT  
E HEADACHE/CT  
L137 24956 SEA ABB=ON HEADACHE/CT  
E FLUID RET/CT  
E NAUSEA/CT  
L138 42819 SEA ABB=ON NAUSEA/CT  
E DEPRESSION/CT  
E E3+ALL  
L139 15233 SEA ABB=ON DEPRESSION/CT  
E WEIGHT-GAIN/CT  
L140 3693 SEA ABB=ON WEIGHT-GAIN/CT  
E GYNECOMASTIA/CT  
L141 606 SEA ABB=ON GYNECOMASTIA/CT  
E PROSTATE ENL/CT  
E PROSTATE-ENL/CT  
L142 676 SEA ABB=ON PROSTATE-HYPERPLASIA/CT OR PROSTATE-HYPERTROPHY/CT  
L143 582 SEA ABB=ON (MAMMARY OR BREAST#) (2A) TENDER?  
L144 1427 SEA ABB=ON (RETENTION OR RETAIN?) (2A) FLUID#  
L145 23742 SEA ABB=ON CARDIOVASCULAR  
L146 5 SEA ABB=ON L130 AND (L136 OR L137 OR L138 OR L139 OR L140 OR  
L141 OR L142 OR L143 OR L144 OR L145)  
L147 6 SEA ABB=ON L146 OR L135

FILE 'IPA' ENTERED AT 12:01:26 ON 02 MAR 2006

L148 71 SEA ABB=ON L12  
L149 81 SEA ABB=ON ESTRADIOL VALERATE  
L150 1 SEA ABB=ON L15  
L151 764 SEA ABB=ON GONADORELIN OR ((LUTEINIZING OR GONADOTROPIN) (1W) RE  
LEASING(W) (HORMONE# OR FACTOR#))

L152 4 SEA ABB=ON (L148 OR L149) AND (L150 OR L151)  
D TRIAL 1-4

FILE 'SCISEARCH' ENTERED AT 12:02:51 ON 02 MAR 2006

FILE 'IMSRESEARCH' ENTERED AT 12:03:09 ON 02 MAR 2006

L153 2 SEA ABB=ON L12  
L154 13 SEA ABB=ON ESTRADIOL VALERATE  
L155 0 SEA ABB=ON L15  
L156 74 SEA ABB=ON GONADORELIN OR ((LUTEINIZING OR GONADOTROPIN) (1W)RE  
LEASING(W) (HORMONE# OR FACTOR#))  
L157 0 SEA ABB=ON (L153 OR L154) AND L156

FILE 'ADISINSIGHT' ENTERED AT 12:03:45 ON 02 MAR 2006

L158 2 SEA ABB=ON L12  
L159 9 SEA ABB=ON ESTRADIOL VALERATE  
L160 0 SEA ABB=ON L15  
L161 64 SEA ABB=ON GONADORELIN OR ((LUTEINIZING OR GONADOTROPIN) (1W)RE  
LEASING(W) (HORMONE# OR FACTOR#))  
L162 1 SEA ABB=ON (L158 OR L159) AND L161  
D SCAN  
D KWIC

FILE 'WPIDS' ENTERED AT 12:04:50 ON 02 MAR 2006

L163 62 SEA ABB=ON ESTRADIOL VALERATE  
L164 678 SEA ABB=ON GONADORELIN OR ((LUTEINIZING OR GONADOTROPIN) (1W)RE  
LEASING(W) (HORMONE# OR FACTOR#))  
L165 1 SEA ABB=ON L163 AND L164  
D TRIAL

FILE 'STNGUIDE' ENTERED AT 12:05:32 ON 02 MAR 2006

FILE 'REGISTRY' ENTERED AT 12:08:13 ON 02 MAR 2006  
D STAT QUE L12

FILE 'CAPLUS' ENTERED AT 12:08:14 ON 02 MAR 2006

D QUE NOS L18  
D QUE NOS L30  
L166 3 SEA ABB=ON L18 OR L30

FILE 'TOXCENTER' ENTERED AT 12:08:16 ON 02 MAR 2006  
D QUE NOS L37

FILE 'BIOSIS' ENTERED AT 12:08:17 ON 02 MAR 2006  
D QUE NOS L66

FILE 'USPATFULL' ENTERED AT 12:08:18 ON 02 MAR 2006  
D QUE NOS L69

FILE 'EMBASE' ENTERED AT 12:08:19 ON 02 MAR 2006  
D QUE NOS L75  
D QUE NOS L78

L167 5 SEA ABB=ON L75 OR L78

FILE 'BIOTECHNO' ENTERED AT 12:08:20 ON 02 MAR 2006  
D QUE NOS L94

FILE 'AGRICOLA' ENTERED AT 12:08:23 ON 02 MAR 2006  
D QUE NOS L116  
D QUE NOS L119

FILE 'DRUGU' ENTERED AT 12:08:24 ON 02 MAR 2006

D QUE NOS L135

D QUE NOS L146

L168 6 SEA ABB=ON L135 OR L146

FILE 'IPA' ENTERED AT 12:08:26 ON 02 MAR 2006

D QUE NOS L152

FILE 'IMSRESEARCH' ENTERED AT 12:08:27 ON 02 MAR 2006

D QUE NOS L157

FILE 'ADISINSIGHT' ENTERED AT 12:08:28 ON 02 MAR 2006

D QUE NOS L162

FILE 'MEDLINE' ENTERED AT 12:08:29 ON 02 MAR 2006

D QUE NOS L100

FILE 'STNGUIDE' ENTERED AT 12:08:36 ON 02 MAR 2006

FILE 'CAPLUS, USPATFULL, MEDLINE, DRUGU, BIOTECHNO, IPA, BIOSIS, EMBASE, TOXCENTER, ADISINSIGHT' ENTERED AT 12:10:30 ON 02 MAR 2006

L169 41 DUP REM L166 L69 L100 L168 L94 L152 L66 L167 L37... (5 DUPLIC

ANSWERS '1-3' FROM FILE CAPLUS

ANSWERS '4-7' FROM FILE USPATFULL

ANSWERS '8-14' FROM FILE MEDLINE

ANSWERS '15-19' FROM FILE DRUGU

ANSWERS '20-24' FROM FILE BIOTECHNO

ANSWERS '25-27' FROM FILE IPA

ANSWERS '28-30' FROM FILE BIOSIS

ANSWERS '31-35' FROM FILE EMBASE

ANSWERS '36-40' FROM FILE TOXCENTER

ANSWER '41' FROM FILE ADISINSIGHT

D IBIB ED ABS HITSTR 1-7

D IALL 8-41

FILE 'CAPLUS' ENTERED AT 12:11:23 ON 02 MAR 2006

D QUE NOS L34

L170 10 SEA ABB=ON L34 NOT L166

D IBIB ED ABS HITSTR L170 1-10

FILE 'HOME' ENTERED AT 12:11:37 ON 02 MAR 2006

D SAVED

D STAT QUE L12

=>

This Page Blank (uspto)